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Chapter I : Introduction and research objectives 
 
1. Role of cytogenetic analysis in hematological malignancies 
 
History of cytogenetic analysis 
 
The importance of chromosomal alterations in the etiology of cancer was first suggested by 
Boveri in 1914 1 who proposed the concept of chromosomal instability as a cause of abnormal 
growth and cancer. However, it was not until 1956 when improved cell culture and slide preparation 
techniques made it possible to accurately enumerate the number of human chromosomes as 46 2. At 
that time, in the pre-banding era, the identification of chromosomes was based on size and 
centromere position and chromosomes fell into 7 groups (A-G). The introduction of chromosome 
banding 3 allowed a much more detailed examination of the tumor karyotype and led to the 
identification of many recurrent structural chromosomal abnormalities particularly in leukemia and 
lymphoma 4. These chromosomal abnormalities assumed particular importance when some were 
recognized to occur regularly in certain types of cancer. Such regularity implies that genes affected 
by these rearrangements might be the first hit in the respective tumors and might serve as a target 
for therapy. The identification of the Philadelphia chromosome as the product of t(9;22)(q34;q11) in 
1973 was a landmark in our understanding of the genetic basis of cancer 5.  
 
Importance of cytogenetics in hematological malignancies 
During the last 20 years, many studies have shown that chromosomal abnormalities found in 
leukemia patients were useful diagnostic and prognostic indicators. Several publications document 
the prognostic significance of recurrent chromosomal abnormalities in the different types of 
hematological malignancies (AML, ALL, MDS, CLL) 6-8. This information is important for the 
stratification of patients for therapy. Patients with poor prognostic features may be treated more 
intensively, whereas patients with good prognostic features could benefit from a less intensive and 
less toxic treatment. Moreover, cytogenetic analysis is often the first step towards the 
identification of leukemia-associated genes and often leads to the identification of candidate genes. 
For some translocations, like t(15;17)(q22;q21) and t(9;22)(q34;q11), the biological networks that 
are disturbed have been largely unraveled allowing patients with these aberrations to benefit from 
a rational targeted therapeutic approach. In the current era of risk-adapted and molecular targeted 
therapy, accurate assessment of the genetic status is of high importance. 
 
Evolution of cytogenetic techniques 
Cytogenetics has been used for many years for clinical diagnostics as well as for basic genomic 
research. The techniques used however, have evolved largely during the last 25 years which were 
initially aimed at increasing the resolution of conventional chromosome analysis. Nowadays, 
fluorescence in situ hybridization (FISH) has become an important additional technique to 
conventional chromosome analysis and overcomes the need for dividing cells and subsequent 
metaphase chromosomes. However, FISH can not replace conventional karyotyping since 
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metaphases are still needed for unraveling unknown chromosomal rearrangements. Both techniques 
however are still based on microscopic analysis, have a limited sensitivity and are labor intensive. 
Although automated karyotyping systems became available, analyzing metaphase spreads remains 
time-consuming. Polymerase chain reaction (PCR) analysis has the advantage to be more sensitive 
and to screen for a specific chromosome aberration without the need for dividing cells. However, 
the molecular analyses are limited to known chromosomal alterations and do not allow the 
screening of the whole genome for other abnormalities. Besides, PCR analysis is very useful in 
searching for aberrant gene expression which can point to an underlying genomic aberration. Recent 
novel technologies were developed that permit high-throughput applications, provide whole genome 
coverage and have become important components of molecular diagnostics. Several array-based 
technologies have been developed which are based on hybridization of patient DNA/cDNA with 
control/reference DNA/cDNA. In array-based comparative genomic hybridization (array-CGH), 
metaphase chromosomes are replaced as the target by large numbers of mapped FISH clones that 
are spotted onto a standard glass slide. The test and reference DNA are differentially labeled and 
co-hybridized to a microarray. The flexibility of array design has allowed the development of 
specialized arrays for applications such as telomeric screening or for specific diseases (i.e. B-CLL 9). 
Array-CGH has been applied to some hematological disorders and detected unknown regions of 
amplification/duplications or deletion which possibly harbor proto-oncogenes or tumor suppressor 
genes respectively 10, 11. Besides amplification and microdeletion screening, array-CGH can be used 
to define breakpoints in unbalanced and even in balanced translocations. In unbalanced 
translocations, loss or gain of genomic material can be detected on the array-CGH profile of the 
derivative chromosome 12.  A more advanced technique that can be used to exactly identify 
breakpoint positions in balanced chromosomal translocations using array-CGH is the flow sorting or 
microdissection of the derivative chromosomes, linear DNA amplification and subsequent 
hybridization on array-CGH slides 13, 14. Instead of FISH mapped clones, DNA sequences have also 
been used for array-CGH, called cDNA arrays. An advantage of cDNA arrays is that expression 
analysis can be carried out using the same platform; a drawback however is the uneven coverage of 
the genome (lack of intronic sequences) and lower sensitivity to small copy number changes than 
arrays produced from genomic clones. cDNA microarray technology not only allows the distinction 
between disease subclasses but also offers a possibility to identify new genes involved in 
leukemogenesis. To this purpose, cDNA libraries from normal and leukemic bone marrow were 
generated and sequenced. cDNA clones identifying unique transcripts from leukemic bone marrow 
were used to enrich an existing cDNA microarray platform. Subsequent hybridization of leukemic 
samples eventually leads to the detection of over –or under-expression of transcripts with previously 
unknown function in oncogenesis i.e. EMCN (endomucin) and USP33 (ubiquitin specific protease 33) 
that appear to be over-expressed in B-ALL compared to T-ALL 15.  While CGH can give information 
on DNA copy number, it provides no information on the parental origin of chromosomes. In some 
cancer associated genetic diseases, a single parental origin, uniparental disomy (UPD), has been 
associated with imprinted genes in the homozygous regions 16. Oligonucleotide arrays which allow 
genotyping of thousands of single nucleotide polymorphisms (SNPs), have been applied to the 
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analysis of loss of heterozygosity (LOH) in normal and tumor samples. Single nucleotide 
polymorphism (SNP) arrays are high-density oligonucleotide-based arrays that can identify both LOH 
at individual nucleotides and copy number alterations. The SNP array probes comprise 25-mer 
oligonucleotides and each SNP is represented by both a sense and an antisense strand. The probe 
intensities that correspond to the two possible alleles of the SNP reveal which of the three expected 
genotypes (AA, BB or AB) is present. SNP analysis in childhood acute lymphoblastic leukemia 
revealed LOH for chromosome 9p in the majority of patients 17. Similarly, SNP analysis revealed 
large regions of homozygosity in 20% of normal karyotype AML cases that could not be accounted for 
by chromosomal loss or gain. One explanation is somatic recombination resulting in large regions of 
UPD. The challenging effect of this acquired UPD could be the unmasking of mutations of leukemia 
associated genes 18. These different techniques however have their own advantages and drawbacks 
















Fig. 1 :  Overview of different genome wide screening techniques and their applicability to detect different types 
of chromosomal aberrations. FISH: fluorescence in situ hybridization, CGH: comparative genomic hybridization, 
SNP: single nucleotide polymorphism. (Adapted from Speicher et al., Nat. Rev. Genet. 2005) 
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2. Normal and malignant hematopoiesis 
 
Hematopoiesis is a complex process during which hematopoietic stem cells (HSC) proliferate 
and differentiate to constitute both the myeloid and lymphoid branches of the hematopoietic 
system (Fig.2). This process takes place in successive organs beginning in the yolk sac and aorto-
gonads-mesonephros (AGM) region, and then migrates from the AGM region to the fetal liver and 
subsequently to the bone marrow 19, 20. HSCs only comprise between 0.01% and 0.05% of the total 
marrow population and are responsible for the production and maintenance of specific types of 
blood cells which have a limited life-span. Therefore, the ancestral pluripotent stem cells must 
ensure its own survival by proliferation before differentiating into all lineages of blood cells. HSC 
possess two characteristic features: 1) self-renewal or the ability to generate daughter cells with 
equivalent developmental possibilities and 2) differentiation potential to produce highly specialized 
mature cell types (erythrocytes, neutrophils, eosinophils, basophils, platelets, 
monocytes/macrophages, osteoclasts and T and B lymphocytes, NK cells, dendritic cells). Upon 
differentiation, cells progressively lose the ability for self-renewal and have a limited life time in 
the peripheral blood where they subsequently undergo apoptosis. This tightly regulated process of 
hematopoietic lineage determination is driven both extrinsically (through growth factors, cytokines 
or other external influences) and intrinsically (pattern of genes expressed by the cell). These 
patterns of gene expression are determined by the positive and negative regulation of transcription 
factors. In the absence of expression of some important transcription factors like SCL/TAL1, mice 
do not generate definitive hematopoietic cells 21, suggesting that intrinsic mechanisms are 
important in lineage commitment whereas extrinsic signals have been suggested to support survival 
and development of committed cells 22. Abnormalities in the normal developmental program for 
blood cell formation result in hematological diseases. These abnormalities are due to modifications 
in gene expression or protein function, resulting from structural or numerical chromosome 
aberrations or other mutations as well as by epigenetic modifications.  
Depending on the affected cell type or lineage, the maturation point and the predominant 
functional defect, hematological malignancies are discerned. Leukemia is a clonal proliferation of 
immature, functionally aberrant white blood cells which results from a maturation arrest and/or 
deficiency of apoptosis. Based on the affected lineage, leukemia can be divided in lymphoid and 
myeloid leukemia. Since T and B lymphopoiesis predominantly occurs in the thymus (T-cells) and 
lymph nodes/spleen (B-cells), lymphoid leukemias frequently involve these organs besides the bone 
marrow whereas myeloid leukemia is mostly confined to the bone marrow (and peripheral blood). 
Furthermore, leukemias are classified into acute and chronic leukemia based upon their clinical 
course without treatment: acute leukemia leads to death within weeks, chronic leukemia within 
years after diagnosis. Depending on the predominant functional defect (proliferation or ineffective 
hematopoiesis), hematological malignancies can be divided into myelo -or lymphoproliferative and 
myelodysplastic disorders. The myeloproliferative disorders are consequent on the proliferation of a 
clone of myeloid cells derived from a neoplastic precursor. Furthermore and in contrast to overt 
leukemia, maturation of neoplastic cells is relatively normal but proliferation is abundant. These 
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myeloproliferative disorders include polycythemia rubra vera, idiopathic myelofibrosis, essential 
thrombocytosis, chronic myeloid leukemia, chronic eosinophilic leukemia and chronic neutrophilic 
leukemia based on the cell type predominantly affected and on the presence/absence of 
characteristic chromosomal defects. The myelodysplastic syndromes (MDS) are a group of clonal 
hematopoietic stem cell diseases characterized by dysplasia and ineffective hematopoiesis in one or 
more of the major myeloid cell lineages. The dysplasia may be accompanied by an increase in 
myeloblasts but the number is less than 20%, which is the requisite threshold recommended for the 
diagnosis of acute myeloid leukemia. Different subtypes of MDS are recognized depending on the 
percentage of blasts, the number of cell lines (red blood cells, white blood cells, platelets) 
affected, the presence of ringed sideroblasts and the presence of characteristic cytogenetic findings 
e.g. the 5q- syndrome. Lymphoproliferative disorders include clonal proliferations of lymphoid cells, 
either as acute or chronic lymphoid leukemia, Hodgkin’s disease and non-Hodgkin’s lymphomas.  the 
Plasma cell dyscrasias are characterized by proliferation of a neoplastic clone closely related to 
plasma cells and include multiple myeloma, monoclonal gammopathy of undetermined significance 
(MGUS) and Waldenström’s macroglobulinemia. Given the focus of my research on T-cell acute 































Fig.2 : The hematopoietic system: from pluripotent stem cell to mature blood cells. HSC: 
hematopoietic stem cell, MPP: multipotent progenitor cell, CLP: common lymphoid progenitor, 
CMP: common myeloid progenitor, CFU-GEMM :colony forming unit-granulocytic-erythroid-
myelo-monocytic. (Adapted from www.molmed.lu.se) 
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3. Normal T cell development and T-ALL 
 
3.1. Normal T cell development 
 
Human T lymphocytes are derived from pluripotent hematopoietic progenitors that migrate 
throughout life from the bone marrow to the thymus, where the majority of T-cell development 
occurs. Immature prothymocytes enter the thymus where they interact with stromal cells that 
produce lineage specific cytokines such as interleukine 7 (IL-7) 23, 24, stem cell factor (SCF) 25, FLT3 
ligand 26 and transforming growth factor-β (TGFβ) 27, 28. Thymocytes are divided as being double 
negative (DN), double positive (DP) or single positive (SP) based on the expression of the CD4 and 
CD8 antigens. The DN stage is heterogeneous and can be subdivided in three stages: a CD34+CD38-
CD1a-, CD34+CD38+CD1a- and a CD34+CD38+CD1a+. Most immature human thymocytes have the 
CD34+CD38- stem cell phenotype but rapidly acquire CD38 expression and subsequently also CD1, a 
marker for T cell lineage commitment 29. These human DN thymocytes pass through an immature 
single positive (ISP CD4+) stage towards a DP stage into CD4+ or CD8+ SP T cells that express 
functional T cell receptors (TCR) 30, 31 (Fig.3). A hallmark of T cell development is the generation of 
T cells that express a functional TCR, TCRαβ or TCRγδ. During T cell development, the variable 
domains of TCRα, TCRβ, TCRγ and TCRδ genes are assembled following somatic rearrangement of 
variable (V), diversity (D) and joining (J) gene segments by a process called VDJ recombination 32. 
This process is responsible for the diversity of an adaptive immune response in both TCR and 
immunoglobulin (IG) genes and uses the recombinase activating genes (RAGs) RAG1 and RAG2 
enzymes that target recombination signal sequences (RSS) that flank V, D and J segments. 
Many studies investigating TCR gene rearrangements during normal T cell development 
suggest that recombinations in TCR genes are sequential between the different genes (TCRδ > TCRγ 
> TCRβ > TCRα) as well as within a particular gene 31, 33. The CD34+CD1a- cells start to rearrange 
their TCRδ genes, but mostly have their TCRγ and TCRβ loci in germline configuration, whereas 
expression of CD1a is accompanied by rearrangements of TCRδ (V to DJ), TCRγ and TCRβ (D to J) 
loci. The immature single positive cells (ISP) have lost CD34 expression and contain mature TCR (V 
to DJ) rearrangements. When the thymocytes have developed into ISP cells, the functionality of the 
TCRβ chain is tested by expression on the cell surface together with a pre-TCR alpha (pTα) chain, a 
process called β selection. Signals emanating from this pre-TCR complex induce the cells first to 
proliferate and subsequently to initiate TCRα gene rearrangements. Productive TCRα 
rearrangements lead to the expression of a TCRαβ complex on the cell surface, which is then tested 
for the recognition of self-MHC molecules (positive selection) and absence of reactivity against self-
antigens (negative selection). The surviving cells become SP thymocytes that mature into either 
CD4+ T helper cells or CD8+ cytotoxic T cells and migrate to the periphery as naïve circulating T 
lymphocytes. Studies in T-ALL have demonstrated that they largely reflect physiologic T-lymphoid 










Many cytokine receptors (especially IL-7), the NOTCH family receptors and transcription 
factor genes (basic helix-loop-helix genes, LIM-domain genes, GATA, homeobox genes) are involved 
in regulating this complex process. Most of these genes have been identified through clonal 
chromosomal abnormalities in blast cells from T-ALL patients and had a profound impact on the 
understanding of the molecular changes involved in leukemogenesis. Some of these are specific for 
T cell development whereas others are involved in general hematopoiesis.  
The basic helix-loop-helix family of transcription factors (bHLH) share the bHLH motif (60aa) 
allowing homo- or heterodimerization through the HLH domain and DNA binding through the basic 
domain 34. Class A bHLH includes the E proteins (E2A and HEB) which bind DNA at specific E-Box 
sites in the enhancers of many T-cell specific regulatory genes like CD4 and pTα 35. E2A proteins 
regulate VDJ recombination, the expression of RAG and pTα genes required for the formation of 
pre-TCR 36. Besides, E2A proteins act as negative regulators of cell proliferation in thymic precursors 
36. Class B bHLH proteins form heterodimers with class A bHLH and are weakly (LYL1, TAL1) or not 
(TAL2) expressed in most primitive thymocytes 37. The TAL-1/SCL gene (stem cell leukemia) was 
originally identified through its translocation in acute T-cell lymphoblastic leukemia 38 and is 
expressed in hematopoietic cells, vascular endothelium and the developing brain 39-41. In the 
absence of SCL/TAL-1, hematopoiesis is undetectable 21. SCL/TAL1 is expressed in the early DN 
Fig.3 : Schematic representation of human T cell development;  : timepoint of TCR rearrangements during T-cell 
development;  : expression of different genes involved in T cell development. DN: double negative, ISP: 
immature single positive, DP: double positive, SP: single positive, DC: dentritic cell, M: myeloid cell. 
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stages of normal T cell development 42, 43 and normally gets downregulated upon differentiation 
towards mature T cells, suggesting a role in early T cell development. Another bHLH protein which 
is closely related to SCL in terms of amino acid identity is the LYL-1 gene. Despite this high 
sequence homology these two transcription factors display a distinct expression pattern in 
hematopoietic cells with LYL-1 being expressed mainly in immature hematopoietic and in B cells 44 
but only weakly in T cell progenitors. TAL2 and BHLH1 are two bHLH proteins which were initially 
identified through involvement in rare translocations t(7;9)(q34;q32) and t(14;21)(q11;q22) in T-ALL 
whereas they are not normally expressed in T cells but are both involved in CNS development 45, 46. 
SCL/TAL1 collaborating genes LMO1 (alias RBTN1) and LMO2 (alias RBTN2) belong to the LIM 
domain only genes which mediate specific protein interactions, but have no direct DNA binding 
capacity. SCL and LMO (especially LMO2) proteins seem to collaborate in normal hematopoiesis 
since both SCL and LMO2 show overlapping expression patterns in early hemogenic sites and in adult 
hematopoietic lineages. In addition, LMO2-/- mice exhibit a complete absence of hematopoietic 
cells and defective yolk sac angiogenesis, a phenotype that is highly similar to that observed in SCL-
/- mice 47, 48. Little is known about the function of LMO1 in normal hematopoiesis whereas LMO2 is 
important in embryonic stem cell development 49. In addition to its association with SCL, LMO2 has 
been demonstrated to interact with hematopoietic GATA family members (GATA 1-2-3).  
Transcription factor GATA-3 is expressed in a T cell specific context and evidence for the 
necessity of GATA-3 in T cell development came from several studies 50, 51 . In contrast, GATA-1 is 
highly expressed in erythroid, megakaryocytic, eosinophils and mast cells whereas GATA-2 is 
expressed in early hematopoietic cells and in megakaryocytic lineages 52.  
NOTCH1 is a transmembrane receptor that is an important regulator of stem cell 
maintenance 53 and required for the commitment of pluripotent progenitors to T cell fate 54 namely 
the T versus B cell lineage choice in early hematopoietic progenitors 55. Moreover, NOTCH1 is 
important for the subsequent assembly of pre-T cell receptor complexes in immature thymocytes 56, 
57 besides involvement in mechanisms of cell interaction. NOTCH1 signalling affects cell 
differentiation, proliferation and apoptotic programs essential for various tissues and organs 58. 
Inactivation of NOTCH1 signaling in bone marrow precursors results in the generation of B cells and 
prevents the development of T cells 59, 60. Several homeobox genes have also been implemented in 
normal T cell development.  Involvement of class I homeobox genes (HOX genes) in thymopoiesis 
was suggested by generation of a HOXA3 knock-out mice model which lacked thymus development 
and it was thought that HOXA3 acts through interaction with PAX1 and Thy-1, which are known to 
be involved in the maturation of thymocytes 61-63. Similarly, HOXA9 knock-out mice exhibit disturbed 
differentiation of myeloid cells and severely affected early T cell development 64. Further evidence 
for involvement of HOXA cluster genes during normal T cell development came from a study from 
Taghon et al. who demonstrated a drastic change in HOXA gene expression from hematopoietic 
precursor cells upon entry into the thymus 65. There was a progressive downregulation of 3’HOXA 
genes upon differentiation towards mature thymocytes while 5’ HOXA genes were present in more 
mature cell types suggesting that sequential up and down regulation of these HOXA cluster genes 
plays an important role in normal T cell development. Besides these homeobox genes, lymphocyte-
 Chapter I : Introduction 19 
specific protein tyrosine kinase (LCK) belonging to the Src family kinases (sarcoma viral oncogene 
homolog) also plays an important role in normal T cell development (TCR signaling) and T cell 
activation 66. An important role for TCL1 in normal T and B cell development was demonstrated in 
TCL1 deficient mice, where a significant reduction of lymphocytes was found in bone marrow, 
thymus and spleen. TCL1 expression was detected in normal lymphocytes in the DN4 and DP stages 
but not in mature T cells. Upon knock out, T cell lymphopoiesis was impaired at the double positive 
stage (CD4+CD8+) 67.  Another effector in pre-TCR signaling, cyclin D3, is crucial for the proliferative 
burst of DN thymocytes. Besides its role in normal T cell development, cyclin D3 also cooperates 
















 Chapter I : Introduction 20 
3.2. Molecular pathogenesis of T-cell acute lymphoblastic leukemia 
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of T cell precursors 
that develops mainly in children and adolescents (10-15% of childhood ALL) but also in adults (25% 
of adult ALLs)6. This aggressive tumor is characterized by high peripheral white blood cell counts, 
frequent mediastinal masses, pleural effusion and involvement of the central nervous system and 
chromosomal features that are distinct from those of B-lineage ALL. Over the past 50 years, 
treatment success rates for pediatric ALL have markedly improved with overall survival rates of 
nearly 80%. However, less success has been achieved in the treatment of adults with T-ALL, with 
long term survival rates of 30-40% among patients < 60 years of age and decreasing to 10% in 
patients over 60 years of age 69, 70.  
Similar to other types of leukemia, T-ALL is caused by multistep mutagenesis involving 
various genetic alterations that shift normal cells into uncontrolled growth and clonal expansion. 
These genetic alterations can affect cell-cycle control, stem cell maintenance and proliferation, 
differentiation and survival 71. Chromosomal translocations affecting transcription factor genes are 
the most common alterations in acute leukemia and functionally impair differentiation and provide 
a proliferative advantage of the leukemic cells. Activation of transcription factor genes by 
chromosomal translocations take two main forms. In T or B lymphoid leukemias, these genes are 
often translocated to the vicinity of genes encoding chains of the T-cell receptor (TCR) or 
immunoglobulin (IG) molecules, resulting in inappropriate expression of the translocated proto-
oncogenes. In other types of leukemia, the coding exons of genes disrupted by a reciprocal 
translocation are incorporated into a single “fusion” gene which generates a chimeric protein with 
unique properties. Besides these chromosomal aberrations, T-ALLs frequently show interstitial 
deletions of 9p21, causing cell cycle defects. Recently, NOTCH1 signaling has been identified as an 
important regulator of stem cell maintenance and was also implicated in the pathogenesis of T-ALL, 
suggesting that NOTCH1 defects may serve the leukemic clone with self-renewal capacity. It is well 
illustrated that these different classes of functional defects cooperate with each other in the 
generation of an overt leukemia and that one genetic defect can lead to more than one functional 
effect.   
Fig.4: A) TF (transcription factor) are activated when placed 
under control of potent enhancer elements within the 
regulatory region of a gene that is normally tightly expressed 
or B) Chromosomal breakpoints occur within introns and 
produce a fusion gene that encodes a chimeric transcription 
factor with altered function. R: regulatory region.  
(Adapted from Look et al., Science, 1997).  
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3.2.1. T- cell oncogenes in T-ALL 
Cytogenetic analyses and molecular cloning of chromosomal translocation breakpoints led to 
the discovery of transcriptional regulatory proteins that are aberrantly expressed in T-ALL owing to 
the juxtapositioning of their respective genes next to strong T-cell receptor gene enhancers and 
promotors. However, recent studies have shown that several of these T cell oncogenes (HOX11, 
TAL1, LYL1, LMO1 and LMO2) are often expressed in the absence of a genomic rearrangement, 
supporting other mechanisms of transcriptional activation like alterations in cis-acting or trans-
acting regulatory sequences without further functional consequences. Indeed, based on similarities 
in gene expression signatures compared to normal T cell developmental stages, these subgroups 
were indicative of leukemic arrest at specific stages of normal thymocyte development and have 
prognostic importance 43(Fig.5). Although these translocated proteins have important functions 
during normal embryogenesis, many are not essential for the development of normal thymocytes 
such as MYC (8q24), HOX11/TLX1(10q24), HOX11L2/TLX3 (5q35), TAL2 (9q34), LMO1/RBTN1(11p15) 
and LMO2/RBTN2 (11p13)(Table 1). Despite absence of hematopoiesis and embryonic lethality 10 
days after inception in LMO2 -/- mice, no effect on T-cell development could be detected when 
LMO2 was selectively deleted in lymphoid progenitor cells 72. 
Prominent among T cell oncogenes are members of the class B bHLH family of transcription 
factors : TAL1, TAL2, LYL1 and BHLHB1. Rearrangements of the TAL1 gene locus are found in up to 
25% of all T-ALL cases,  but only 3% involve TCR loci in a t(1;14)(p32;q11) whereas the remainder 
have a deletion that places TAL1 under the control of the SIL gene promoter leading to TAL1 
transcriptional activation. Because the TAL1 protein forms a pentameric DNA-binding complex with 
E2A, LMO2, GATA3, LDB-1 its ectopic expression in T cells might activate specific target genes that 
are normally quiescent in T-cell progenitors. Alternatively, TAL1 might be leukemogenic via a 
dominant-negative effect since overexpression of TAL1 can lead to a functional inactivation of E2A 
homodimers by sequestering E2A in a pentameric complex. This model is supported by the 
observations that E2A-deficient mice develop T-ALL 73, 74. Moreover, it has been shown that TAL1 
tumors undergo apoptosis after administration of histone deacetylase inhibitors (HDAC) suggesting 
that aberrant expression of TAL1 causes gene silencing 75. Ectopic expression of TAL1 in the absence 
of the cytogenetic aberration was found in  50% 76 of childhood T-ALLs and only 5% of adult T-ALL 77 
and reflects the stage of maturation arrest in the late cortical stage of T cell development (Fig.5). 
The clinical relevance of TAL1 rearrangements remains unclear, although a trend for a favorable 
outcome have been described 78. The LYL1 gene (19p13) was initially identified through molecular 
characterization of the t(7;19)(q35;p13) associated with T-ALL which results in the constitutive 
expression of LYL1. Ectopic expression of LYL1 in the absence of the corresponding genetic defect is 
associated with maturation arrest of thymocytes in the double negative stage 43 (Fig.5). However, 
recent studies show that LYL1 expression is not limited to immature cases and is expressed in 
almost all T-ALL cases, especially in CALM-AF10 positive cases 78. The TAL2 (9q32) and BHLHB1 
(21q22) genes were identified as a consequence of t(7;9)(q34;q32) and t(14;21)(q11;q22) and share 
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many properties with TAL1, supporting the idea that these proteins promote T-ALL by a common 
mechanism 79.  
The genes encoding the LIM-domain only genes LMO1 (11p15) and LMO2 (11p13) are often 
translocated in T-ALL but are primarily expressed in the central nervous system and only minimally 
expressed or absent in T cell progenitors. Both LMO1 and LMO2 possess zinc-finger-like structures in 
their LIM domains but lack the DNA-binding domains common to other transcription factors in this 
family, suggesting that the LIM domain functions in protein-protein rather than protein-DNA 
interactions. Most common translocations are the t(11;14)(p15;q11) and t(11;14)(p13;q11) 
juxtaposing LMO1 or LMO2 to the TCRα or TCRδ loci respectively 49, 80, 81. Studies in mice show that 
LMO2 overexpression induces leukemia with long latency 82. Interestingly, ectopic expression of 
these genes also occurred in the absence of the chromosomal rearrangements and was frequently 
found in T-ALL cases that already have deregulated TAL1 (LMO1 and LMO2) or LYL1 (LMO2) 
expression. The observations of co-deregulation of both TAL1, LMO1, LMO2 and LYL1 were 
consistent with animal model studies showing that LMO proteins form heterocomplexes and act in 
concert with TAL1 and LYL1. As a consequence, ectopic expression of LMO1 and LMO2 cannot be 
shown independently in Fig.5 but is overlapping with TAL1 and LYL1 expression. In a recent study 83, 
a novel LMO2 activation mechanism was suggested i.e. a cryptic deletion on chromosome 11, 
del(11)(p12p13), with loss of a negative regulatory region upstream of LMO2.  
Class I homeobox genes, HOXA cluster genes in particular, have only recently been 
associated with T-ALL due to genomic rearrangements with TCR loci (TCRδ and TCRβ). The 
unraveling of these new genomic rearrangements was the result of the present study and is 
described in detail in chapter II. 
Class II homeobox genes HOX11 and HOX11L2 are frequently involved in T-ALL whereas both 
have no specific role in normal T cell development 43, 84 but in spleen morphogenesis (HOX11) and in 
CNS development (HOX11L2). Ectopic expression of HOX11 was found in 3% of childhood and 33% of 
adult T-ALL and was associated with chromosomal translocation to the TCRδ or TCRβ locus in only 
half of these cases. These findings suggest that other trans-acting mechanisms can lead to this 
aberrant gene expression, probably by disrupting gene silencing mechanisms that operate during 
normal T cell development. Microarray analysis revealed that HOX11 expressing T-ALLs show a gene 
expression pattern resembling that of early cortical thymocytes and the favorable clinical outcome 
of these patients 85 may be explained by their high expression of genes associated with increased 
cell proliferation and lack of expression of anti-apoptotic genes at this stage of thymocyte 
development 43. Enforced expression of HOX11 in CD34+ progenitor cells block T cell differentiation 
prior to the DP thymocyte stage 86 and lead to immortalization of hematopoietic precursor cells 87.  
Approximately 25-30 % of childhood and 13% of adult T-ALL cases are characterized by ectopic 
HOX11L2 expression 88-90 and in most cases, this ectopic expression is caused by the cryptic 
t(5;14)(q35;q32) juxtaposing HOX11L2 to the distal region of BCL11B, a gene highly expressed during 
T cell differentiation. Variant translocations have been described involving both the HOX11L2 and 
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the BCL11B genes. The CDK6 gene on 7q21 was involved in a t(5;7)(q35;q21) with HOX11L2, whereas 
a rearrangement of the NKX2-5(5q35) gene and the BCL11B gene is described in a t(5;14)(q35;q32). 
Although HOX11 and HOX11L2 expression profiles predominantly occur at the early cortical stages of 
thymocyte development, these two subgroups seem to have a different clinical outcome. Whereas 
HOX11 expression was associated with a favorable outcome, conflicting results exist for patients 
with ectopic HOX11L2 expression 78, 88, 90. The majority of HOX11 positive T-ALL express CD1a, a 
marker of cortical thymocytes, whereas this expression is heterogeneous in HOX11L2 positive cases. 
This indicates that these subgroups are arrested at slightly different developmental stages and may 
have different responses to therapy 78 since CD1a expression is a good prognostic marker. Indeed,  
Asnafi et al. 77 have shown that HOX11L2 rearranged T-ALL comprises not only the early cortical 
developmental stage, but also a more immature phenotype, intermediate between the αβ and γδ 
TCR lineages. The differences in prognostic relevance of HOX11L2 expression between several 
studies may also depend on the presence of other genetic aberrations like NUP214-ABL1 episomal 
amplification 78.   
Recent studies showed first evidence for involvement of cyclin D2 in T cell oncogenesis due 
to a recurrent chromosomal translocation affecting the TCRαδ locus and the CCND2 locus at 12p13. 
This was the first example of a T-cell neoplasm with a targeted deregulation of a member of a 
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Type of protein Oncogene Chromosomal 
translocation 
% of T-ALL carrying 
the chromosomal 
translocation  




Homeodomain HOX11 (10q24) t(7;10)(q34;q24) 
t(10;14)(q24;q11) 
7 % c                     
14%  a 




Homeodomain HOX11L2 (5q35) t(5;14)(q35;q32) 
t(5;14)(q35;q11) 
t(5;7)(q35;q21) 
25-30%c                 
13% a 
25-30% c             
13% a 
BCL11B(14q32)   
TCRδ(14q11)  
CDK6(7q21)  





 TCRβ (7q34) 
TCRαδ(14q11)      
bHLH LYL1 (19p13) t(7;19)(q34;p13) <1% 35%  TCRβ (7q34) 
bHLH TAL1 (1p32) t(1;14)(p32;q11) 3%                          
22% SIL-TAL1 fusion 
50% c                                       
5% a 
TCRαδ (14q11) 
bHLH TAL2 (9q34) t(7;9)(q34;q34) <1-2%  TCRβ (7q34) 
bHLH MYC (8q24) t(8;14)(q24;q11) 2%  TCRαδ (14q11) 
bHLH BHLHB1 (21q22) t(14;21)(q11;q22) <1%  TCRαδ (14q11) 
LIM domain LMO1 (11p15) t(11;14)(p15;q11) 5% 8% c+a                         TCRαδ (14q11) 
LIM domain LMO2 (11p13) t(11;14)(p13;q11) 
t(7;11)(q34;p13) 
5-10% 31%c+a                    TCRαδ(14q11)      
TCRβ (7q34) 
Tyrosine kinase LCK (1p34) t(1;7)(p34;q34) <1%  TCRβ (7q34) 
Cyclin CCND2 (12p13) t(12;14)(p13;q11) <1%  TCRαδ (14q11) 
CC-domain-
Tyrosine kinase 
EML1-ABL1 t(9;14)(q34;q32) <1%  Gene fusion 
ETS-domain-
Tyrosine kinase 
ETV6-JAK2 t(9;12)(p24;p13) <1%  Gene fusion 
ETS-domain-
Tyrosine kinase 
ETV6-ABL1 t(9;12)(q34;p13) <1%  Gene fusion 
Nucleoporin-GEF NUP98-
RAP1GDS1 
t(4;11)(q21;p15) 2%  Gene fusion 
Nucleoporin-
Tyrosine kinase 
NUP214-ABL1 Episomal 6%  Gene fusion 
ENTH-domain-AT-
hook 
CALM-AF10 t(10;11)(p13;q21) 5-10%  Gene fusion 
 MLL-ENL t(11;19)(q23;p13) 4%  Gene fusion 
 MLL-AF6 t(6;11)(q27;q23) <1%  Gene fusion 
 PCM1-JAK2 t(8;9)(p22;p24) <1%  Gene fusion 
Notch receptor NOTCH1 t(7;9)(q34;q34) 50%  truncation; 
activation 







del(9)(p21) 40-80%  gene 
inactivation 
 
Table 1 : Genomic alterations in T-cell acute lymphoblastic leukemia 
For abbreviations of oncogenes, see list p. 5-7  
a: adult ; c: childhood 




3.2.2. Fusion genes in T-ALL 
A second class of chromosomal translocations that have been identified in T-ALL result in 
fusion proteins. MLL(mixed lineage leukemia)-ENL fusions result from t(11;19)(q23;p13) and are 
associated with AML, B cell precursor ALL and T-ALL. In T-ALL, this fusion gene is associated with an 
early thymocyte differentiation arrest leading to increased expression of HOXA9, HOXA10, HOXC6  
and MEIS1 43. Another MLL fusion rarely described in T-ALL is the MLL-AF6 fusion resulting from the 
t(6;11)(q27;q23) 93. The CALM-AF10 fusion resulting from the t(10;11)(p13-14;q14-21) was identified 
in 10% of T-ALL but has also been described in lymphomas and acute leukemias of several lineages 
and has to be considered nonlineage specific 94-98. Within the T-ALL however, this fusion is specific 
for the TCRγδ lineage 99 and is associated with upregulation of HOXA5, HOXA9, HOXA10 and BMI-1 
100. Unexpectedly, several ABL1 fusions have recently been detected in T-ALL: ETV6-ABL1, EML1-
ABL1 and NUP214-ABL1 101-103. NUP214-ABL1 is found on episomal elements in about 6% of T-ALL 
patients and is associated with increased expression of HOX11 and HOX11L2. These ABL1 fusion 
kinases are constitutively phosphorylated resulting in excessive activation of survival and 
proliferation, which can be inhibited upon addition of imatinib, a selective inhibitor of ABL1 kinase 
activity. NUP98-RAP1GDS1 resulting from a t(4;11)(q21;p15) is a recurrent but infrequent 
translocation in T-ALL (<5%) and was the first fusion gene involving NUP98 in lymphoblastic leukemia 
104.  The rare ETV6-JAK2 fusion was originally identified in pediatric T-ALL 105 and has been shown to 
induce T cell leukemia in a transgenic mouse model 106. Very recently, a second gene fusion 
involving JAK2 and PCM1 has been detected in an adult patient with T-cell lymphoma 107.  
Fig.5 : Correlation between gene-expression profiles and stages of thymocyte 
differentiation. DN: double negative, ISP: immature single positive, DP: double positive, 
SP: single positive. 
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3.2.3. Other aberrations involving tumor suppressor genes or receptor proteins 
 A common genetic defect in 40 to 60 % of childhood and adult T-ALL is the inactivation of 
the tumor suppressor genes CDKN2A and to a lesser extent CDKN2B located at chromosome 9p21 by 
mono- or biallelic deletion, promoter hypermethylation or by mutation 108, 109. The CDKN2A gene 
encodes the tumor suppressor proteins p14INK4 and p16INK4 whereas CDKN2B encodes p15INK4, 
which inhibit the activity of cyclin-CDK complexes involved in cell cycle progression. Inactivation of 
CDKN2A and CDKN2B by homozygous deletion has been described in 65% and 23% whereas 
hemizygous deletions are less frequent (10% and 15%). Ferrando et al. found 9p21 deletions in most 
T-ALL cases also expressing HOX11 or TAL1 43. Several reports have showed an association of 
homozygous 9p deletions and adverse prognosis both in pediatric B- and T-ALL 110 which could not be 
confirmed in recent studies in pediatric B-ALL cases 111, 112. Disagreement exists about the 
correlation of 9p21 deletions with prognosis in adult ALL 113.  
Recent findings point to a central role for aberrant NOTCH1 signaling in the pathogenesis of 
T-ALL. Activating NOTCH1 mutations were found in 50% of primary T-ALL samples 114, including most 
molecular subtypes of T-ALL (HOX11, HOX11L2, TAL1, CALM-AF10) suggesting that these defects 
predominantly affect immature T cells or uncommitted pluripotent progenitor cells. NOTCH1 has 
been reported as an important regulator of stem cell maintenance 53, which implicates that these 
mutations could provide the leukemic cells with self-renewal capacity. Enforced NOTCH1 signaling 
is a potent inducer of T-ALL in the mouse 115, 116. Most interestingly the identification of NOTCH1 
mutations has therapeutic implications, as most mutant forms of NOTCH1 still require gamma-
secretase activity to generate downstream signals. Gamma-secretase inhibitors have been 
developed for treatment of Alzheimer’s disease so these drugs could provide a rational, molecular 
targeted therapy in T-ALL patients carrying these NOTCH1 mutations 117. 
The FLT3 gene encodes a receptor tyrosine kinase playing an important role in the 
development of HSC. Activating mutations of FLT3 are the most common genetic abnormality in AML 
but are quite rare in T-ALL and seem to be restricted to CD117/Kit+ T-ALL lymphoblasts with high 
expression of LYL1 and LMO2 118. The finding of FLT3 activating mutations was confirmed in another 
study but failed to show any link with CD117+ T-ALLs 119. Similar to AML, the mutations in T-ALL are 
internal tandem duplications (ITD) in the juxtamembrane domain of the receptor and point 
mutations in the activation loop of the kinase domain, leading to constitutive kinase activity, 
suggesting FLT3 inhibitors as a valuable therapeutic option in this subgroup of patients. However, 
one report 119 claims that the FLT3 mutated subclone was eradicated by classical chemotherapy, 
destroying the need for additional therapeutic agents in T-ALL patients carrying FLT3 activating 
mutations. 
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4. Roles of HOX and HOX cofactors in normal and malignant 
hematopoiesis  
In the last decade, it has become clear that homeobox containing genes not only play a 
significant role in embryogenesis (especially determining the developmental fate of a cell) but also 
contribute to organization and regulation of hematopoiesis. A number of studies have indicated that 
homeobox gene expression can be detected in specific cell lineages and differentiation stages 
during hematopoiesis 120-124. Furthermore, homeobox genes have been involved in translocation 
events in certain leukemic cells, suggesting that mutant forms of these genes may be important in 
oncogenesis. The term homeobox gene arose from an earlier genetic term, the so-called homeotic 
mutation, a mutation in which the identity of one body segment is converted to that of another. 
Such mutations were first described in Drosophila 125 and are exemplified by a mutation in which 
flies have legs in stead of their antennae. The cloning of the gene, called Antennapedia, 
represented the identification of the first homeobox gene. These genes contain a highly conserved 
183 bp homeobox encoding a DNA binding motif, the homeodomain. Homeodomain proteins are 
transcription factors which play a role in specifying relative positions and tissue fate in the embryo, 
particularly along various body axes, including the anterior-posterior axis and the axes of the 
developing limb bud. The three dimensional structure of the homeobox is a helix-turn-helix motif, 
consisting of four helices. Mammalian homeobox genes are categorized in two classes.  
The class I homeobox genes are highly homologous (>80%) to the first discovered homeobox 
gene of Drosophila, Antennapedia and consists of 39 genes, organized in four clusters (HOXA, HOXB, 
HOXC, HOXD) as the result of an ancestral quadruplication of a single gene cluster.  These four 
clusters each contain 8-11 genes and are localized on different chromosomes (HOXA on 7p15, HOXB 
on 17q21, HOXC on 12q13 and HOXD on 2q31) (Fig.6). Based on the strong vertical conservation 
within the homeobox domains, these four clusters can further be divided in 13 paralogs (Fig.6). The 
order of genes within each cluster is also highly conserved throughout evolution, suggesting that the 
physical organization of HOX genes is essential for their expression.  In human hematopoietic cells, 
it was demonstrated that HOX genes are coordinately switched on or off in blocks following a wave 
of gene expression starting at the 3’ end of the HOX locus and proceeding to the 5’ end along with 
maturation of the cells 126. 
Class II homeobox genes (non-HOX genes) are dispersed throughout the genome, show < 50% 
homology to Antennapedia and some have been shown to act as cofactors for HOX proteins. These 
HOX cofactors which enhance DNA-binding specificity and avidity include the three-amino-acid-loop-
extension (TALE) proteins such as PBX1 (pre-B-cell leukemia transcription factor 1), MEIS1 (myeloid 
ecotropic viral integration site 1 homolog), and PREP1 (PBX-regulating protein 1) and are co-
synthesized during embryonic development. Products of the 3’ HOX genes (paralog groups 1-8) 
preferentially associate with PBX1, whereas products of the 5’ HOX genes (paralog groups 11-13) 
associate with MEIS1 127, 128. Other non-HOX genes like HOX11 are more restricted in their patterns 
of expression and are involved in organogenesis or differentiation of specific cell types. 












Individual HOX genes and HOX cofactors have been implicated in normal and malignant 
hematopoiesis. First evidence of HOX gene expression in unfractionated normal human bone marrow 
cells came from RNase protection assays that demonstrated expression of HOXB2, HOXB6 and 
HOXA10 129. Furthermore, RT-PCR analysis on purified subpopulations of CD34+ progenitor cells 
showed that the number of HOX genes expressed was the highest for the HOXA cluster, and 
decreased for genes of the HOXB and HOXC clusters whereas no expression of HOXD clusters was 
found 126, 130, 131. Not only the number of HOXA genes, but also the expression level of these genes 
was higher than that of HOXB and HOXC genes in CD34+ populations. In addition, genes in the 3’ 
region of the HOXA and HOXB clusters are downregulated as CD34+ cells progress to the stage of 
committed erythroid and myeloid progenitors, while 5’ genes remain active into the committed 
progenitor stage and are inactivated as cells leave the CD34+ compartment 126. Inversely, expression 
of HOX regulatory genes like Polycomb (PcG) genes seem to show progressive upregulation upon 
differentiation of CD34+ cells which possibly induces formation of condensed chromatin resulting in 
3’ to 5’ closure of the HOX cluster 132. Whereas some HOX genes show broad expression in cells of 
different cell phenotypes, several appear to have lineage-restricted patterns of expression. 
Expression of all HOXB cluster genes is mainly associated with cell lines with erythroid potential 133-
135 except for HOXB4 and HOXB7 which are also expressed in T and B cell lines, and for HOXB1 which 
is not expressed in the hematopoietic department. HOXC4 expression is limited to lymphoid 
leukemias 122 while HOXA10 is strongly expressed in myeloid leukemias 129 and until the results 
presented in this thesis, unnoticed in lymphoid leukemia. 
Fig.6: Drosophila HOX genes and their human homologs. Drosophila HOM-C genes at the 3’ end 
comprise the Antennapedia complex (Lab, Pb, Dfd, Scr and Antp) that controle the formation of 
anterior structures. Posterior segments are controlled by genes of the Bithorax complex (Ubx, Abd-
A, Abd-B). Human counterparts of drosophila HOM-C genes are designated HOX-A through HOX-D 
and are arranged on four different chromosomes. Genes within the HOM-C and HOX clusters show 
striking structural and functional conservation as indicated by the color coding. This vertical 
conservation lead to the division in 13 paralog groups for each HOX  cluster. 
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Early evidence for involvement of HOX genes in human leukemia came from the 
identification of translocations involving the nucleoporin gene NUP98 and HOXA9 in rare cases of 
AML and subsequently a number of NUP98 fusions with other HOX genes have been described 136-139. 
Although translocations involving HOX genes are uncommon, other studies demonstrated that HOXA 
and HOXB genes are frequently overexpressed in human AML 140-143 and may portend a worse 
prognosis 140, 144. Further evidence for HOX gene function in malignant hematopoiesis came from 
knock-out mouse models and enforced expression studies in hematopoietic stem cells from murine 
fetal liver and bone marrow and in human cord blood progenitors. Forced expression of certain HOX 
genes such as HOXB3, HOXA9, HOXB8, HOXB6 and HOXA10 lead to myeloid leukemia after several 
months 145-149. This latency period can be shortened dramatically if the HOX cofactors like PBX1 and 
MEIS1 are co-overexpressed with their HOX partner. Conversely ectopic expression of HOXB4 leads 
to hematopoietic stem cell expansion without induction of leukemia. Knock-out animal models have 
been described for the HOXA9 gene and exhibited disturbed differentiation of myeloid and 
megakaryocytic cells, while early T cell development was seriously diminished 64, 150. Similarly 
HOXA3 mutant mice have a spectrum of abnormalities in the pharyngeal tissues derived from the 
mesenchymal neural crest. Amongst these were defects in the generation of the thymus and thyroid 
glands leading to defective thymocyte development. Satokata et al. 151 generated a HOXA10 knock-
out mouse which show an anterior homeotic transformation of lumbar vertebrae and had severe 
fertility defects in both genders. Likewise, targeted disruption of HOXA11 was shown to result in 
both male and female sterility 152 and the mutant males show a partial homeotic transformation of 
the vas deferens to an epididymis. Besides these defects, disruption of HOXA10 or HOXA11 
established limb malformations to varying degrees 153. The hematopoietic consequences of HOXA10 
and HOXA11 knock-out were apparently not lethal but in fact have not been studied in these mouse 
models yet. The only HOXA gene mutation associated with a non-neoplastic hematological disorder 
thus far, is the germline HOXA11 mutation described in the amegakaryocytic thrombocytopenia with 
radio-ulnar synostosis 154. Thus HOX and HOX cofactors are critical components for normal 
hematopoiesis and their cis-deregulation may be the underlying mechanisms for different 
hematological disorders. 
Several mechanisms have been identified that regulate expression of HOX genes. The 
identification of TAAT sequences 155, 156 and retinoic acid response elements in upstream regions 
allows the binding and activation or repression by homeoproteins (autoregulation) and activation of 
expression by retinoic acid 157, 158. Also the maintenance of HOX gene expression is guided by the 
Polycomb 159-160 (PcG) and Trithorax genes (Trx) where PcG genes repress HOX gene transcription 
while Trx genes contribute to strong expression 161. Following their discovery in Drosophila, PcG 
genes have also been identified in humans where they appear to have a similar role, while the MLL 
(mixed lineage leukemia) gene and its homologs ares the only known human Trx homologs 162, 163. 
Recently, a miRNA-mediated mechanism for the posttranscriptional restriction of HOXB8 gene 
expression during vertebrate development has been suggested for miR-196 164. miR-196 directs the 
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cleavage of HOXB8 messenger RNA during mouse development, and other evidence suggests that 
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5. Research objectives 
 
 The aim of this thesis was the identification of new partner genes in chromosomal 
rearrangements affecting the T cell receptor (TCR) loci in T-ALL. This work was triggered by 
previous work on childhood ALL from our group which resulted in the detection of a cryptic 
chromosomal rearrangement between the TCRβ locus (7q34) and an unknown partner gene on 
chromosome 11q24 in a childhood T-ALL patient. 
 
Study of cryptic TCRβ rearrangements in T-ALL 
In a first step we decided to screen for additional cases of t(7;11)(q34;q24) in a cohort of 94 
T-ALL cases. To this purpose, FISH was used with BAC clones flanking the TCRβ locus (7q34). This 
lead to the detection of a new recurrent inv(7)(p15q34) involving the TCRβ and the HOXA cluster 
genes (7p15) (paper 1). 
 
Study of TCR  chromosomal rearrangements in T-ALL 
Given the unexpected high incidence of TCRβ chromosomal rearrangements in T-ALL, we 
decided to perform a comprehensive screening for rearrangements of all three TCR loci (TCRβ, 
TCRαδ and TCRγ) in an extend cohort of 126 T-ALLs. This provided the first complete and unbiased 
assessment of TCR chromosomal rearrangements in T-ALL (paper 2). This study also lead to the 
identification of the first HOXA chromosomal rearrangement with the TCRδ locus in a T-ALL patient 
already carrying a CALM-AF10 translocation (paper 4). 
 
Molecular and cytogenetic profile of patients carrying a t(7;7)(p15;q34) or 
inv(7)(p15q34) 
In order to get a comprehensive molecular and cytogenetic picture of the patients carrying 
the new TCRβ-HOXA chromosomal aberration and in search for additional patients, a large series of 
T-ALL patients (n= 424) from Belgium and France was investigated which yielded 5 additional cases. 
Subsequently, all 14 cases carrying a t(7;7)(p15;q34) or inv(7)(p15q34) were analysed in detail in 
order to determine the clinical and biological profile of this new T-ALL subentity (paper 3).  
 
Identification of new partner regions involved in TCR rearrangements in T-ALL 
Using the TCR screening strategy, we could detect three new TCR partner regions located at 
chromosome bands 6q22, 11q24 and 20q12 (paper 2). Further investigation of these regions could 







 Chapter I : Introduction 32 
6. References 
 
1. Boveri. Zur Frage der Entstehung malinger Tumoren. Hereditas 1914.  
2. Tjio Joe Hin LA. Classic pages in obstretics and gynecology. The chromosome number in 
man. Hereditas 1956; 42:  1-6. 
3. Caspersson T, Zech L, Johansson C, Modest EJ. Identification of human chromosomes by 
DNA-binding fluorescent agents. Chromosoma 1970; 30:  215-27. 
4. Mitelman F. ISCN (1995): An International System for Human Cytogenetic Nomenclature. 
S.Karger, Basel 1995.  
5. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous 
leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243:  
290-3. 
6. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004; 350:  
1535-48. 
7. Cherian S, Bagg A. The genetics of the myelodysplastic syndromes: classical cytogenetics 
and recent molecular insights. Hematology 2006; 11:  1-13. 
8. Glassman AB, Hayes KJ. The value of fluorescence in situ hybridization in the diagnosis and 
prognosis of chronic lymphocytic leukemia. Cancer Genet Cytogenet 2005; 158:  88-91. 
9. Schwaenen C, Nessling M, Wessendorf S, Salvi T, Wrobel G, Radlwimmer B et al. Automated 
array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical 
tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci U S A 2004; 101:  
1039-44. 
10. van Vlierberghe P, Meijerink JP, Lee C, Ferrando AA, Look AT, van Wering ER et al. A new 
recurrent 9q34 duplication in pediatric T-cell acute lymphoblastic leukemia. Leukemia 
2006; 20: 1245-53.  
11. Hosoya N, Sanada M, Nannya Y, Nakazaki K, Wang L, Hangaishi A et al. Genomewide 
screening of DNA copy number changes in chronic myelogenous leukemia with the use of 
high-resolution array-based comparative genomic hybridization. Genes Chromosomes Cancer 
2006; 45:  482-94. 
12. Menten B, Buysse K, Vandesompele J, De Smet E, De Paepe A, Speleman F et al. 
Identification of an unbalanced X-autosome translocation by array CGH in a boy with a 
syndromic form of chondrodysplasia punctata brachytelephalangic type. European journal 
of medical genetics 2005; 48:  301-9. 
13. Fauth C, Gribble SM, Porter KM, Codina-Pascual M, Ng BL, Kraus J et al. Micro-array analyses 
decipher exceptional complex familial chromosomal rearrangement. Human genetics 2006; 
119:  145-53. 
14. Gribble SM, Fiegler H, Burford DC, Prigmore E, Yang F, Carr P et al. Applications of 
combined DNA microarray and chromosome sorting technologies. Chromosome research 
2004; 12:  35-43. 
 Chapter I : Introduction 33 
15. De Pitta C, Tombolan L, Campo Dell'Orto M, Accordi B, te Kronnie G, Romualdi C et al. A 
leukemia-enriched cDNA microarray platform identifies new transcripts with relevance to 
the biology of pediatric acute lymphoblastic leukemia. Haematologica 2005; 90:  890-8. 
16. Jirtle RL. Genomic imprinting and cancer. Exp Cell Res 1999; 248:  18-24. 
17. Irving JA, Minto L, Bailey S, Hall AG. Loss of heterozygosity and somatic mutations of the 
glucocorticoid receptor gene are rarely found at relapse in pediatric acute lymphoblastic 
leukemia but may occur in a subpopulation early in the disease course. Cancer Res 2005; 
65:  9712-8. 
18. Raghavan M, Lillington DM, Skoulakis S, Debernardi S, Chaplin T, Foot NJ et al. Genome-
wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy 
due to somatic recombination in acute myeloid leukemias. Cancer Res 2005; 65:  375-8. 
19. Auerbach R, Huang H, Lu L. Hematopoietic stem cells in the mouse embryonic yolk sac. 
Stem Cells 1996; 14:  269-80. 
20. Zon LI. Developmental biology of hematopoiesis. Blood 1995; 86:  2876-91. 
21. Porcher C, Swat W, Rockwell K, Fujiwara Y, Alt FW, Orkin SH. The T cell leukemia 
oncoprotein SCL/tal-1 is essential for development of all hematopoietic lineages. Cell 1996; 
86:  47-57. 
22. Bonnet D. Haematopoietic stem cells. The Journal of pathology 2002; 197:  430-40. 
23. Plum J, De Smedt M, Leclercq G, Verhasselt B, Vandekerckhove B. Interleukin-7 is a critical 
growth factor in early human T-cell development. Blood 1996; 88:  4239-45. 
24. Zlotnik A, Moore TA. Cytokine production and requirements during T-cell development. 
Current opinion in immunology 1995; 7:  206-13. 
25. Moore NC, Anderson G, Smith CA, Owen JJ, Jenkinson EJ. Analysis of cytokine gene 
expression in subpopulations of freshly isolated thymocytes and thymic stromal cells using 
semiquantitative polymerase chain reaction. European journal of immunology 1993; 23:  
922-7. 
26. Karsunky H, Merad M, Cozzio A, Weissman IL, Manz MG. Flt3 ligand regulates dendritic cell 
development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic 
cells in vivo. The Journal of experimental medicine 2003; 198:  305-13. 
27. Rodewald HR. Pathways from hematopoietic stem cells to thymocytes. Curr Opin Immunol 
1995; 7:  176-87. 
28. Carding SR, Hayday AC, Bottomly K. Cytokines in T-cell development. Immunology today 
1991; 12:  239-45. 
29. Sanchez MJ, Muench MO, Roncarolo MG, Lanier LL, Phillips JH. Identification of a common 
T/natural killer cell progenitor in human fetal thymus. J Exp Med 1994; 180:  569-76. 
30. Staal FJ, Weerkamp F, Langerak AW, Hendriks RW, Clevers HC. Transcriptional control of t 
lymphocyte differentiation. Stem Cells 2001; 19:  165-79. 
31. Dik WA, Pike-Overzet K, Weerkamp F, de Ridder D, de Haas EF, Baert MR et al. New insights 
on human T cell development by quantitative T cell receptor gene rearrangement studies 
and gene expression profiling. J Exp Med 2005; 201:  1715-23. 
 Chapter I : Introduction 34 
32. Lieber M. Immunoglobulin diversity: rearranging by cutting and repairing. Curr Biol 1996; 6:  
134-6. 
33. Asnafi V, Beldjord K, Boulanger E, Comba B, Le Tutour P, Estienne MH et al. Analysis of 
TCR, pT alpha, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of 
early human T-lymphoid lineage commitment. Blood 2003; 101:  2693-703. 
34. Jones S. An overview of the basic helix-loop-helix proteins. Genome biology 2004; 5:  226. 
35. Tremblay M, Herblot S, Lecuyer E, Hoang T. Regulation of pT alpha gene expression by a 
dosage of E2A, HEB, and SCL. The Journal of biological chemistry 2003; 278:  12680-7. 
36. Bain G, Romanow WJ, Albers K, Havran WL, Murre C. Positive and negative regulation of 
V(D)J recombination by the E2A proteins. The Journal of experimental medicine 1999; 189:  
289-300. 
37. Herblot S, Steff AM, Hugo P, Aplan PD, Hoang T. SCL and LMO1 alter thymocyte 
differentiation: inhibition of E2A-HEB function and pre-T alpha chain expression. Nature 
immunology 2000; 1:  138-44. 
38. Begley CG, Aplan PD, Davey MP, Nakahara K, Tchorz K, Kurtzberg J et al. Chromosomal 
translocation in a human leukemic stem-cell line disrupts the T-cell antigen receptor delta-
chain diversity region and results in a previously unreported fusion transcript. Proc Natl 
Acad Sci U S A 1989; 86:  2031-5. 
39. Green AR, Salvaris E, Begley CG. Erythroid expression of the 'helix-loop-helix' gene, SCL. 
Oncogene 1991; 6:  475-9. 
40. Visvader J, Begley CG, Adams JM. Differential expression of the LYL, SCL and E2A helix-
loop-helix genes within the hemopoietic system. Oncogene 1991; 6:  187-94. 
41. Green AR, Lints T, Visvader J, Harvey R, Begley CG. SCL is coexpressed with GATA-1 in 
hemopoietic cells but is also expressed in developing brain. Oncogene 1992; 7:  653-60. 
42. Ferrando AA, Herblot S, Palomero T, Hansen M, Hoang T, Fox EA et al. Biallelic 
transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic 
leukemia. Blood 2004; 103:  1909-11. 
43. Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC et al. Gene expression 
signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer 
Cell 2002; 1:  75-87. 
44. Capron C, Lecluse Y, Kaushik AL, Foudi A, Lacout C, Sekkai D et al. The SCL relative LYL-1 is 
required for fetal and adult hematopoietic stem cell function and B-cell differentiation. 
Blood 2006; 107:  4678-86. 
45. Xia Y, Brown L, Yang CY, Tsan JT, Siciliano MJ, Espinosa R, III et al. TAL2, a helix-loop-helix 
gene activated by the (7;9)(q34;q32) translocation in human T-cell leukemia. Proceedings of 
the National Academy of Sciences of the United States of America 1991; 88:  11416-20. 
46. Wang J, Jani-Sait SN, Escalon EA, Carroll AJ, de Jong PJ, Kirsch IR et al. The 
t(14;21)(q11.2;q22) chromosomal translocation associated with T-cell acute lymphoblastic 
leukemia activates the BHLHB1 gene. Proceedings of the National Academy of Sciences of 
the United States of America 2000; 97:  3497-502. 
 Chapter I : Introduction 35 
47. Yamada Y, Pannell R, Forster A, Rabbitts TH. The oncogenic LIM-only transcription factor 
Lmo2 regulates angiogenesis but not vasculogenesis in mice. Proc Natl Acad Sci U S A 2000; 
97:  320-4. 
48. Yamada Y, Warren AJ, Dobson C, Forster A, Pannell R, Rabbitts TH. The T cell leukemia LIM 
protein Lmo2 is necessary for adult mouse hematopoiesis. Proc Natl Acad Sci U S A 1998; 
95:  3890-5. 
49. Boehm T, Foroni L, Kaneko Y, Perutz MF, Rabbitts TH. The rhombotin family of cysteine-rich 
LIM-domain oncogenes: distinct members are involved in T-cell translocations to human 
chromosomes 11p15 and 11p13. Proc Natl Acad Sci U S A 1991; 88:  4367-71. 
50. Rothenberg EV, Taghon T. Molecular genetics of T cell development. Annu Rev Immunol 
2005; 23:  601-49. 
51. Ting CN, Olson MC, Barton KP, Leiden JM. Transcription factor GATA-3 is required for 
development of the T-cell lineage. Nature 1996; 384:  474-8. 
52. Kitajima K, Tanaka M, Zheng J, Yen H, Sato A, Sugiyama D et al. Redirecting differentiation 
of hematopoietic progenitors by a transcription factor, GATA-2. Blood 2006; 107:  1857-63. 
53. Duncan AW, Rattis FM, DiMascio LN, Congdon KL, Pazianos G, Zhao C et al. Integration of 
Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat Immunol 2005; 6:  
314-22. 
54. Radtke F, Wilson A, Stark G, Bauer M, van Meerwijk J, MacDonald HR et al. Deficient T cell 
fate specification in mice with an induced inactivation of Notch1. Immunity 1999; 10:  547-
58. 
55. Grabher C, von Boehmer H, Look AT. Notch 1 activation in the molecular pathogenesis of T-
cell acute lymphoblastic leukaemia. Nat Rev Cancer 2006; 6:  347-59. 
56. Wolfer A, Wilson A, Nemir M, MacDonald HR, Radtke F. Inactivation of Notch1 impairs 
VDJbeta rearrangement and allows pre-TCR-independent survival of early alpha beta 
Lineage Thymocytes. Immunity 2002; 16:  869-79. 
57. Allman D, Punt JA, Izon DJ, Aster JC, Pear WS. An invitation to T and more: notch signaling 
in lymphopoiesis. Cell 2002; 109 Suppl:  S1-11. 
58. Artavanis-Tsakonas S, Matsuno K, Fortini ME. Notch signaling. Science 1995; 268:  225-32. 
59. Radtke F, Ferrero I, Wilson A, Lees R, Aguet M, MacDonald HR. Notch1 deficiency dissociates 
the intrathymic development of dendritic cells and T cells. J Exp Med 2000; 191:  1085-94. 
60. Wilson A, MacDonald HR, Radtke F. Notch 1-deficient common lymphoid precursors adopt a 
B cell fate in the thymus. J Exp Med 2001; 194:  1003-12. 
61. Wallin J, Eibel H, Neubuser A, Wilting J, Koseki H, Balling R. Pax1 is expressed during 
development of the thymus epithelium and is required for normal T-cell maturation. 
Development 1996; 122:  23-30. 
62. Manley NR, Capecchi MR. The role of Hoxa-3 in mouse thymus and thyroid development. 
Development 1995; 121:  1989-2003. 
63. Manley NR, Capecchi MR. Hox group 3 paralogs regulate the development and migration of 
the thymus, thyroid, and parathyroid glands. Dev Biol 1998; 195:  1-15. 
 Chapter I : Introduction 36 
64. Lawrence HJ, Helgason CD, Sauvageau G, Fong S, Izon DJ, Humphries RK et al. Mice bearing 
a targeted interruption of the homeobox gene HOXA9 have defects in myeloid, erythroid, 
and lymphoid hematopoiesis. Blood 1997; 89:  1922-30. 
65. Taghon T, Thys K, De Smedt M, Weerkamp F, Staal FJ, Plum J et al. Homeobox gene 
expression profile in human hematopoietic multipotent stem cells and T-cell progenitors: 
implications for human T-cell development. Leukemia 2003; 17:  1157-63. 
66. Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development 
and activation. Oncogene 2004; 23:  7990-8000. 
67. Kang SM, Narducci MG, Lazzeri C, Mongiovi AM, Caprini E, Bresin A et al. Impaired T- and B-
cell development in Tcl1-deficient mice. Blood 2005; 105:  1288-94. 
68. Sicinska E, Aifantis I, Le Cam L, Swat W, Borowski C, Yu Q et al. Requirement for cyclin D3 
in lymphocyte development and T cell leukemias. Cancer Cell 2003; 4:  451-61. 
69. Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N et al. Outcome of 
treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin 
Oncol 2004; 22:  4075-86. 
70. Annino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G et al. Treatment of adult 
acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 
randomized study. Blood 2002; 99:  863-71. 
71. De Keersmaecker K, Marynen P, Cools J. Genetic insights in the pathogenesis of T-cell acute 
lymphoblastic leukemia. Haematologica 2005; 90:  1116-27. 
72. McCormack MP, Forster A, Drynan L, Pannell R, Rabbitts TH. The LMO2 T-cell oncogene is 
activated via chromosomal translocations or retroviral insertion during gene therapy but has 
no mandatory role in normal T-cell development. Molecular and cellular biology 2003; 23:  
9003-13. 
73. Bain G, Engel I, Robanus Maandag EC, te Riele HP, Voland JR, Sharp LL et al. E2A deficiency 
leads to abnormalities in alphabeta T-cell development and to rapid development of T-cell 
lymphomas. Mol Cell Biol 1997; 17:  4782-91. 
74. Yan W, Young AZ, Soares VC, Kelley R, Benezra R, Zhuang Y. High incidence of T-cell tumors 
in E2A-null mice and E2A/Id1 double-knockout mice. Mol Cell Biol 1997; 17:  7317-27. 
75. O'Neil J, Shank J, Cusson N, Murre C, Kelliher M. TAL1/SCL induces leukemia by inhibiting 
the transcriptional activity of E47/HEB. Cancer Cell 2004; 5:  587-96. 
76. Bash RO, Hall S, Timmons CF, Crist WM, Amylon M, Smith RG et al. Does activation of the 
TAL1 gene occur in a majority of patients with T-cell acute lymphoblastic leukemia? A 
pediatric oncology group study. Blood 1995; 86:  666-76. 
77. Asnafi V, Beldjord K, Libura M, Villarese P, Millien C, Ballerini P et al. Age-related 
phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect 
thymic atrophy. Blood 2004; 104:  4173-80. 
78. van Grotel M, Meijerink JP, Beverloo HB, Langerak AW, Buys-Gladdines JG, Schneider P et 
al. The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic 
 Chapter I : Introduction 37 
leukemia: a retrospective study of patients treated according to DCOG or COALL protocols. 
Haematologica 2006; 91:  1212-21. 
79. Xia Y, Hwang LY, Cobb MH, Baer R. Products of the TAL2 oncogene in leukemic T cells: 
bHLH phosphoproteins with DNA-binding activity. Oncogene 1994; 9:  1437-46. 
80. McGuire EA, Hockett RD, Pollock KM, Bartholdi MF, O'Brien SJ, Korsmeyer SJ. The 
t(11;14)(p15;q11) in a T-cell acute lymphoblastic leukemia cell line activates multiple 
transcripts, including Ttg-1, a gene encoding a potential zinc finger protein. Mol Cell Biol 
1989; 9:  2124-32. 
81. Royer-Pokora B, Loos U, Ludwig WD. TTG-2, a new gene encoding a cysteine-rich protein 
with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). 
Oncogene 1991; 6:  1887-93. 
82. Larson RC, Osada H, Larson TA, Lavenir I, Rabbitts TH. The oncogenic LIM protein Rbtn2 
causes thymic developmental aberrations that precede malignancy in transgenic mice. 
Oncogene 1995; 11:  853-62. 
83. Van Vlierberghe P, van Grotel M, Beverloo HB, Lee C, Helgason T, Buijs-Gladdines J et al. 
The cryptic chromosomal deletion, del(11)(p12p13), as a new activation mechanism of LMO2 
in pediatric T- cell acute lymphoblastic leukemia. Blood 2006;  
84. Salvati PD, Ranford PR, Ford J, Kees UR. HOX11 expression in pediatric acute lymphoblastic 
leukemia is associated with T-cell phenotype. Oncogene 1995; 11:  1333-8. 
85. Ferrando AA, Neuberg DS, Dodge RK, Paietta E, Larson RA, Wiernik PH et al. Prognostic 
importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic 
leukaemia. Lancet 2004; 363:  535-6. 
86. Owens BM, Hawley TS, Spain LM, Kerkel KA, Hawley RG. TLX1/HOX11-mediated disruption 
of primary thymocyte differentiation prior to the CD4+CD8+ double-positive stage. Br J 
Haematol 2006; 132:  216-29. 
87. Keller G, Wall C, Fong AZ, Hawley TS, Hawley RG. Overexpression of HOX11 leads to the 
immortalization of embryonic precursors with both primitive and definitive hematopoietic 
potential. Blood 1998; 92:  877-87. 
88. Cave H, Suciu S, Preudhomme C, Poppe B, Robert A, Uyttebroeck A et al. Clinical 
significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of 
SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. 
Blood 2004; 103:  442-50. 
89. Berger R, Dastugue N, Busson M, Van Den Akker J, Perot C, Ballerini P et al. 
t(5;14)/HOX11L2-positive T-cell acute lymphoblastic leukemia. A collaborative study of the 
Groupe Francais de Cytogenetique Hematologique (GFCH). Leukemia 2003; 17:  1851-7. 
90. Ballerini P, Blaise A, Busson-Le Coniat M, Su XY, Zucman-Rossi J, Adam M et al. HOX11L2 
expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis. 
Blood 2002; 100:  991-7. 
91. Karrman K, Andersson A, Bjorgvinsdottir H, Strombeck B, Lassen C, Olofsson T et al. 
Deregulation of cyclin D2 by juxtaposition with T-cell receptor alpha/delta locus in 
 Chapter I : Introduction 38 
t(12;14)(p13;q11)-positive childhood T-cell acute lymphoblastic leukemia. European journal 
of haematology 2006; 77:  27-34. 
92. Clappier E, Cuccuini W, Cayuela JM, Vecchione D, Baruchel A, Dombret H et al. Cyclin D2 
dysregulation by chromosomal translocations to TCR loci in T-cell acute lymphoblastic 
leukemias. Leukemia 2006; 20:  82-6. 
93. Tanabe S, Zeleznik-Le NJ, Kobayashi H, Vignon C, Espinosa R, 3rd, LeBeau MM et al. Analysis 
of the t(6;11)(q27;q23) in leukemia shows a consistent breakpoint in AF6 in three patients 
and in the ML-2 cell line. Genes, chromosomes & cancer 1996; 15:  206-16. 
94. Dreyling MH, Martinez-Climent JA, Zheng M, Mao J, Rowley JD, Bohlander SK. The 
t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, 
encoding a new member of the AP-3 clathrin assembly protein family. Proc Natl Acad Sci U S 
A 1996; 93:  4804-9. 
95. Salmon-Nguyen F, Busson M, Daniel M, Leblanc T, Bernard OA, Berger R. CALM-AF10 fusion 
gene in leukemias: simple and inversion-associated translocation (10;11). Cancer Genet 
Cytogenet 2000; 122:  137-40. 
96. Carlson KM, Vignon C, Bohlander S, Martinez-Climent JA, Le Beau MM, Rowley JD. 
Identification and molecular characterization of CALM/AF10fusion products in T cell acute 
lymphoblastic leukemia and acute myeloid leukemia. Leukemia 2000; 14:  100-4. 
97. Kumon K, Kobayashi H, Maseki N, Sakashita A, Sakurai M, Tanizawa A et al. Mixed-lineage 
leukemia with t(10;11)(p13;q21): an analysis of AF10-CALM and CALM-AF10 fusion mRNAs 
and clinical features. Genes Chromosomes Cancer 1999; 25:  33-9. 
98. t(10;11)(p13-14;q14-21): a new recurrent translocation in T-cell acute lymphoblastic 
leukemias. Groupe Francais de Cytogenetique Hematologique (GFCH). Genes Chromosomes 
Cancer 1991; 3:  411-5. 
99. Asnafi V, Radford-Weiss I, Dastugue N, Bayle C, Leboeuf D, Charrin C et al. CALM-AF10 is a 
common fusion transcript in T-ALL and is specific to the TCRgammadelta lineage. Blood 
2003; 102:  1000-6. 
100. Dik WA, Brahim W, Braun C, Asnafi V, Dastugue N, Bernard OA et al. CALM-AF10+ T-ALL 
expression profiles are characterized by overexpression of HOXA and BMI1 oncogenes. 
Leukemia 2005; 19:  1948-57. 
101. De Keersmaecker K, Graux C, Odero MD, Mentens N, Somers R, Maertens J et al. Fusion of 
EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood 
2005; 105:  4849-52. 
102. Van Limbergen H, Beverloo HB, van Drunen E, Janssens A, Hahlen K, Poppe B et al. 
Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Genes 
Chromosomes Cancer 2001; 30:  274-82. 
103. Graux C, Cools J, Melotte C, Quentmeier H, Ferrando A, Levine R et al. Fusion of NUP214 to 
ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004; 36:  
1084-9. 
 Chapter I : Introduction 39 
104. Hussey DJ, Nicola M, Moore S, Peters GB, Dobrovic A. The (4;11)(q21;p15) translocation 
fuses the NUP98 and RAP1GDS1 genes and is recurrent in T-cell acute lymphocytic leukemia. 
Blood 1999; 94:  2072-9. 
105. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M et al. A TEL-JAK2 
fusion protein with constitutive kinase activity in human leukemia. Science 1997; 278:  
1309-12. 
106. Carron C, Cormier F, Janin A, Lacronique V, Giovannini M, Daniel MT et al. TEL-JAK2 
transgenic mice develop T-cell leukemia. Blood 2000; 95:  3891-9. 
107. Adelaide J, Perot C, Gelsi-Boyer V, Pautas C, Murati A, Copie-Bergman C et al. A t(8;9) 
translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma. Leukemia 2006; 20:  
536-7. 
108. Hebert J, Cayuela JM, Berkeley J, Sigaux F. Candidate tumor-suppressor genes MTS1 
(p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells 
from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood 1994; 84:  4038-
44. 
109. Bertin R, Acquaviva C, Mirebeau D, Guidal-Giroux C, Vilmer E, Cave H. CDKN2A, CDKN2B, 
and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 
deletions in childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 2003; 37:  
44-57. 
110. Heerema NA, Sather HN, Sensel MG, Liu-Mares W, Lange BJ, Bostrom BC et al. Association of 
chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic 
leukemia: A report from the Children's Cancer Group. Blood 1999; 94:  1537-44. 
111. van Zutven LJ, van Drunen E, de Bont JM, Wattel MM, Den Boer ML, Pieters R et al. CDKN2 
deletions have no prognostic value in childhood precursor-B acute lymphoblastic leukaemia. 
Leukemia 2005; 19:  1281-4. 
112. Mirebeau D, Acquaviva C, Suciu S, Bertin R, Dastugue N, Robert A et al. The prognostic 
significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic 
leukemia of childhood. Results of the EORTC studies 58881 and 58951. Haematologica 2006; 
91:  881-5. 
113. Mancini M, Scappaticci D, Cimino G, Nanni M, Derme V, Elia L et al. A comprehensive 
genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 
0496 protocol. Blood 2005; 105:  3434-41. 
114. Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-Irizarry C et al. Activating 
mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306:  
269-71. 
115. Feldman BJ, Hampton T, Cleary ML. A carboxy-terminal deletion mutant of Notch1 
accelerates lymphoid oncogenesis in E2A-PBX1 transgenic mice. Blood 2000; 96:  1906-13. 
116. Hoemann CD, Beaulieu N, Girard L, Rebai N, Jolicoeur P. Two distinct Notch1 mutant alleles 
are involved in the induction of T-cell leukemia in c-myc transgenic mice. Mol Cell Biol 
2000; 20:  3831-42. 
 Chapter I : Introduction 40 
117. Wolfe MS. Therapeutic strategies for Alzheimer's disease. Nat Rev Drug Discov 2002; 1:  859-
66. 
118. Paietta E, Ferrando AA, Neuberg D, Bennett JM, Racevskis J, Lazarus H et al. Activating 
FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. Blood 2004; 104:  
558-60. 
119. Van Vlierberghe P, Meijerink JP, Stam RW, van der Smissen W, van Wering ER, Beverloo HB 
et al. Activating FLT3 mutations in CD4+/CD8- pediatric T-cell acute lymphoblastic 
leukemias. Blood 2005; 106:  4414-5. 
120. Bijl JJ, van Oostveen JW, Walboomers JM, Horstman A, van den Brule AJ, Willemze R et al. 
HOXC4, HOXC5, and HOXC6 expression in non-Hodgkin's lymphoma: preferential expression 
of the HOXC5 gene in primary cutaneous anaplastic T-cell and oro-gastrointestinal tract 
mucosa-associated B-cell lymphomas. Blood 1997; 90:  4116-25. 
121. Lawrence HJ, Largman C. Homeobox genes in normal hematopoiesis and leukemia. Blood 
1992; 80:  2445-53. 
122. Lawrence HJ, Stage KM, Mathews CH, Detmer K, Scibienski R, MacKenzie M et al. Expression 
of HOX C homeobox genes in lymphoid cells. Cell Growth Differ 1993; 4:  665-9. 
123. Magli MC, Barba P, Celetti A, De Vita G, Cillo C, Boncinelli E. Coordinate regulation of HOX 
genes in human hematopoietic cells. Proc Natl Acad Sci U S A 1991; 88:  6348-52. 
124. Bijl J, van Oostveen JW, Kreike M, Rieger E, van der Raaij-Helmer LM, Walboomers JM et al. 
Expression of HOXC4, HOXC5, and HOXC6 in human lymphoid cell lines, leukemias, and 
benign and malignant lymphoid tissue. Blood 1996; 87:  1737-45. 
125. Dessain S, McGinnis W. Regulating the expression and function of homeotic genes. Curr Opin 
Genet Dev 1991; 1:  275-82. 
126. Sauvageau G, Lansdorp PM, Eaves CJ, Hogge DE, Dragowska WH, Reid DS et al. Differential 
expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone 
marrow cells. Proc Natl Acad Sci U S A 1994; 91:  12223-7. 
127. Chang CP, Brocchieri L, Shen WF, Largman C, Cleary ML. Pbx modulation of Hox 
homeodomain amino-terminal arms establishes different DNA-binding specificities across the 
Hox locus. Mol Cell Biol 1996; 16:  1734-45. 
128. Shen WF, Chang CP, Rozenfeld S, Sauvageau G, Humphries RK, Lu M et al. Hox 
homeodomain proteins exhibit selective complex stabilities with Pbx and DNA. Nucleic Acids 
Res 1996; 24:  898-906. 
129. Lowney P, Corral J, Detmer K, LeBeau MM, Deaven L, Lawrence HJ et al. A human Hox 1 
homeobox gene exhibits myeloid-specific expression of alternative transcripts in human 
hematopoietic cells. Nucleic Acids Res 1991; 19:  3443-9. 
130. Moretti P, Simmons P, Thomas P, Haylock D, Rathjen P, Vadas M et al. Identification of 
homeobox genes expressed in human haemopoietic progenitor cells. Gene 1994; 144:  213-
9. 
131. Vieille-Grosjean I, Roullot V, Courtois G. Identification of homeobox-containing genes 
expressed in hematopoietic blast cells. Biochem Biophys Res Commun 1992; 185:  785-92. 
 Chapter I : Introduction 41 
132. Lessard J, Baban S, Sauvageau G. Stage-specific expression of polycomb group genes in 
human bone marrow cells. Blood 1998; 91:  1216-24. 
133. Mathews CH, Detmer K, Boncinelli E, Lawrence HJ, Largman C. Erythroid-restricted 
expression of homeobox genes of the human HOX 2 locus. Blood 1991; 78:  2248-52. 
134. Shen WF, Largman C, Lowney P, Hack FM, Lawrence HJ. Expression of homeobox genes in 
human erythroleukemia cells. Adv Exp Med Biol 1989; 271:  211-9. 
135. Kappen C. Disruption of the homeobox gene Hoxb-6 in mice results in increased numbers of 
early erythrocyte progenitors. Am J Hematol 2000; 65:  111-8. 
136. Taketani T, Taki T, Ono R, Kobayashi Y, Ida K, Hayashi Y. The chromosome translocation 
t(7;11)(p15;p15) in acute myeloid leukemia results in fusion of the NUP98 gene with a HOXA 
cluster gene, HOXA13, but not HOXA9. Genes Chromosomes Cancer 2002; 34:  437-43. 
137. Taketani T, Taki T, Shibuya N, Kikuchi A, Hanada R, Hayashi Y. Novel NUP98-HOXC11 fusion 
gene resulted from a chromosomal break within exon 1 of HOXC11 in acute myeloid 
leukemia with t(11;12)(p15;q13). Cancer Res 2002; 62:  4571-4. 
138. Raza-Egilmez SZ, Jani-Sait SN, Grossi M, Higgins MJ, Shows TB, Aplan PD. NUP98-HOXD13 
gene fusion in therapy-related acute myelogenous leukemia. Cancer Res 1998; 58:  4269-73. 
139. La Starza R, Trubia M, Crescenzi B, Matteucci C, Negrini M, Martelli MF et al. Human 
homeobox gene HOXC13 is the partner of NUP98 in adult acute myeloid leukemia with 
t(11;12)(p15;q13). Genes Chromosomes Cancer 2003; 36:  420-3. 
140. Drabkin HA, Parsy C, Ferguson K, Guilhot F, Lacotte L, Roy L et al. Quantitative HOX 
expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia 
2002; 16:  186-95. 
141. Giampaolo A, Felli N, Diverio D, Morsilli O, Samoggia P, Breccia M et al. Expression pattern 
of HOXB6 homeobox gene in myelomonocytic differentiation and acute myeloid leukemia. 
Leukemia 2002; 16:  1293-301. 
142. Roche J, Zeng C, Baron A, Gadgil S, Gemmill RM, Tigaud I et al. Hox expression in AML 
identifies a distinct subset of patients with intermediate cytogenetics. Leukemia 2004; 18:  
1059-63. 
143. Debernardi S, Lillington DM, Chaplin T, Tomlinson S, Amess J, Rohatiner A et al. Genome-
wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of 
homeobox gene expression distinct from those with translocation-mediated fusion events. 
Genes Chromosomes Cancer 2003; 37:  149-58. 
144. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP et al. Molecular 
classification of cancer: class discovery and class prediction by gene expression monitoring. 
Science 1999; 286:  531-7. 
145. Sauvageau G, Thorsteinsdottir U, Hough MR, Hugo P, Lawrence HJ, Largman C et al. 
Overexpression of HOXB3 in hematopoietic cells causes defective lymphoid development 
and progressive myeloproliferation. Immunity 1997; 6:  13-22. 
 Chapter I : Introduction 42 
146. Knoepfler PS, Sykes DB, Pasillas M, Kamps MP. HoxB8 requires its Pbx-interaction motif to 
block differentiation of primary myeloid progenitors and of most cell line models of myeloid 
differentiation. Oncogene 2001; 20:  5440-8. 
147. Fujino T, Yamazaki Y, Largaespada DA, Jenkins NA, Copeland NG, Hirokawa K et al. 
Inhibition of myeloid differentiation by Hoxa9, Hoxb8, and Meis homeobox genes. Exp 
Hematol 2001; 29:  856-63. 
148. Fischbach NA, Rozenfeld S, Shen W, Fong S, Chrobak D, Ginzinger D et al. HOXB6 
overexpression in murine bone marrow immortalizes a myelomonocytic precursor in vitro 
and causes hematopoietic stem cell expansion and acute myeloid leukemia in vivo. Blood 
2005; 105:  1456-66. 
149. Buske C, Feuring-Buske M, Antonchuk J, Rosten P, Hogge DE, Eaves CJ et al. Overexpression 
of HOXA10 perturbs human lymphomyelopoiesis in vitro and in vivo. Blood 2001; 97:  2286-
92. 
150. Izon DJ, Rozenfeld S, Fong ST, Komuves L, Largman C, Lawrence HJ. Loss of function of the 
homeobox gene Hoxa-9 perturbs early T-cell development and induces apoptosis in primitive 
thymocytes. Blood 1998; 92:  383-93. 
151. Satokata I, Benson G, Maas R. Sexually dimorphic sterility phenotypes in Hoxa10-deficient 
mice. Nature 1995; 374:  460-3. 
152. Hsieh-Li HM, Witte DP, Weinstein M, Branford W, Li H, Small K et al. Hoxa 11 structure, 
extensive antisense transcription, and function in male and female fertility. Development 
(Cambridge, England) 1995; 121:  1373-85. 
153. Small KM, Potter SS. Homeotic transformations and limb defects in Hox A11 mutant mice. 
Genes & development 1993; 7:  2318-28. 
154. Thompson AA, Nguyen LT. Amegakaryocytic thrombocytopenia and radio-ulnar synostosis 
are associated with HOXA11 mutation. Nature genetics 2000; 26:  397-8. 
155. Desplan C, Theis J, O'Farrell PH. The sequence specificity of homeodomain-DNA interaction. 
Cell 1988; 54:  1081-90. 
156. Affolter M, Schier A, Gehring WJ. Homeodomain proteins and the regulation of gene 
expression. Curr Opin Cell Biol 1990; 2:  485-95. 
157. Boncinelli E, Simeone A, Acampora D, Mavilio F. HOX gene activation by retinoic acid. 
Trends Genet 1991; 7:  329-34. 
158. Popperl H, Featherstone MS. Identification of a retinoic acid response element upstream of 
the murine Hox-4.2 gene. Mol Cell Biol 1993; 13:  257-65. 
159. Simon J, Chiang A, Bender W. Ten different Polycomb group genes are required for spatial 
control of the abdA and AbdB homeotic products. Development 1992; 114:  493-505. 
160. van der Lugt NM, Alkema M, Berns A, Deschamps J. The Polycomb-group homolog Bmi-1 is a 
regulator of murine Hox gene expression. Mech Dev 1996; 58:  153-64. 
161. Pirrotta V. Polycombing the genome: PcG, trxG, and chromatin silencing. Cell 1998; 93:  
333-6. 
 Chapter I : Introduction 43 
162. Nam DK, Honoki K, Yu M, Yunis JJ. Alternative RNA splicing of the MLL gene in normal and 
malignant cells. Gene 1996; 178:  169-75. 
163. Hess JL, Yu BD, Li B, Hanson R, Korsmeyer SJ. Defects in yolk sac hematopoiesis in Mll-null 
embryos. Blood 1997; 90:  1799-806. 
164. Yekta S, Shih IH, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. Science 2004; 
304:  594-6. 
 
 
44Chapter I : Introduction 









CHAPTER II:  
 
STUDY OF GENOMIC REARRANGEMENTS OF THE 














Chapter II: Study of genomic rearrangements of the TCR loci in T-ALL 46 
CHAPTER II : Study of genomic rearrangements of the T-cell receptor loci in T-
cell acute lymphoblastic leukemia 
Paper 1:                  47 
A new recurrent inversion, inv(7)(p15q34) leads to transcriptional activation of 
HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias.                        
F. Speleman*, B. Cauwelier*, N. Dastugue, J. Cools, B. Verhasselt, B. Poppe, N. Van Roy, J. 
Vandesompele, C. Graux, A. Uyttebroeck, M. Boogaerts, B. De Moerloose, Y. Benoit, D. 
Selleslag,  J. Billiet, A. Robert, F. Huguet,  P. Vandenberghe, A. De Paepe, P. Marynen, A. 
Hagemeijer. * Both authors contributed equally. 
Leukemia, 2005, Mar 19(3):358-366.  
 
Paper 2:                  57 
Cytogenetic study of 126 unselected T-ALL cases and 19 T-ALL cell lines reveals 
unexpected high incidence of cryptic rearrangements of the TCRβ locus with at 
least 2 new recurrent partner genes.  
B. Cauwelier, N. Dastugue, J. Cools, B. Poppe, C. Herens, A. De Paepe , A. Hagemeijer, F. 
Speleman. 
Leukemia, 2006, Jul 20(7):1238-1244.  
 
 
Paper 3:                  65 
Clinical, cytogenetic and molecular characteristics of 14 T-ALL patients carrying 
the TCRβ-HOXA rearrangement: a study of the Groupe Francophone de 
Cytogénétique Hématologique (GFCH). 
B. Cauwelier, H. Cavé, C. Gervais , M. Lessard , C. Barin, C. Perot , J. Van den Akker, F. 
Mugneret , C. Charrin, M.P. Pagès, M.J. Grégoire, P. Jonveaux , M. Lafage-Pochitaloff, M. J. 
Mozzicconacci, C. Terré, I. Luquet, P. Cornillet-Lefebvre, B. Laurence, G. Plessis, C. 
Lefebvre, D. Leroux, H. Antoine-Poirel, C. Graux, L. Mauvieux,  P. Heimann, C. Chalas, E. 
Clappier, B. Verhasselt, Y. Benoit, B. De Moerloose, B. Poppe, N. Van Roy, K. De 
Keersmaecker, J. Cools, F. Sigaux, J. Soulier, A. Hagemeijer, A. De Paepe, N. Dastugue, R. 
Berger, F. Speleman. 
Leukemia, 2006, in press. 
 
Paper 4:                  75 
HOXA cluster deregulation by a TCRδ-HOXA chromosomal translocation in a 
CALM-AF10+ T-ALL.  
J. Bergeron, E. Clappier, B. Cauwelier, N. Dastugue, C. Millien, E. Delabesse, K. Beldjord, F. 
Speleman, J. Soulier, E. Macintyre, V. Asnafi. 
Leukemia, 2006, Jun 20(6):1184-1187.  
 












Paper 1:                   
A new recurrent inversion, inv(7)(p15q34) leads to transcriptional activation of 
HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias.                        
F. Speleman*, B. Cauwelier*, N. Dastugue, J. Cools, B. Verhasselt, B. Poppe, N. Van Roy, J. 
Vandesompele, C. Graux, A. Uyttebroeck, M. Boogaerts, B. De Moerloose, Y. Benoit, D. 
Selleslag,  J. Billiet, A. Robert, F. Huguet,  P. Vandenberghe, A. De Paepe, P. Marynen, A. 
Hagemeijer. * Both authors contributed equally. 


























































































A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of
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Chromosomal translocations with breakpoints in T-cell recep-
tor (TCR) genes are recurrent in T-cell malignancies. These
translocations involve the TCRad gene (14q11), the TCRb gene
(7q34) and to a lesser extent the TCRc gene at chromosomal
band 7p14 and juxtapose T-cell oncogenes next to TCR
regulatory sequences leading to deregulated expression of
those oncogenes. Here, we describe a new recurrent chromo-
somal inversion of chromosome 7, inv(7)(p15q34), in a subset
of patients with T-cell acute lymphoblastic leukemia character-
ized by CD2 negative and CD4 positive, CD8 negative blasts.
This rearrangement juxtaposes the distal part of the HOXA gene
cluster on 7p15 to the TCRb locus on 7q34. Real time
quantitative PCR analysis for all HOXA genes revealed high
levels of HOXA10 and HOXA11 expression in all inv(7) positive
cases. This is the ﬁrst report of a recurrent chromosome
rearrangement targeting the HOXA gene cluster in T-cell
malignancies resulting in deregulated HOXA gene expression
(particularly HOXA10 and HOXA11) and is in keeping with a
previous report suggesting HOXA deregulation in MLL-rear-
ranged T- and B cell lymphoblastic leukemia as the key factor in
leukaemic transformation. Finally, our observation also sup-
ports the previous suggested role of HOXA10 and HOXA11 in
normal thymocyte development.
Leukemia (2005) 19, 358–366. doi:10.1038/sj.leu.2403657
Published online 27 January 2005
Keywords: HOXA; inversion 7; T-ALL
Introduction
T-cell acute lymphoblastic leukemia (T-ALL) represents 10–15%
of childhood and 25% of adult ALLs, and are associated with an
intermediate prognosis within the total group of ALLs.1 In T-ALL,
chromosomal rearrangements affecting the T-cell receptor loci
(TCR) were among the ﬁrst to be detected. Similar to
translocations involving the IGH locus, these chromosomal
changes cause ectopic expression of target genes due to
juxtaposition to TCR gene enhancers. These pivotal studies
showed that T-ALLs were genetically very heterogeneous with
the most frequently detected translocation, the t(11;14)(p15;q11),
being found in less than 10% of cases.2 One particular rare
translocation, t(1;14)(p32;q11), lead to the discovery of the
TAL1(SCL) gene that turned out to be of crucial importance
in normal T-cell development. Most interestingly, TAL1(SCL)
was later shown to be transcriptionally activated due to a cryptic
90 kb interstitial deletion in as much as 20% of T-ALLs, thus
representing the most frequent genetic abnormality in this
disease.3 Similarly, other T-cell leukemia speciﬁc genes
(HOX11, LYL1, LMO1, LMO2, HOX11L2), initially identiﬁed
through rare chromosomal rearrangements involving TCR loci,
were also shown to be transcriptionally activated in T-ALLs
without evidence for particular translocations. Also, recent
studies showed biallelic overexpression of some of these genes
thus further supporting the notion for a broader implication in
T-ALL through mechanisms other than the known translocation
events.4 Furthermore, the unexpected ﬁnding of ampliﬁcation of
a NUP214/ABL1 fusion gene in a minority of T-ALL patients,5,6
further illustrated the diversity of genetic events involved in
T-ALLs. Likewise, the NOTCH1 gene, involved in the
t(7;9)(q34;q34) in less than 1% of T-ALLs, was shown to harbor
activating mutations in more than 50% of T-ALLs.7
Although involvement of each of the three TCR loci in
recurrent chromosomal changes in T-ALL is well recognized,8
both the incidence and the exact contribution of each of
these loci in recurrent chromosome abnormalities have
not yet been assessed in detail. The ﬁnding of a previously
unreported t(7;11)(q34;q24) in a child with T-ALL, as the
result of a multicolor ﬂuorescence in situ hybridization
(M-FISH) study on T-ALLs, prompted us to screen a large cohort
of 94 patients with T-ALL. This resulted in the ﬁnding of a new
recurrent chromosomal rearrangement, that is, a pericentric
inversion of chromosome 7, inv(7)(p15q34), in a subset of T-ALL
patients. This inversion was associated with an elevated
expression of HOXA10 and HOXA11, most probably due to
juxtaposition near strong enhancers embedded within the TCRb
locus. This is the second report providing evidence




Diagnostic bone marrow, peripheral blood or pleural ﬂuid
samples from 49 adults and 45 children with T-ALL were
collected from three institutes, retrospectively. For 32 T-ALL
cases (16 children and 16 adults) frozen cells were available for
expression analysis. These selected cases contained all cases
positive for TCRb chromosomal rearrangement and 13 cases
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without TCRb rearrangement, which were investigated by FISH
(see below). Table 1 lists biological and cytogenetic ﬁndings for
these patients. Total child thymocyte suspension (CT) and
puriﬁed CD34þ thymus cells (CD34þ T) were isolated as
described before.9
Immunophenotyping
Immunophenotypic studies were carried out in the respective
centers according to established protocols. Cases were classiﬁed
using the European Group for the Immunological Characteriza-
tion of Leukemias (EGIL) recommendations.10 Brieﬂy, EGIL T1
(pro-T ALL) was deﬁned by the presence of only CD7, T2 (pre-T
ALL) by CD2 and/or CD5 and/or CD8 positivity, T3 (cortical
T-ALL) by CD1a positivity and T4 (mature T-ALL) by the
presence of surface CD3 and lack of CD1a.
Cytogenetic studies
The different diagnostic specimens (bone marrow, blood and
pleural ﬂuid) were cultured and harvested for cytogenetic
analysis according to established methods. Chromosome slides
were G-, Q- or R-banded. Chromosome aberrations are
described according to guidelines of an International System
for Human Cytogenetic Nomenclature (ISCN 1995).11
Table 1 Biological characteristics and cytogenetic ﬁndings of TCRb positive (case n1 1–19; with identiﬁed partner gene) and negative T-ALL
patients (case n1 20–32)
Case
no.
Age Sex Karyotype TCRb partner
gene
Revised karyotype
1 4 M 46,XY, t(1;14)(p32;q11) [20] Unknown 46,XY, t(1;14)(p32;q11), t(6;10)(q25;q24),
t(7;11)(q34;q24)a
2 19 M 46, XY, t(1;7)(p32;q34), del(6)(q12q16) [14]/46, XY [1] TAL1 (1p32) 46, XY, t(1;7)(p32;q34), del(6)(q12q16)
[14]/46, XY [1]
3 45 M 46,XY [9] Unknown 46,XY, t(7;?)(q34;?) [9]
4 6 M 47,XY,+8,del(9)(p21) [3]/46,XY [8] Unknown 47,XY, t(7;?)(q34;?),+8, del(9)(p21)
[3] /46,XY [8]
5 12 F 46, XX,del(6)(q23q26),add(7)(q31),del(11)(q13),
14,+mar mar ¼?der(1) i(1)(q10)add(1)(q32)
[18]/92, idem x 2 [2]
Unknown 46, XX,del(6)(q23q26),
t(7;?)(q34;?),del(11)(q13),14,+mar
mar ¼ ?der(1) i(1)(q10)add(1)(q32) [18]/92,
idem x 2 [2]
6 6 M 46,XY,del(7)(q21),?inv(14)(q11q32) [14]/46,XY [6] Unknown 46,XY,t(7;?)(q34;?),?inv(14)(q11q32)
[14]/46,XY [6]
7 15 F 46,XX [20] RBTN2 (11p13) 46,XX, t(7;11)(q34;p13) [20]
8 10 M 46,XY [20] Unknown 46,XY, t(7;?)(q34;?) [20]
9 9 F 46,XX,del(7)(q34),t(10;14)(q22;q32) [11] RBTN1 (11p15) 46,XX,t(7;11)(q34;p15),t(10;14)(q22;q32) [11]
10 9 M 46,XY,t(8;14)(q24;q11) [8]/46,XY [9] RBTN1 (11p15) 46,XY,t(8;14)(q24;q11), t(7;11)(q34;p15)
[8]/46,XY [9]
11 26 M 46,XY[20] Unknown 46,XY, t(7;?)(q34;?) [20]
12 15 M 47,XY,t(7;9)(q34;q34),+20 [2]/47,
idem, add(11)(q24) [9]
TAN1 (9q34) 47,XY,t(7;9)(q34;q34),+20 [2]/47, idem,
add(11)(q24) [9]
13 30 M 46–47,XY,+mar1, +mar2, [cp5] Unknown 46–47,XY, t(7;?)(q34;?), +mar1, [cp5]
14 23 M 42–48,XY,t(3;11)(p12;p15),t(7;10)(q35;q24),
t(8;10)(q21;q?24),
+11, +12 [5]/46,XY [4]
HOX11 (10q24) 42–48,XY,t(3;11)(p12;p15),t(7;10)(q35;q24),
t(8;10)(q21;q?24), +11, +12 [5]/46,XY [4]
15 35 F 46,XX [4] failure HOXA (7p15) 46,XX, inv(7)(p15q34) [4]
16 27 F 46, XX, add(5)(q31) [11]/ 46, XX [9] HOXA (7p15) 46, XX, add(5)(q31), inv(7)(p15q34) [11]/
46, XX [9]
17 15 M 46,XY [20] HOXA (7p15) 46,XY, inv(7)(p15q34) [20]
18 34 M 46,XY [20] HOXA (7p15) 46,XY, inv(7)(p15q34) [20]




20 35 M 46, XY, t(9;20)(p21;q12), t(10;14)(q24;q11),
del(12)(p12) [13]/46, XY [12]
Negative
21 26 M 46,XY,t(6;11)(q21–22;p15),add(12)(p13)
[17]/46,XY [3]
Negative
22 35 M 46, XY [20] Negative
23 27 M 47, XY, t(7;14)(p12;q24), del(9)(q21q31),
+10 [16]/46, XY [4]
Negative
24 35 M 46, XY [25] Negative
25 24 M 46, XY [25] Negative
26 45 M 47, XY, +8 [2]/ 46, XY[20] Negative
27 5 M 47,XY,del(6)(q12),+8, del(10)(q24)[5]/ 46,XY [18] Negative 47,XY,del(6)(q12),+8, del(10)(q24), t(5;14)
(q35;q32)* [5]/ 46,XY [18]
28 9 M 46,XY [20] Negative
29 9 M 46,XY [20] Negative
30 3 M 46,XY,add(19)(p13.3),del(6)(q15q24) [6]/ 46,XY [13] Negative
31 15 M 46,XY,add(14)(q32) [9]/46,XY [18] Negative
32 16 F 46,XX,del(1)(q32),del(5)(q22q34),7,+mar [5]/46,XX [7] Negative
aIncluding M-FISH analysis.







































Fluorescence in situ hybridization (FISH)
Cytogenetic cell suspensions (methanol/acetic acid ﬁxed cells)
or unstained slides were available for all 94 patients. For FISH
the following TCRb (7q34) and HOXA (7p15) ﬂanking BAC
clones were selected: RP11-1220K2 (located centromeric to
TCRb) and RP11-556I13 (located telomeric to TCRb); RP1-
167F23 (containing telomeric HOXA genes HOXA1, HOXA2
and part of HOXA3) and RP5-1103I5 (located centromeric to
HOXA); RP11-1036C18, RP11-163M21, RP11-1132K14 and
RP11-1025G19 clones represent a contig spanning the entire
HOXA gene cluster (Figure 2). For further delineation of the
TCRb breakpoint, following gene covering clones were selected:
RP11-785K24 (centromeric) and RP11-701D14 (telomeric)
(Figure 3).
RPCI-11 (Human BAC Library) clones were provided by the
Welcome Trust Sanger Institute (Cambridge, UK) and Invitrogen
(Paisley, Scotland). Clone DNA isolation, labeling and FISH
were performed as previously described,12 using biotin-16-
dUTP and digoxigenin-11-dUTP (Roche Diagnostics Belgium,
Vilvoorde, Belgium) as haptens.
Disruption of the TCRb locus was assessed by dual color FISH
with TCRb ﬂanking probes (RP11-1220K2 and RP11-556I13).
Cases carrying TCRb chromosomal rearrangement (identiﬁed by
a split signal of the ﬂanking probes) were further analyzed to
conﬁrm the presumed TCRb partner genes using ﬂanking probes
for the respective partner loci (RBTN1 on 11p15, RBTN2 on
11p13, HOX11 on 10q24, TAN1 on 9q34, TAL1(SCL) on 1p32).
For those cases, which showed inversion of the distal TCRb
ﬂanking probe to 7p, dual color FISH using HOXA ﬂanking
probes was performed.
Hybridization signals were evaluated by two independent
observers and interpreted at the interphase (100 nuclei) and
metaphase level (when available).
RNA isolation, cDNA synthesis and quantitative
real-time RT-PCR
Patients were selected retrospectively on the basis of the
availability of frozen material at diagnosis. All human samples
were obtained according to the guidelines of the local ethical
committees. These included 13 TCRb positive cases including
ﬁve inv(7) positive and 13 TCRb negative cases. Cells obtained
from total child thymus (CT), and puriﬁed CD34þ thymocytes
(CD34þ T) were used as a reference for HOX gene expression
in normal developing T-cells.13 RNA was isolated using Trizol
(Invitrogen, Merelbeke, Belgium) and RNeasy Mini Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions.
DNase treatment, cDNA synthesis, primer design and SYBR
Green I quantitative real-time RT-PCR were performed as
previously described.14 Reactions were performed on an ABI
Prism 5700 Sequence Detector (Applied Biosystems, Foster City,
CA, USA). Real-time quantitative PCR data analysis and
expression normalization were performed using three internal
control genes (RPL13A, UBC, YWHAZ), as described15 and
correlated to the mean expression level of each gene. Primers for
HOXA1, HOXA4, HOXA5, HOXA7, HOXA11 were designed
according to Thompson et al.16 Primers for the other HOXA
genes (HOXA2, HOXA3, HOXA6, HOXA9, HOXA10,
HOXA13) and for HOXB3 and HOXC4 expression analysis
were designed and developed according to Wang et al17 at the
Primer Bank. Primer sequences for the tested genes are
deposited in RTPrimerDB, a public database for real-time PCR
primers (http://medgen.ugent.be/rtprimerdb) (RTPrimerDB).18
Data analysis
Statistical analysis was performed using SPSS Software (SPSS
Inc., Chicago, IL, USA) version 12.0. The nonparametric Mann–
Whitney U test (two-tailed) was used to evaluate the signiﬁ-
cance of difference in mean expression levels between the
patients subgroups (inv(7) positive vs inv(7) negative patients).
The Fisher exact test was used to evaluate the relationship between
the speciﬁc immunophenotype and the presence of the inv(7).
Results
Frequency of chromosomal rearrangements affecting
the TCRb locus in T-ALL
A previously conducted M-FISH analysis in one T-ALL patient
(case no. 1) with a known t(1;14)(p32;q11) and TAL1(SCL)
overexpression, uncovered a cryptic translocation
t(7;11)(q34;q24) affecting the TCRb locus. No known T-cell
oncogene is located on distal 11q and breakpoint analysis is
currently ongoing. FISH screening for TCRb chromosomal
rearrangements in a large series of 93 T-ALLs yielded split
signals for the TCRb locus in 18 cases, which brings the total of
detected TCRb alterations to 20% (19/94). In six of these 19
cases, the distal probe for TCRb was translocated to recurrent
TCRb partner genes: TAL1 (case no. 2), RBTN2 (case no. 7),
RBTN1 (cases no. 9–10), TAN1 (case no. 12), HOX11 (case no.
14) as conﬁrmed by FISH with the appropriate probes (Table 1).
In eight of the 19 cases showing TCRb rearrangement,
involvement of known partner genes was excluded. Interest-
ingly, in ﬁve other cases with split signals for the TCRb ﬂanking
probes, the telomeric BAC clone for TCRb moved to the distal
end of the short arm of chromosome 7, thus revealing the
presence of a pericentric inversion with an unknown partner
gene (Figure 1a).
Biological characteristics, immunophenotyping and
cytogenetics
Biological characteristics for all TCRb positive cases (cases no.
1–19) and selected TCRb negative T-ALLs (case no. 20–32) are
summarized in Table 1. TCRb positive cases with inv(7), aged
15–49 years (median 32 years), showed an M/F ratio: 1.5:1.0.
TCRb positive cases without inv(7) showed a lower age of onset
compared to inv(7) positive cases: median 16.6 years (range 4–
45 years) and a pronounced male predominance (M/F ratio
3.6:1.0). Compared to inv(7) positive cases, TCRb negative cases
also showed a lower age of onset with a median of 21.8 years
(range 3–45 years) and a striking male predominance (M/F ratio
12:1).
Immunophenotypic ﬁndings from all but two cases are listed
in Table 2. Inv(7) positive cases were classiﬁed as either T3
(n¼ 1) or T4 (n¼ 4) T-ALL immunophenotypes but with a
distinct pattern of CD2 and CD8 negativity and CD1a, CD4,
CD5, CD7 and CD10 positivity. Four inv(7) positive cases were
analyzed for CD13 and CD33 expression and were found to be
negative.
Cytogenetic analysis showed abnormal karyotypes in 11 out
of 19 TCRb positive cases (Table 1). Translocations affecting the
7q34 locus were detected upon banding analysis in three of 19
cases and partial deletions of chromosome 7q or 7p in three
cases; one case showed additional material on 7q. Altoge-
ther, TCRb genomic rearrangement was unsuspected from
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cytogenetic analysis in 16/19 cases, partly due to inferior quality
of metaphase chromosomes in T-ALL. Details on cytogenetic
ﬁndings for all 94 cases including additional FISH analysis for
the other TCR loci will be reported elsewhere (Cauwelier et al,
in preparation).
Inv(7)(p15q34) is a new recurrent rearrangement in T-ALL
Since the HOXA gene cluster is known to be involved in normal
human T-cell development,13 this locus was considered as
candidate partner gene for rearrangement with the TCRb locus.
Therefore, dual color hybridization was performed on the inv(7)
positive cases using probes ﬂanking the HOXA gene cluster
located at 7p15 (RP1-167F23 telomeric and RP5-1103I5
centromeric clones). In all ﬁve inv(7) positive cases, a split for
the HOXA ﬂanking probes was observed, with the telomeric
clone being inverted to distal 7q (Figure 1b). To conﬁrm these
results, we combined the centromeric ﬂanking TCRb probe
RP11-1220K2 with the telomeric HOXA ﬂanking probe RP1-
167F23, which yielded the expected fusion signals on the
inverted chromosome 7 in metaphases as well as in interphase
nuclei (Figure 1c).
Figure 1 Dual colour FISH results using (a) TCRb ﬂanking probes RP11-1220K2 (green) and RP11-556I13 (red) demonstrating disruption of the
TCRb locus due to the inv(7) (case no. 18); (b) HOXA ﬂanking centromeric probe RP5-1103I5 (green) with the telomeric and partly covering probe
RP1-167F23 (red) demonstrating disruption of the HOXA gene cluster due to the inv(7) (case no. 18); (c) centromeric ﬂanking TCRb probe RP11-
1220K2 (green) with the telomeric HOXA ﬂanking probe RP1-167F23 (red), which yielded the expected fusion signals on the inverted
chromosome 7 in interphase nuclei (case no. 17); (d) HOXA covering probes RP11-1132K14 (red) and RP11-1025G19 (green) revealing two fusion
signals and an extra red signal (case no. 16); (e) HOXA covering probes RP11-163M21(red) and RP11-1025G19 (green) yielding one fusion and
one split signal (case no. 16); (f) HOXA covering probes RP11-1036C19(red) and RP11-1025G16(green) yielding one fusion and one split
signal(case no. 16); (g) TCRb covering clones RP11-785K24 (red) and RP11-701D14 (green) gave the expected split signals in inv(7) (case no. 17).
Table 2 Immunophenotype of 30 T-ALL patients
Case no. 1 2 4 5 6 7 8 9 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
CD34 60 2 0 0 1 0 0 54 nd 0 0 56 3 0 0 0 nd 0 0 0 88 1 0 0 3 0 3 31 0 82
cyCD3 90 99 99 nd 99 49 82 100 nd 95 nd 92 98 94 86 nd nd 24 91 98 90 59 99 98 76 99 nd 89 88 37
CD2 86 99 100 73 99 96 50 91 0 100 100 79 2 6 0 26w 9 96 99 17 1 97 99 99 75 0 nd 92 99 13
CD7 86 99 99 70 99 95 99 87 99 97 97 95 96 73 98 99 72 96 99 97 98 94 99 99 88 99 nd 92 98 92
CD5 88 99 99 76 15 96 97 92 96 98 99 96 96 74 91 98 94 95 99 87 86 96 99 99 43 80 nd 92 98 72
CD1a 38 24 98 56 88 0 0 5 50w 98 97 40 75 41 43 98 5 94 0 0 0 2 21 99 14w 60 nd 29 0 0
CD3m 80 95 99 98 95 23 98 96 59 1 2 1 3 73 85w 98 73 3 0 97 0 21 98 0 50w 83 3 60 96 0
CD4 22 56 99 13 1 36 95 3 50w 0 98 20 93 58 43 75 48 95 0 1 0 92 80 100 54 76 0 0 69 0
CD8 12 96 99 76 99 74 96 5 84 99 34 91 1 15 0 1 3 50 0 1 0 95 90 100 15 15 95 60 86 0
CD10 0 2 99 74 99 16 0 0 97 96 1 94 95 69 73 70 92 50 99 0 11 9 20 99 0 37 98 73 34 77
TCRgd 0 0 0 2 1 0 0 0 57w 0 nd nd 2 56 0 nd 1 0 0 87 0 1 0 0 0 45 nd 2 0 0
TCRab 0 93 49 3 1 0 0 99 0 0 nd nd 0 5 0 nd 6 3 0 3 0 20 97 99 0 0 nd 8 0 0
EGIL T4 T4 T4 T4 T4 T4 T4 T4 T4 T3 T3 T3 T3 T4 T4 T4 T4 T3 T2 T4 T2 T4 T4 T3 T4 T4 ? T4 T4 T2
TCRb + + + + + + + + + + + + + + + + +             
Data represent % of blast cells positive for the respective antigen (CD); nd: not done; w: weak.
TCRb genomic rearrangement: +: present; : absent.
Case numbers correspond to those in table n11.
Antigens are arranged in order in which they appear during T-cell differentiation.
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Further characterization of the chromosome 7p breakpoint
using three different probe combinations covering the HOXA
locus (Figure 2) yielded similar hybridization patterns in all ﬁve
inv(7) positive cases. For each of the three probe combinations
(centromeric clone RP11-1025G19 combined with more
telomeric located clones RP11-1036C18, RP11-163M21 or
RP11-1132K14, respectively) split signals of the combined
probes and complete (RP11-1036C18, RP11-163M21) or partial
(RP11-1132K14) inversion of the more telomeric located probes
were observed (Figure 1d–f). Consequently, these experiments
further conﬁrmed the localization of the inversion 7p15 break-
point within the HOXA gene cluster and more speciﬁcally
allowed us to assign the breakpoint to the region covered by
BAC clone RP11-1132K14. Given the relative position of the
four BAC clones used in these experiments and absence of
disruption of RP11-1036C18, RP11-163M21 or RP11-1025G19,
we assume that the most probable position of the 7p15
breakpoint is within a B20 kb segment located between
HOXA5 and HOXA9 (Figure 2).
Two clones spanning most of the TCRb locus (RP11-785K24
centromeric and RP11-701D14 telomeric) revealed split signals
in all inv(7) positive cases (Figure 1g), and thus conﬁrmed the
involvement of the TCRb gene in the inv(7) positive cases
(Figure 3). Moreover, in two inv(7) positive cases a partial
deletion of the centromeric TCRb probe in 95% (case no. 15) and
96% of cells (case no. 18) carrying the inversion was observed.
Real time quantitation of gene expression for HOXA,
HOXB3 and HOXC4 genes
Expression level measurements of all eleven members of the
HOXA gene cluster (HOXA1, HOXA2, HOXA3, HOXA4,
HOXA5, HOXA6, HOXA7, HOXA9, HOXA10, HOXA11 and
HOXA13) were performed on a total of 26 patient samples, total
CT and CD34þ puriﬁed child thymocytes (CD34þ T). Patient
samples included ﬁve inv(7) positive cases (group A), eight TCRb
positive without inv(7) (group B) and 13 TCRb negative selected
cases (group C). As no signiﬁcant differences in the observed
expression pattern was noted for group B as compared to group
C (Student’s t-test: P40.05), both patient groups were joined
and inv(7) positive cases were compared to inv (7) negative
cases. A high HOXA10 and HOXA11 expression was noted for
all inv(7) positive cases whereas two inv(7) negative T-ALLs
showed similar increased levels of HOXA10 and HOXA11
transcripts (cases no. 21 and 22) (Figure 4A, B). Levels of
HOXA10 and HOXA11 expression in total CT and CD34þ
puriﬁed child thymocytes were comparable but at least 10-fold
lower than the mean expression of these genes in inv(7) positive
T-ALL samples. HOXA11 expression levels were statistically
signiﬁcant increased in the inv(7) positive cases vs inv(7)
negative cases (P¼ 4.5 10E-4 and P¼ 8.8 10E-4, respec-
tively), the latter showing only marginal expression for HOXA10
and HOXA11. HOXA9 expression was slightly increased in
inv(7) positive patients as compared to the inv(7) negative
samples (P¼ 1.8 10E-3). Remarkably, in one inv(7) positive
case (no. 15), all other HOXA genes also showed increased
expression (Figure 4C(a) and (b)). Likewise, one inv(7) negative
case (no. 28) showed elevated expression for all HOXA genes
except for HOXA11 (Figure 4C(a) and (b)). For these three cases
showing elevated expression for HOXA10 and/or HOXA11
(cases no. 21, no. 22, no. 28), dual color FISH using the HOXA
ﬂanking probes was performed to evaluate disruption of the
HOXA gene cluster but no evidence for any disruption of the
HOXA gene cluster was found.
In addition to HOXA gene expression, we tested the inv(7)
positive patients, total CT cells and CD34þ puriﬁed child
thymocytes (CD34þ T) for expression of HOXB3 and HOXC4
Figure 2 Base position of HOXA ﬂanking (RP11-167F23 telomeric and RP11-1103I5 centromeric) and HOXA covering clones (RP11-
1132K14, RP11-1036C18, RP11-163M21 and RP11-1025G19), according to UCSC Genome Browser May 2004 Freeze.
Figure 3 Base position of TCRb ﬂanking (RP11-1220K2 centromeric and RP11-556I13 telomeric) and covering clones (RP11-785K24, RP11-
701D14), according to UCSC Genome Browser May 2004 Freeze.









































gene expression since, according to Taghon et al,13 these were
the only homeobox genes apart from HOXA7, HOXA9,
HOXA10 and HOXA11 that were expressed at all major stages
of human thymopoiesis. In comparison with child thymocytes
and CD34þ puriﬁed child thymocytes, HOXB3 was only
weakly expressed in the inv(7) positive patients whereas HOXC4
expression was clearly detected in all inv(7) positive patients
and slightly higher than expression levels of total child
thymocytes and CD34 puriﬁed child thymocytes (Figure 5).
Discussion
In this study, we describe a new recurrent chromosomal
alteration, a pericentric inversion of chromosome 7,
inv(7)(p15q34), in ﬁve patients with T-ALL leading to disruption
of the HOXA gene cluster and juxtaposition to sequences within
the TCRb locus. As a consequence of this rearrangement,
increased HOXA10 and HOXA11 expression was evident in all
inv(7)(p15q34) positive cases as compared to most inv(7)
negative T-ALLs.
A number of ﬁndings support our assumption that this
inv(7)(p15q34) indeed represents a new recurrent chromosomal
abnormality in T-ALL. First of all, FISH results with BAC clones
covering the HOXA gene cluster at 7p15 were similar in all
cases and were in keeping with a breakpoint cluster within the
B107 kb genomic region containing all HOXA genes, most
probably distal to HOXA5 and proximal to HOXA10. Second,
gene expression analysis showed consistent increased expres-
sion of HOXA10 and HOXA11 in all inv(7) positive cases.
Thirdly, all inv(7) positive T-ALLs were classiﬁed as mature T-
ALLs (T3–4 group according to the EGIL recommendations10)
but with characteristic CD2 negative CD4 positive, CD8
negative blast cells.
The present study was initially triggered by the ﬁnding of a
cryptic t(7;11)(q34;q24) in an M-FISH study of childhood ALLs
with complex karyotypic rearrangements. Based upon this
observation, we anticipated that the distal chromosomal
localization of the TCRb locus might also predispose to the
formation of other undetected rearrangements, which indeed
turned out to be the case as demonstrated by the ﬁnding of the
recurrent inv(7)(p15q34). In addition to this new discovery, the
ﬁnding of chromosomal rearrangements affecting the TCRb
locus in as much as 20% in an unselected group of T-ALLs is in
itself remarkable. Although the study by Gesk et al8 showed a
relatively high proportion of TCRb rearrangements in a series of
T-ALLs with cytogenetically detectable rearrangements affecting
Figure 4 (A) Geometric averages of normalized expression of
HOXA10 in inv(7) positive T-ALL cases (white boxes), inv(7) negative
T-ALL cases (black boxes), total child thymocytes (CT) and CD34þ
sorted stem cells (CD34þ T). (B) Geometric averages of normalized
expression of HOXA11 in inv(7) positive T-ALL cases (white boxes),
inv(7) negative T-ALL cases (black boxes), total child thymocytes (CT)
and CD34þ sorted stem cells (CD34þ T). (C (a and b)) Global
overview of normalized expression of all class I HOX genes tested in
inv(7) positive T-ALLs (cases no. 15–19), inv(7) negative T-ALLs (cases
no. 2–11 and no. 20–32) and total child thymocytes (CT).
Figure 5 Geometric averages of normalized expression of HOXB3
and HOXC4 in inv(7) positive T-ALL cases (no. 15–19), total child
thymocytes (CT) and CD34þ sorted stem cells (CD34þT).








































the TCR loci, no systematic study on unselected cases
investigating TCRb rearrangements has been reported thus far.
The high percentage of TCRb rearrangements is only partly
explained by the presence of the ﬁve inv(7) cases. Indeed, for 8/
19 TCRb positive cases, FISH screening for known TCRb
partners was negative and further testing for partner identiﬁca-
tion is currently ongoing. In addition, some chromosomal
disruptions of the TCRb locus were found in patients with
apparent normal karyotypes and representing partly cryptic
rearrangements with known T-cell oncogenes such as RBTN2
and RBTN1 with subtelomeric localization.
Homeobox genes are a particular class of transcription factors
that play an important role in regulating aspects of morphogen-
esis and cell differentiation during normal embryonic develop-
ment. Class I HOX genes are located in tightly linked physical
clusters, whereas class II HOX genes are dispersed throughout
the genome. In humans, a total of 39 class I HOX genes are
located in four distinct gene clusters on 7p15.3 (HOXA),
17q21.3 (HOXB), 12q13.3 (HOXC) and 2q31.1 (HOXD).19
They encode a complex network of transcription regulatory
proteins whose precise targets remain poorly understood. HOX
genes were shown to play a signiﬁcant role not only in
regulating body formation but also in organization and
regulation of hematopoiesis20 and leukemogenesis.21–23 Direct
effects of class I HOX gene function in hematopoiesis have been
shown in various studies where HOX gene expression has been
modulated by antisense oligonucleotides,24,25 gene disruption
by homologous recombination26,27 or by overexpression stu-
dies.28–31 In brief, forced expression of HOXA10 in murine31,32
and cord blood28,29 hematopoietic stem cells resulted in
increased proliferation and impaired myeloid differentiation
besides a profound reduction in B and T cell differentiation.
HOXA9 overexpression studies showed similar effects in
myeloid lineages but without effect on T lymphoid develop-
ment.33 Both overexpression studies of HOXA10 and HOXA9
however failed to produce any lymphoid neoplasms. In myeloid
leukemia, several class I HOX genes have been implicated
predominantly due to formation of fusion transcripts with
NUP98.34 A role for class I homeobox genes in T-ALL was ﬁrst
suggested by Ferrando et al,35 who demonstrated consistently
increased expression levels of a subset of HOX genes (HOXA9,
HOXA10, HOXC6 and MEIS1) in MLL rearranged T- and B-ALL,
while myeloid lineage genes were only expressed in MLL
rearranged B-ALL and not in T-ALL cases. These ﬁndings
suggested HOX gene deregulation rather than myeloid gene
deregulation being the key factor in leukaemic transformation
mediated by MLL fusion proteins.35 Further support for a crucial
role of HOXA genes came from a study of HOXA gene
expression in developing thymocytes13 where high HOXA10
expression was found in the earliest T-cell precursors in human
thymus, which showed subsequent downregulation in CD4 and
CD8 single positive mature thymocytes. This observation
suggested a role for HOXA10 in T-cell maturation, which was
in keeping with their previous studies that showed impairment
of ﬁnal T-cell differentiation upon enforced HOXA10 expression
in cord blood cells.29 In contrast to HOXA genes, expression of
the other HOX cluster genes was less prominent or absent
except for HOXB3 and HOXC4. HOXA11 was expressed at all
major stages of T-cell development also underlining the putative
important role of this particular HOX gene in thymocyte
maturation. Taken together, the present ﬁndings and published
data on HOXA expression in T-cell precursors and maturing
thymocytes strongly suggest that the HOXA gene cluster and
HOXA10 and HOXA11 genes, in particular, are of crucial
importance in normal T-cell development.
In contrast to class I homeobox genes, two particular class II
homeobox genes has been extensively studied in T-ALL, that is
HOX11, initially discovered through the t(10;14)(q24;q11),36
and HOX11L2 more recently shown to be implicated in the
cryptic t(5;14)(q35;q32).37
Chromosomal rearrangements disrupting HOX gene clusters
might also shed light onto the mechanisms controlling HOX
gene expression, that is, locally cis-acting control sequences,
global enhancer sequences located outside the gene clus-
ters.38,39 Here, we propose two possible oncogenetic mechan-
isms resulting from the inv(7). First, the disruption of the HOXA
gene cluster could interfere with the normal scheduled program
of sequential up and downregulation following the 30 to 50
localization of the HOXA genes, that is, 30 region HOXA genes
being expressed in the more primitive cells and 50 genes in more
differentiated cells. The physical disruption of the cluster could
therefore block downregulation of HOXA10 and HOXA11
required in order to allow the cells to complete their further
differentiation and maturation. The second and more classical
hypothesis is that enhancers embedded within the TCRb locus
lead to sustained high expression levels of HOXA10 and
HOXA11. Based upon the 10-fold higher expression levels
observed for HOXA10 and HOXA11 in the inv(7) positive cases
as compared to normal developing thymocytes, we favor the
latter hypothesis.
Immunophenotypically, the ﬁve inv(7) patients showed a
distinct pattern of CD2 negativity and CD4 single positivity
within the T3–4 subgroup of T-ALLs. Obviously, lack of CD2
expression on their leukaemic blasts is the most striking feature
as this pan T-cell marker is present on the leukaemic blasts of
85% of T-ALL.40 CD4 single positivity is another intriguing
ﬁnding within the T3–4 group as most cases either show CD4/
CD8 double positivity or CD8 single positivity. Taken together,
the phenotypic combination of CD2, CD4þ and CD8
showed signiﬁcant correlation with the presence of the inv(7)
genomic rearrangement (P¼ 5 10E-5).
In addition to the inv(7)(p15q34) positive cases, our study
indicates that other mechanisms can lead to abnormal HOXA
gene expression as two inv(7) negative cases also showed an
elevated HOXA10 and HOXA11 expression. Moreover, a third
case was noted, which like one of the inv(7) positive cases,
showed upregulated expression of all HOXA genes. This
observation is intriguing and somewhat reminiscent to the
observed enhanced expression of certain T-cell oncogenes
(HOX11, LYL1, TAL1, LMO1 and LMO2) in the absence of any
detectable chromosomal rearrangement affecting these loci.41
Further study of these remarkable cases might increase our
understanding of the mechanisms governing the tight control of
expression of these developmentally important genes.
In conclusion, the present report describes a new recurrent
cryptic chromosomal inversion inv(7)(p15q34) in T-ALL,which
leads to elevated expression of HOXA10 and HOXA11 in ﬁve
cases and increased expression of all HOXA genes in one case
and seems to delineate a speciﬁc subset of CD2 negative CD4
single positive T-ALLs. This observation for the second time
implicates class I HOXA genes, and in particular HOXA10 and
HOXA11, in T-cell oncogenesis and strongly supports the
previously proposed role for HOXA genes in thymocyte
development. We are currently collecting additional cases of
inv(7) patients in order to determine in more detail the clinical
and biological proﬁle of this patient subgroup and, most
importantly, in order to assess the prognostic importance of
inv(7)(p15q34) within a large cohort of uniformly treated
patients. Finally, we anticipate that this study might trigger a
search for compounds interfering with T-cell differentiation








































pathways controlled by HOXA genes and will also stimulate
new investigations focused at determining the role of HOXA
genes in T-cell development.
Acknowledgements
This study was supported by the Fonds voor Wetenschappelijk
Onderzoek-Vlaanderen, Grants nr. G.0310.01 and G.0106.05
and GOA, Grant nr. 12051203. BC is supported by the Belgian
program of Interuniversity Poles of Attraction. JV is supported by a
post-doctoral grant from the Institute for the Promotion of
Innovation by Science and Technology in Flanders (IWT). NVR
and JC are postdoctoral researchers and BV and PV are senior
clinical investigators of the Fonds voor Wetenschappelijk Onder-
zoek-Vlaanderen. We are thankful to Betty Emanuel and Nurten
Yigit for excellent technical assistance.
References
1 Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia.
N Engl J Med 2004; 350: 1535–1548.
2 Hwang LY, Baer RJ. The role of chromosome translocations in T
cell acute leukemia. Curr Opin Immunol 1995; 7: 659–664.
3 Robb L, Begley CG. The SCL/TAL1 gene: roles in normal and
malignant haematopoiesis. Bioessays 1997; 19: 607–613.
4 Ferrando AA, Herblot S, Palomero T, Hansen M, Hoang T, Fox EA
et al. Biallelic transcriptional activation of oncogenic transcription
factors in T-cell acute lymphoblastic leukemia. Blood 2004; 103:
1909–1911.
5 Barber KE, Martineau M, Harewood L, Stewart M, Cameron E,
Strefford JC et al. Ampliﬁcation of the ABL gene in T-cell acute
lymphoblastic leukemia. Leukemia 2004; 18: 1153–1156.
6 Graux C, Cools J, Melotte C, Quentmeier H, Ferrando A,
Levine R et al. Fusion of NUP214 to ABL1 on ampliﬁed episomes
in T-cell acute lymphoblastic leukemia. Nat Genet 2004; 36:
1084–1089.
7 Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-
Irizarry C et al. Activating mutations of NOTCH1 in human T cell
acute lymphoblastic leukemia. Science 2004; 306: 269–271.
8 Gesk S, Martin-Subero JI, Harder L, Luhmann B, Schlegelberger B,
Calasanz MJ et al. Molecular cytogenetic detection of chromoso-
mal breakpoints in T-cell receptor gene loci. Leukemia 2003; 17:
738–745.
9 Stove V, Naessens E, Stove C, Swigut T, Plum J, Verhasselt B.
Signaling but not trafﬁcking function of HIV-1 protein Nef is
essential for Nef-induced defects in human intrathymic T-cell
development. Blood 2003; 102: 2925–2932.
10 Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A
et al. Proposals for the immunological classiﬁcation of acute
leukemias. European Group for the Immunological Characteriza-
tion of Leukemias (EGIL). Leukemia 1995; 9: 1783–1786.
11 Mitelman F. An international system for Human Cytogenetic
Nomenclature. 1995, ISCN; S Karger, Basel.
12 Van Limbergen H, Poppe B, Michaux L, Herens C, Brown J, Noens
L et al. Identiﬁcation of cytogenetic subclasses and recurring
chromosomal aberrations in AML and MDS with complex
karyotypes using M-FISH. Genes Chromosomes Cancer 2002;
33: 60–72.
13 Taghon T, Thys K, De Smedt M, Weerkamp F, Staal FJ, Plum J et al.
Homeobox gene expression proﬁle in human hematopoietic
multipotent stem cells and T-cell progenitors: implications for
human T-cell development. Leukemia 2003; 17: 1157–1163.
14 Vandesompele J, De Paepe A, Speleman F. Elimination of primer-
dimer artifacts and genomic coampliﬁcation using a two-step
SYBR green I real-time RT-PCR. Anal Biochem 2002; 303:
95–98.
15 Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De
Paepe A et al. Accurate normalization of real-time quantitative RT-
PCR data by geometric averaging of multiple internal control
genes. Genome Biol 2002; 3: 1–11.
16 Thompson A, Quinn MF, Grimwade D, O’Neill CM,
Ahmed MR, Grimes S et al. Global down-regulation of HOX gene
expression in PML-RARalpha+acute promyelocytic leukemia
identiﬁed by small-array real-time PCR. Blood 2003; 101:
1558–1565.
17 Wang X, Seed B. A PCR primer bank for quantitative gene
expression analysis. Nucleic Acids Res 2003; 31: 1–8.
18 Pattyn F, Speleman F, De Paepe A, Vandesompele J. RTPrimerDB:
the real-time PCR primer and probe database. Nucleic Acids Res
2003; 31: 122–123.
19 Owens BM, Hawley RG. HOX and non-HOX homeobox genes in
leukemic hematopoiesis. Stem Cells 2002; 20: 364–379.
20 Magli MC, Barba P, Celetti A, De Vita G, Cillo C, Boncinelli E.
Coordinate regulation of HOX genes in human hematopoietic
cells. Proc Natl Acad Sci USA 1991; 88: 6348–6352.
21 van Oostveen J, Bijl J, Raaphorst F, Walboomers J, Meijer C. The
role of homeobox genes in normal hematopoiesis and hematolo-
gical malignancies. Leukemia 1999; 13: 1675–1690.
22 Lawrence HJ, Largman C. Homeobox genes in normal hematopoi-
esis and leukemia. Blood 1992; 80: 2445–2453.
23 Buske C, Humphries RK. Homeobox genes in leukemogenesis. Int J
Hematol 2000; 71: 301–308.
24 Takeshita K, Bollekens JA, Hijiya N, Ratajczak M, Ruddle FH,
Gewirtz AM. A homeobox gene of the Antennapedia class is
required for human adult erythropoiesis. Proc Natl Acad Sci USA
1993; 90: 3535–3538.
25 Wu J, Zhu JQ, Zhu DX, Scharfman A, Lamblin G, Han KK.
Selective inhibition of normal murine myelopoiesis ‘in vitro’ by a
Hox 2.3 antisense oligodeoxynucleotide. Cell Mol Biol 1992; 38:
367–376.
26 Lawrence HJ, Helgason CD, Sauvageau G, Fong S, Izon DJ,
Humphries RK et al. Mice bearing a targeted interruption of the
homeobox gene HOXA9 have defects in myeloid, erythroid, and
lymphoid hematopoiesis. Blood 1997; 89: 1922–1930.
27 Izon DJ, Rozenfeld S, Fong ST, Komuves L, Largman C, Lawrence
HJ. Loss of function of the homeobox gene Hoxa-9 perturbs early
T-cell development and induces apoptosis in primitive thymo-
cytes. Blood 1998; 92: 383–393.
28 Buske C, Feuring-Buske M, Antonchuk J, Rosten P, Hogge DE,
Eaves CJ et al. Overexpression of HOXA10 perturbs human
lymphomyelopoiesis in vitro and in vivo. Blood 2001; 97:
2286–2292.
29 Taghon T, Stolz F, De Smedt M, Cnockaert M, Verhasselt B, Plum J
et al. HOX-A10 regulates hematopoietic lineage commitment:
evidence for a monocyte-speciﬁc transcription factor. Blood 2002;
99: 1197–1204.
30 Sauvageau G, Thorsteinsdottir U, Hough MR, Hugo P, Lawrence
HJ, Largman C et al. Overexpression of HOXB3 in hematopoietic
cells causes defective lymphoid development and progressive
myeloproliferation. Immunity 1997; 6: 13–22.
31 Bjornsson JM, Andersson E, Lundstrom P, Larsson N, Xu X,
Repetowska E et al. Proliferation of primitive myeloid progenitors
can be reversibly induced by HOXA10. Blood 2001; 98:
3301–3308.
32 Thorsteinsdottir U, Sauvageau G, Hough MR, Dragowska W,
Lansdorp PM, Lawrence HJ et al. Overexpression of HOXA10 in
murine hematopoietic cells perturbs both myeloid and lymphoid
differentiation and leads to acute myeloid leukemia. Mol Cell Biol
1997; 17: 495–505.
33 Thorsteinsdottir U, Mamo A, Kroon E, Jerome L, Bijl J, Lawrence HJ
et al. Overexpression of the myeloid leukemia-associated Hoxa9
gene in bone marrow cells induces stem cell expansion. Blood
2002; 99: 121–129.
34 Fujino T, Suzuki A, Ito Y, Ohyashiki K, Hatano Y, Miura I et al.
Single-translocation and double-chimeric transcripts: detection of
NUP98-HOXA9 in myeloid leukemias with HOXA11 or HOXA13
breaks of the chromosomal translocation t(7;11)(p15;p15). Blood
2002; 99: 1428–1433.
35 Ferrando AA, Armstrong SA, Neuberg DS, Sallan SE,
Silverman LB, Korsmeyer SJ et al. Gene expression signatures
in MLL-rearranged T-lineage and B-precursor acute
leukemias: dominance of HOX dysregulation. Blood 2003; 102:
262–268.































36 Hatano M, Roberts CW, Minden M, Crist WM, Korsmeyer SJ.
Deregulation of a homeobox gene, HOX11, by the t(10;14) in T
cell leukemia. Science 1991; 253: 79–82.
37 Bernard OA, Busson-LeConiat M, Ballerini P, Mauchauffe M,
Della Valle V, Monni R et al. A new recurrent and speciﬁc cryptic
translocation, t(5;14)(q35;q32), is associated with expression of the
Hox11L2 gene in T acute lymphoblastic leukemia. Leukemia
2001; 15: 1495–1504.
38 Santini S, Boore JL, Meyer A. Evolutionary conservation of
regulatory elements in vertebrate Hox gene clusters. Genome
Res 2003; 13: 1111–1122.
39 Martinez P, Amemiya CT. Genomics of the HOX gene cluster.
Comp Biochem Physiol B Biochem Mol Biol 2002; 133: 571–580.
40 Uckun FM, Steinherz PG, Sather H, Trigg M, Arthur D, Tubergen D
et al. CD2 antigen expression on leukemic cells as a predictor of
event-free survival after chemotherapy for T-lineage acute
lymphoblastic leukemia: a Children’s Cancer Group study. Blood
1996; 88: 4288–4295.
41 Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C,
Raimondi SC et al. Gene expression signatures deﬁne novel
oncogenic pathways in T cell acute lymphoblastic leukemia.
Cancer Cell 2002; 1: 75–87.








 CHAPTER II: 
 
Paper 2:  
Cytogenetic study of 126 unselected T-ALL cases and 19 T-ALL cell lines reveals 
unexpected high incidence of cryptic rearrangements of the TCRβ locus with at 
least 2 new recurrent partner genes.  






































































































Molecular cytogenetic study of 126 unselected T-ALL cases reveals high incidence
of TCRb locus rearrangements and putative new T-cell oncogenes
B Cauwelier1, N Dastugue2, J Cools3,4, B Poppe1, C Herens5, A De Paepe1, A Hagemeijer3, F Speleman1
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Toulouse, France; 3Center for Human Genetics, University of Leuven, Leuven, Belgium; 4Flanders Interuniversity Institute
for Biotechnology (VIB), University of Leuven, Leuven, Belgium and 5CHU Sart Tilman, Universite´ de Lie`ge, Lie`ge, Belgium
Chromosomal aberrations of T-cell receptor (TCR) gene loci
often involve the TCRad (14q11) locus and affect various known
T-cell oncogenes. A systematic ﬂuorescent in situ hybridization
(FISH) screening for the detection of chromosomal aberrations
involving the TCR loci, TCRad (14q11), TCRb (7q34) and TCRc
(7p14), has not been conducted so far. Therefore, we initiated a
screening of 126 T-cell acute lymphoblastic leukemia (T-ALL)
and T-cell lymphoblastic lymphoma cases and 19 T-ALL cell
lines using FISH break-apart assays for the different TCR loci.
Genomic rearrangements of the TCRb locus were detected in
24/126 cases (19%), most of which (58.3%) were not detected
upon banding analysis. Breakpoints in the TCRad locus were
detected in 22/126 cases (17.4%), whereas standard cyto-
genetics only detected 14 of these 22 cases. Cryptic TCRad/
TCRb chromosome aberrations were thus observed in 22 of 126
cases (17.4%). Some of these chromosome aberrations target
new putative T-cell oncogenes at chromosome 11q24, 20p12
and 6q22. Five patients and one cell line carried chromosomal
rearrangements affecting both TCRb and TCRad loci. In conclu-
sion, this study presents the ﬁrst inventory of chromosomal
rearrangements of TCR loci in T-ALL, revealing an unexpected
high number of cryptic chromosomal rearrangements of the
TCRb locus and further broadening the spectrum of genes
putatively implicated in T-cell oncogenesis.
Leukemia (2006) 20, 1238–1244. doi:10.1038/sj.leu.2404243;
published online 4 May 2006
Keywords: T-ALL; cytogenetics; TCR rearrangements; HOXA
Introduction
T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lympho-
blastic lymphoma (T-LL) are lymphoid malignancies represent-
ing a heterogeneous group of diseases that vary with respect to
morphological, cytogenetic and immunologic features of the
T-lymphoblasts.1 The discovery of chromosomal rearrangements
in these disorders has been pivotal in the identiﬁcation of the
genes involved in T-ALL development and normal thymocyte
differentiation.2,3 In most instances, these chromosomal aberra-
tions are translocations that preferentially involve the T-cell
receptor TCRad locus (14q11) and to a much lesser extent the
TCRb locus (7q34) and affect a wide array of genes with
oncogenic properties 1p32(TAL1), 1p34(LCK), 8q24(MYC),
9q34(TAL2), 9q34(TAN1/NOTCH1), 10q24 (HOX11), 11p13
(RBTN2/LMO2), 11p15(RBTN1/LMO1), 14q32(TCL1), 19p13
(LYL1), 21q22(BHLHB1) and Xq28 (MTCP1).3–6 Translocations
affecting TCR genes largely result in deregulated expression
of proto-oncogenes by juxtaposing promoter and enhancer
elements of TCR genes in the proximity of these development-
ally important genes.7 Interestingly, further molecular studies
revealed that some of these genes (TAL1, HOX11, NOTCH1)
were functionally activated in a much higher frequency than
expected from a cytogenetic point of view,8–10 further under-
lining the importance of the original cytogenetic investigations.
Also, biallelic expression has been reported in about half of the
cases with TAL1, LMO2 and HOX11 expression pointing
at disturbance of an upstream regulatory control mechanism.11
In contrast to B-ALL, in which predominantly chimeric
transcription factor proteins are generated, gene fusions occur
in a much lower rate in T-ALL (predominantly MLL/ENL and
CALM/AF10).12–14
Recently, the spectrum of chromosomal abnormalities in
T-ALL has been further widened by the ﬁnding of new recurrent
but cryptic alterations. First, a cytogenetically undetectable
translocation t(5;14)(q35;q32) was found in about 20% of
childhood T-ALL juxtaposing the HOX11L2 gene (5q35) to the
distal region of the BCL11B gene.5 A further remarkable ﬁnding
was the extrachromosomal (episomal) ampliﬁcation of
NUP214-ABL1 fusion genes in 6% of T-ALL cases leading to
constitutively phosphorylated tyrosine kinase activity, which
can be inhibited upon addition of imatinib, a selective inhibitor
of ABL1 kinase activity.10,15,16 Recently, we observed yet
another recurrent chromosomal rearrangement, that is, an
inv(7)(p15q34) in a subset of T-ALLs. This rearrangement
juxtaposes the distal part of the HOXA gene cluster on 7p15
to the TCRb locus on 7q34 and causes increased HOXA10 and
HOXA11 expression levels.17 The occurrence of this inv(7) as
well as a t(7;7)(p15;q34) was subsequently also demonstrated by
Soulier et al.18 Interestingly, upregulated HOXA gene expression
was also found in MLL-ENL and CALM-AF10-positive T-ALLs,
thus pointing at a more general role of HOXA genes in T-cell
oncogenesis.19,20
These observations thus indicate that a plethora of genes
can be implicated in the development of T-ALL as a result
of various recurrent chromosomal changes, many of which
remained undetected upon cytogenetic investigation until
recently. In particular, the ﬁnding of a cryptic t(7;11)-
(q34;q24) involving the TCRb locus (7q34) in a childhood
T-ALL case21 and the new recurrent inv(7)(p15q34) triggered
the screening for additional cryptic TCR rearrangements
in a cohort of 126 T-ALL patients and 19 T-ALL cell lines.
Our ﬁndings show that the majority of TCRb chromosomal
rearrangements remained undetected upon routine karyotyping
and that new T-cell oncogenes may be implicated in some of
these cases (Figure 1).
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Cytogenetic cell suspensions or unstained slides from 126
diagnostic T-ALL (n¼ 109) and T-LL (n¼ 17) samples were
collected retrospectively from cytogenetic centers between
1988 and 2005. Diagnosis of T-ALL/LL was made according to
the morphological and cytochemical criteria of the French–
American–British classiﬁcation22 and by imunophenotyping.
The selection of cases was based on the availability of ﬁxed cell
suspension or unstained slides, which permit ﬂuorescent in situ
hybridization (FISH) investigation. Molecular data and immuno-
phenotype were available only for most recent cases and are
not shown. This cohort of T-ALL and T-LL cases included 80
children and 46 adults.
The 19 T-ALL cell lines were purchased from DSMZ (http://
www.dsmz.de, Braunschweig, Germany). Peripheral blood
lymphocytes from healthy donors with normal karyotypes
served as negative controls for validation and cutoff level
determination of the different FISH assays. Cell suspensions from
T-ALL cases or cell lines with cytogenetically proven break-
points at the different known T-cell oncogenes (LCK, MYC,
HOX11, LMO2, LMO1, NOTCH1) were used as positive
controls.
Methods
Cytogenetic analysis. Diagnostic specimens (bone marrow,
blood and pleural ﬂuid) and cell lines were cultured and
harvested for cytogenetic analysis according to established
methods. Chromosome slides were G or R banded. Chromo-
some aberrations are described according to guidelines of an
International System for Human Cytogenetic Nomenclature
(ISCN 1995).23
Clone selection and validation. RPCI-11 (Human BAC
Library) clones were selected using the bioinformatics resources
available at National Center for Biological Information (http://
genome.ucsc.edu) and Ensembl Genome Browser (http://
www.ensembl.org/). Clones were provided by the Welcome
Trust Sanger Institute (Cambridge, UK) and Invitrogen (Paisley,
Scotland).
Disruption of the TCR loci was assessed by dual color FISH
with TCR ﬂanking probes. Clones for the TCRad, TCRb and
TCRg applied in the present study are listed in Table 1.
Additional FISH probes used to conﬁrm the involvement of
TCR partner genes in cases carrying TCRb and/or TCRad
chromosomal rearrangement (identiﬁed by a split signal of the
ﬂanking probes) are listed in Table 1, with the exception ofMYC
for which we applied the LSI MYC Dual Color, Break Apart
Rearrangement Probe (Vysis, Abbott, Ottignies, Belgium). DNA
isolation of bacterial artiﬁcial chromosome (BAC) clones and
FISH was performed as described previously.24 Subsequently,
large-scale DNA ampliﬁcation was performed using the
GenomiPhi Ampliﬁcation Kit (Amersham Biosciences, Roosen-
daal, The Netherlands), which utilizes bacteriophage Phi-
29DNA polymerase and exponentially ampliﬁes single- or
double-stranded linear DNA templates during an isothermal
(301C), strand displacement reaction.25 Phi-ampliﬁed DNA was
labeled as described previously24 using spectrum green- and
spectrum orange-dUTP (SG-dUTP and SO-dUTP, Vysis, Abbott).
Validation of BAC clone genomic positions of TCRad, TCRb
and TCRg ﬂanking clones was performed using STS (sequence
tagged site) PCR with two STS genomic markers per BAC clone.
Using this approach, the genomic positions of the different TCR
gene loci provided by the bioinformatics resources were conﬁrmed.
Determination of cutoff levels. Determination of cutoff
levels of these new probe sets was performed by counting 200
nuclei in ﬁve negative controls (peripheral blood lymphocytes
from healthy donors) for each probe set.
Based on the results in negative controls, a split was deﬁned
as a spatial separation of the ﬂanking probes of more than three
times the estimated signal diameter.26
Using these criteria, the cutoff levels of the different probe
combinations were 6% for TCRad, 6.5% for TCRb and 2%
for TCRg.
Results
A total of 126 T-ALL/LL cases and 19 T-ALL cell lines were
investigated. Karyotypic analysis was successful in 119 cases,
Figure 1 Fluorescent in situ hybridization analysis in patient no. 23
carrying a reciprocal TCRb-TCRad chromosomal rearrangement.
T-cell receptorb ﬂanking BACs are labeled in Spectrum Green (white)
and TCRad ﬂanking BACs in Spectrum Orange (black).
Table 1 Flanking bacterial artiﬁcial chromosomes clones used for
FISH analysis in the present study
Locus Centromeric Telomeric
TCRb (7q34) RP11-1220K2 RP11-556I13
TCRad (14q11) RP11-242H9 RP11-447G18
TCRg (7p15) RP11-273L18 RP11-243E12
LCK (1p34) RP11-22K3 RP11-68H10
TAL1 (1p32) RP11-332M15 RP11-346M5
TAL2 (9q32) RP11-287A8 RP11-576E23
NOTCH1 (9q34) RP11-83N9 RP11-251M1
HOX11 (10q24) RP11-108L7 RP11-107I14
LMO2 (11p13) RP11-313G13 RP11-60G13
LMO1 (11p15) RP11-782G4 RP11-1065L8
TCL1 (14q32) RP11-952P19 RP11-760A15
LYL1 (19p13) RP11-1078F11 RP11-963I8
CDKN2A (9p21) RP11-478M20 RP11-454D15
HOXA (7p14) RP5-1103I5 RP1-167F23
OLIG2 (21q22) RP11-94I18 RP11-76I24
CDKN2A (9p21) RP11-478M20 RP11-454D15
MTCP1 (Xq28) RP11-402H20
Abbreviations: FISH, ﬂuorescent in situ hybridization; TCR, T-cell
receptor.























































































































whereas seven cases did not yield metaphases. Clonal abnorm-
alities were present in a high percentage of cases (74.7%:89/
119) (data not shown), which can be biased by the selection of
patient samples with possibly higher white blood cell counts at
presentation. Fluorescent in situ hybridization screening for TCR
rearrangements using dual color break apart assays showed
TCRad rearrangements in 22/126 patients (17.4%) in keeping
with data from the literature, a surprisingly similar high number
of patients (24/126, 19%) with TCRb aberrations and no TCRg
rearrangements. Split signals with the speciﬁc probe sets were
observed in 15–95% of cells for TCRad and in 20–98% for
TCRb. Simultaneous rearrangements targeting both the TCRb
and TCRad genes were observed in six patients and in one T-ALL
cell line (SUP-TI).
Translocations affecting the TCRb locus in T-cell acute
lymphoblastic leukemia
Fluorescent in situ hybridization screening for TCRb chromo-
somal rearrangements yielded split signals for the TCRb locus
in 24 cases (19%: 24/126) (Tables 2 and 4); these included three
T-LL and 21 T-ALL. In 19 of these 24 positive cases, involvement
of a known recurrent TCRb partner gene could be conﬁrmed by
FISH with the appropriate probes (Table 1): TAL1 (case no. 2),
HOXA (case nos. 15–22), HOX11 (case nos. 3,4–8–14–20),
LMO2 (case no. 7), LMO1 (cases nos. 9 and 10), TCRad (case
nos. 13–23) and NOTCH1 (case no. 12). HOXA gene expression
levels were reported previously for case nos. 15–19. In the
additional cases 21 and 22 detected by FISH screening, a similar
pattern of increased HOXA10 and HOXA11 was observed
(details will be published elsewhere). Owing to poor quality
and/or paucity of metaphases, the partner chromosome
remained undetermined in the remaining ﬁve cases showing
TCRb rearrangement. These rearrangements were slightly more
frequent in adults compared to children, 14/80 children (17.5%)
versus 10/46 adults (21.7%). One patient (case no. 1) showed
rearrangement of the TCRb locus with an as yet unidentiﬁed
partner gene on chromosome 11q24. Further analysis to identify
this new partner gene is ongoing and will be reported elsewhere.
Abnormal karyotypes were found in 16 out of 24 TCRb-
positive cases (Table 2), whereas translocations affecting the
7q34 locus were detected in only four of 24 cases. Partial
deletions of chromosome 7q or 7p were detected in three cases
and two cases showed additional material on 7q. Taken
together, TCRb genomic rearrangement was unsuspected from
cytogenetic analysis in as much as 14 of 24 (58.3%) cases when
excluding failures. Two out of 19 cell lines screened with the
TCRb ﬂanking probes showed genomic rearrangement of this
locus with LCK (T-ALL cell line HSB2) and NOTCH1 (T-ALL cell
line SUP-TI) as partner genes (Table 2).
Translocations affecting the TCRad locus in T-cell acute
lymphoblastic leukemia
Translocations involving the TCRad locus were detected in
approximately the same number of patients as for TCRb, that is,
22/126 (17.4%) cases (Tables 2 and 4) and mostly included
T-ALL (n¼ 21). However, involvement of known T-cell oncogenes
was conﬁrmed in only 12 of 22 rearranged cases. Unexpectedly,
one TCRad rearranged case (no. 23) showed a balanced
rearrangement with the TCRb locus, which brings the total
number of identiﬁed TCRad partner genes to 13 out of 22. These
ﬁndings suggest that many of these rearrangements targeted
unknown T-cell oncogenes. Within the TCRad rearranged group
involving known T-cell oncogenes, HOX11 was most frequently
involved followed by LMO2, TAL1 and MYC, which involved
two cases each. TCL1, HOXA and TCRb were detected in
single cases. For the remaining nine cases carrying a TCRad
rearrangement, partner genes could not be identiﬁed. Interest-
ingly, TCRad rearrangements showed involvement of an
unknown partner gene on chromosome 6q22 (case no. 40)
and 20p12 (case no. 41) (Table 2). Of the 19 cell lines screened
with TCRad ﬂanking clones, ﬁve showed rearrangements with
partner genes LMO1 (RPMI 8402), LMO2 (TALL 104), MYC
(MOLT16 and KE-37), HOX11 (ALL-SIL) and an unidentiﬁed
gene (SUP-TI). In contrast to TCRb rearrangements, TCRad
rearrangements were more frequent in children (16/80; 20%)
versus adult T-ALL patients (6/46: 13%).
In this group of TCRad rearranged cases (n¼ 22), abnormal
karyotypes were present in 19 patients (Table 2). Of these,
translocations involving the TCRad locus were obvious from
banding analysis in only 12 of these 19 patients. In seven cases
with clonal karyotypes, no 14q11 rearrangement was apparent,
indicating that at least 30% (7/22) of TCRad-positive cases in this
series was cryptic. This could be explained in one of these cases
through the presence of complex abnormalities. This case (no.
28) showed two subclones carrying rearrangement of chromo-
some 14 at different chromosome bands. One subclone carried
a rearrangement of chromosome 14 at the B14q32 band (IgH
locus) and was translocated to the long arm of chromosome
20,24 revealing a t(14;20)(q32;q12). In another subclone,
chromosome 14 showed disruption of the TCRad locus
(14q11) with inversion of the distal probe to the short arm of
chromosome 14 thus revealing a new inv(14)(p?q11).
Simultaneous occurrence of TCRb and TCRad genomic
rearrangements
Five T-ALL patients (cases nos. 1, 6, 10, 13, 23) and one T-ALL
cell line (SUP-TI) carried genomic rearrangements of both TCRb
and TCRad loci. In four of these patients, both TCR genes
targeted different T-cell oncogenes (Table 2) as conﬁrmed by
FISH with the appropriate probes. Unexpectedly, patient nos. 13
and 23 showed a rearrangement between the TCRb and TCRad
gene loci, unbalanced in case no. 13 and balanced in patient
no. 23. Five of these patients were children, possibly reﬂecting
the higher susceptibility to genomic rearrangements involving
TCR loci during childhood.
Previously unreported chromosome aberrations in
T-cell acute lymphoblastic leukemia
Chromosome aberrations found in this series, which have not
been reported previously in T-ALL, are listed in Table 3.
Fluorescent in situ hybridization investigation for oncogenes
known to be involved in leukemogenesis (LMO1, LMO2,
HOX11, HOXA, ETV6, NUP98) were applied and in most cases
turned out to be negative, indicating that a large set of putative
T-cell oncogenes still remains undiscovered.
Discussion
Here we report the results of a comprehensive FISH screening
performed in 109 T-ALL, 17 T-LL and 19 T-ALL cell lines using
TCR ﬂanking FISH probes to determine the incidence of
chromosomal rearrangements involving the TCR genomic loci
TCRad (14q11), TCRb (7q34) and TCRg (7p15). This approach
allowed us to demonstrate for the ﬁrst time that TCRb
rearrangements occur in a similarly high frequency as TCRad




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































rearrangements, that is, in 19% of T-ALL patients. Of further
importance, we showed that as much as half (14/24) of the TCRb
and about one-third (8/22) of the TCRad rearrangements were
not detected upon karyotypic analysis. Our study thus indicates
that using standard karyotyping, chromosomal rearrangements
involving T-cell receptors (in particular TCRb) have been
significantly underestimated so far.27 In line with previous
reports, no TCRg aberrations were observed in this series.
Apparently, these TCRg rearrangements are confined to T-cell
tumors in patients with ataxia telangiectasia (ATM) where these
rearrangements are frequently found.28 The frequency and age
distribution of TCRad rearrangements in our study are in line
with the series reported by Heerema et al.,29 whereas other
larger studies of adult T-ALL found that the frequency of TCRad
rearrangements was much higher in adults compared to
childhood T-ALL.30,31 For patients showing a TCRb locus
rearrangement, conventional karyotyping showed aberrations
in only 3.1%, which is somewhat in between previous
cytogenetic reports of 7q34 abnormalities in adult (7.5%)27
and childhood (1%)30 T-ALL. The incidence of TCR rearrange-
ments (TCRb and/or TCRad) was slightly higher in the T-ALL
group, which was possibly biased by the much larger number of
patients with T-ALL compared to T-LL. In the T-LL subgroup,
4/17 (23.5%) were positive for a TCR rearrangement, whereas
36/109 (33%) T-ALL showed one of these rearrangements.
The high incidence of cytogenetically undetected TCRb
(14 out of 24 TCRb-positive cases) and TCRad (eight out of
22 TCRad-positive cases) rearrangements is remarkable. For
TCRb rearrangements, eight of 14 cytogenetically undetected
cases showed other clonal rearrangements and re-evaluation
of the karyotypes allowed us to detect the TCRb aberration in
two cases (nos. 3 and 4). This could be explained by the
distal localization of the TCRb locus (7q34) together with
a distal chromosomal position of the breakpoints of the TCRb
partner genes, that is, t(7;11)(q34;q24), t(7;10)(q34;q24) and
inv(7)(p15q34). In two cases (nos. 7 and 8) only normal
metaphases were found at diagnosis and re-evaluation of
karyotypes did not show the aberration, suggesting that only
non-leukemic cells were cultured. This explanation is not valid
for the TCRad locus rearrangements, which should be readily
detectable on G-banding analysis. For TCRad rearrangements
that remained undetected upon karyotyping, two were
presented as a marker chromosome (case nos. 13–28), one
resulted form a complex rearrangement (case no. 28) and a
third (case no. 26) was not detected as probably only normal
cells were karyotyped. Re-evaluation of case no. 26 remained
negative. Interestingly, for the remaining TCRad-positive
cases that remained undetected, chromosomal rearrangements
were found in karyotypically abnormal cells (case nos. 32, 33,
35, 37) raising the question that these represent true cryptic
rearrangements.
Preferential partner genes for TCRb in our series include
HOXA (7p15)17 and HOX11 (10q24), which were involved in
seven and four cases, respectively. Recently, HOXA cluster
genes were shown to be involved in a chromosomal rearrange-
ment with the TCRad (14q11) locus in a T-ALL patient (case no.
30) carrying a t(7;14)(p15;q11) (unpublished observation).
The finding that in 14 TCRad or TCRb chromosomal
rearrangements the partner gene could not be identified
after testing of all genes known to be implicated in T-ALL is of
great potential importance. Also, two new translocations
involving the TCRad locus were found in this series, that is,
t(6;14)(q22;q11) (case no. 40) and t(14;20)(q11;p12) (case no.
41) (Table 2). Further efforts to identify these putative new
partner genes are ongoing. Recently, a new translocation, that
is, t(7;11)(q34;q24)21 affecting the TCRb locus and an as yet
unidentified partner gene on chromosome 11q24 was described
(case no. 1 in Table 3) and is analyzed further. Other
chromosomal aberrations not reported previously in T-ALL
(Table 2) include three cases with rearrangements of chromo-
some 9p21–24. This is the region harboring the CDKN2A
(encoding p14 and p16 proteins) and CDKN2B (encoding p15
protein) tumor suppressor genes, which are the primary targets
of 9p21 deletions in T-ALL and have been described to be
present in 65% of T-ALLs.32,33 Translocations affecting this gene
locus have been reported in ALL but mostly in B-ALL.30,34,35
Interestingly, two of these patients carrying a rearrangement of
9p also showed a homozygous deletion of p16.
An interesting observation is the presence of rearrangements
of both TCRad and TCRb loci in six patients and one cell line.
Five of these patients were children, possibly reflecting the
higher susceptibility for errors in VDJ recombination as a
consequence of greater antigen exposure during childhood. In
four patients, involvement of different T-cell oncogenes by both
TCRb and TCRad genes was confirmed using FISH with the
appropriate flanking BAC clones. No preferential involvement of
a particular gene seems evident from this small series, but it
should be noted that four of the 12 partner genes in these cases
remained unidentified. Interestingly, two patients (case nos. 13
and 23) carried a translocation between the two TCR loci: TCRb
(7q34) and TCRad (14q11); unbalanced in case no. 13 and
balanced in case no. 23. So far, rearrangements between two
























Abbreviation: T-ALL, T-cell acute lymphoblastic leukemia.
Table 4 Frequency of detected TCR chromosomal rearrangement




TCRad (14q11) 9.5a 24.7b 17.4a
TCRb (7q34) 3.1a 26.9b 19a
TCRg (7p15) 0 0 0
Abbreviations: FISH, fluorescent in situ hybridization; TCR, T-cell
receptor.
aIn percentage of all T-ALL.
bIn percentage of T-ALL abnormal karyotypes.























































































































TCR loci, TCRg (7p15) and TCRad (14q11), have been reported
in a high frequency in patients with ATM.28 However, this
aberration has also been found at very low frequencies in
T-lymphocytes from healthy individuals.36 These observations
raise the possibility that rearrangements affecting both TCR loci
are not merely chromosomal aberrations associated with
tumorigenesis, but could represent the capacity of the recombi-
nase system to generate additional immune diversity.37
In the light of the present findings, we would recommend
thorough cytogenetic and molecular cytogenetic screening for
cases included in ongoing and future gene expression profiling
studies in T-ALL. This information may be critically important in
the data analysis and delineation of genetic subgroups. Also, it
will broaden our understanding of the various genetic mecha-
nisms that lead to unscheduled activation or sustained expres-
sion of the plethora of genes implicated in T-cell oncogenesis.
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Recently, we and others described a new chromosomal
rearrangement, that is, inv(7)(p15q34) and t(7;7)(p15;q34) invol-
ving the T-cell receptor beta (TCRb) (7q34) and the HOXA gene
locus (7p15) in 5% of T-cell acute lymphoblastic leukemia
(T-ALL) patients leading to transcriptional activation of
especially HOXA10. To further address the clinical, immuno-
phenotypical and molecular genetic findings of this chromo-
somal aberration, we studied 330 additional T-ALLs. This
revealed TCRb-HOXA rearrangements in five additional
patients, which brings the total to 14 cases in 424 patients
(3.3%). Real-time quantitative PCR analysis for HOXA10 gene
expression was performed in 170 T-ALL patients and detected
HOXA10 overexpression in 25.2% of cases including all the
cases with a TCRb-HOXA rearrangement (8.2%). In contrast,
expression of the short HOXA10 transcript, HOXA10b, was
almost exclusively found in the TCRb-HOXA rearranged cases,
suggesting a specific role for the HOXA10b short transcript in
TCRb-HOXA-mediated oncogenesis. Other molecular and/or
cytogenetic aberrations frequently found in subtypes of T-ALL
(SIL-TAL1, CALM-AF10, HOX11, HOX11L2) were not detected
in the TCRb-HOXA rearranged cases except for deletion 9p21
and NOTCH1 activating mutations, which were present in 64
and 67%, respectively. In conclusion, this study defines TCRb-
HOXA rearranged T-ALLs as a distinct cytogenetic subgroup
by clinical, immunophenotypical and molecular genetic
characteristics.
Leukemia advance online publication, 12 October 2006;
doi:10.1038/sj.leu.2404410
Keywords: TCRb-HOXA rearrangement; T-ALL; HOXA10;
HOXA10b
Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive
malignancy of immature T cells characterized by high numbers
of bone marrow and circulating blast cells, enlargement of
mediastinal lymph nodes and often central nervous system
involvement.1 T-ALL accounts for approximately 15% of
pediatric and 25% of adult ALL cases. During the past 20 years,
a large number of genes involved in the pathogenesis of T-ALL
have been identified by molecular characterization of recurrent
chromosomal aberrations and cryptic alterations.2 Several
oncogenes initially identified by rare genetic alterations were
shown to be functionally activated in subsets of T-ALLs such as
LMO1, LMO2, LYL1, NOTCH1 in the absence of the
corresponding genetic aberration. Recently, we3 and others4
described a new recurrent chromosomal aberration in a
subgroup of T-ALLs affecting the TCRb (7q34) and HOXA
(7p15) loci. This group of patients showed a significant
upregulation of particular HOXA cluster genes, under the
influence of regulatory sequences embedded in the TCRb locus.
In this study,3 especially HOXA10 showed a significant higher
expression level in the TCRb-HOXA rearranged subgroup
compared to non-TCRb-HOXA rearranged T-ALLs. Ectopic
expression of HOXA cluster genes was already described in
other cytogenetic subgroups of T-ALL, that is, MLL5,6 and
CALM-AF10 rearranged cases,4,7,8 further underlining the
importance of HOXA genes in T-cell oncogenesis. The
mechanisms underlying this overexpression are however differ-
ent. Human leukemias and cell lines carrying MLL rearrange-
ments show upregulated expression of especially 50 HOXA
cluster genes, that is, HOXA5, HOXA7, HOXA9, HOXA10 and
HOXA11.5,9,10 In contrast, 30 HOXA genes showed low levels or
no expression.11 The transcriptional activation of HOX cluster
genes by MLL was shown to be dependent on histone H3
methylation of HOX genes, with HOXA9 and HOXA7 proven to
be the direct targets.12–15 Similarly, T-ALLs carrying the CALM-
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AF10 rearrangement show an elevated expression of especially
HOXA5, HOXA9, HOXA10 and BMI1,7 suggesting that these
two aberrations activate common oncogenic pathways. How-
ever, as no obvious DNA binding domain exists in CALM, the
mechanism of HOXA gene activation must be different. Previous
gene expression analysis on a large group of T-ALLs already
showed the existence of a HOXA-expressing subgroup, consist-
ing of MLL, CALM-AF10 and TCRb-HOXA rearranged cases.4
Interestingly, these data pointed to the expression of a specific
short HOXA10b transcript in the TCRb-HOXA rearranged cases,
which was absent in other T-ALLs. Given these findings and in
order to make a comprehensive picture of patients carrying the
TCRb-HOXA rearrangements, we analyzed additional T-ALL
patients using fluorescent in situ hybridization (FISH) and real-
time quantitative reverse transcriptase-PCR (RT-PCR) for expres-
sion of the long HOXA10 transcript. Cases showing over-
expression of the long transcript of HOXA10 were subsequently
analyzed for expression of the short HOXA10b transcript,
which was shown to be specifically expressed in TCRb-HOXA
rearranged cases. This study described the largest group of
TCRb-HOXA rearranged T-ALLs identified so far and interest-
ingly showed one patient carrying a triplication of a TCRb-
HOXA on a ring chromosome 7, pointing to an additional
mechanism of transcriptional activation of HOXA cluster genes.
Moreover, all 14 TCRb-HOXAþ patients showed absence
of additional molecular–cytogenetic alterations like SIL-TAL1,
HOX11, HOX11L2, CALM-AF10 andNUP214-ABL1, providing
further evidence for a distinct cytogenetic entity. In contrast,
deletions of 9p21 harboring the tumor suppressor genes
CDKN2A and CKDN2B and NOTCH1 activating mutations
were present in 64 and 67% of TCRb-HOXAþ patients,
pointing to a multistep oncogenesis in this cytogenetic T-ALL
subgroup. Of further interest is the finding of the highly clustered
breakpoints in three TCRb-HOXA-positive cases and all three
showed breakpoints in intron 1A from HOXA9 and JB2.7–JB2.1
segments of the TCRb gene.
Materials and methods
Patients
Diagnostic bone marrow or pleural fluid samples from T-ALL
patients were collected retrospectively at different cytogenetic
centers. The only inclusion criterion was the diagnosis of T-ALL
and the availability of fixed cells for FISH (n¼ 424) and/or RNA
or frozen cells for real-time quantitative RT-PCR (n¼ 170 of
424). Besides newly diagnosed T-ALLs, these series of patient
samples includes 229 cases analyzed in the HOX11L2 study of
the Groupe Francophone de Cytoge´ne´tique He´matologique
(GFCH),16 patients analyzed in the first study,3 that is, 94
patients analyzed with FISH and 26 with real-time quantitative
PCR, and patients of another study,4 that is, 92 patients analyzed
by FISH and 21 with real-time quantitative PCR. This total series
of patients included 50% children and adults. Diagnosis of
T-ALL was made according to the morphological and cyto-
chemical criteria of the French–American–British classi-
fication17 and by immunophenotyping.18
Methods
Immunophenotyping. Immunophenotypical analyses were
carried out in the respective centers according to established
protocols. Blast cells were analyzed for forward/side scatter and
fluorescence by BD FACS Calibur using monoclonal antibodies
directed against CD34, CD33, CD13, CD2, CD3, CD5, CD7,
CD1a, TdT, CD10, CD4, CD8, TCRab, TCRgd, CD19 and CD20.
Karyotyping. Diagnostic specimens were cultured and
harvested for cytogenetic analysis according to established
methods. Chromosome slides were G- or R-banded. Chromo-
somal aberrations are described according to the guidelines of
an International System for Human Cytogenetic Nomenclature
(ISCN 1995).19
Fluorescence in situ hybridization. RPCI-11 (Human BAC
Library) clones were selected using the bioinformatics resources
available at NCBI (http://genome.ucsc.edu) and Ensembl Gen-
ome Browser (http://www.ensembl.org/). Clones were provided
by the Welcome Trust Sanger Institute (Cambridge, UK) and
Invitrogen (Paisley, Scotland).
Disruption of the TCRb or HOXA gene locus was assessed in
all 424 cases by dual-color FISH with TCRb or HOXA flanking
probes. Clones for the TCRb and HOXA gene locus applied
in the present study are shown in Figure 2. DNA isolation of
bacterial artificial chromosome (BAC) clones, labelling and
FISH were performed as described previously.20 Amplification
of NUP214-ABL1 was investigated by the LSI BCR/ABL1 dual-
color, ES probe (Vysis, Abbott, Ottignies, Belgium) in 137
samples from which cytogenetic cell suspension was left out.
Disruption of the MLL genomic locus was assessed by FISH with
the commercial LSI MLL dual-color, break-apart probe (Vysis,
Abbott, Ottignies, Belgium) in all patients (n¼ 43) showing
overexpression of HOXA10. Deletion of 9p21 was detected
using the LSI p16 (9p21)/CEP 9 dual-color probe (Vysis, Abbott,
Ottignies, Belgium) in all TCRb-HOXA rearranged cases.
RNA isolation, cDNA synthesis and real-time quantita-
tive PCR. Frozen cells or RNA were available for expression
analysis in 170 of 424 T-ALL patients. These included all
TCRb-HOXA rearranged cases (n¼ 14). All human samples
were obtained according to the guidelines of the local ethical
committees. RNA isolation from frozen cells was performed
using TRIzol (Invitrogen, Merelbeke, Belgium) and the RNeasy
mini kit (Qiagen, Hilden, Germany) or RNA Plus (Appligene,
Illkirch, France) for detection of the NUP214-ABL1 amplifica-
tion at different laboratories. DNase pretreatment, cDNA
synthesis and SYBR green real-time quantitative PCR were
performed for HOXA10 and HOXA10b expression as described
previously.3 Reactions were performed on an ABI Prism 5700
sequence detector (Applied Biosystems, Foster City, CA, USA).
Real-time quantitative RT-PCR data analysis and expression
normalization were performed using three internal control genes
with the qBase data analysis software (Hellemans et al., in
preparation; medgen.ugent.be/qbase). Expression analysis for
the full-length transcript of the HOXA10 gene (Fw: 50-GAGAG
CAGCAAAGCCTCGC-30; Rev: 50-CCAGTGTCTGGTGCTTCG
TG-30) was performed in all 170 T-ALL patients. Cases showing
‘overexpression’ of this transcript were subsequently tested for
the expression of the short HOXA10b transcript (Fw: 50-GCAC
TTCCGATCAATGTCAA-30; Rev: 50-AGCGAACAAAGGCCAAG
TT-30), or as described.4 Cytogenetically proven TCRb-HOXA
rearranged cases were analyzed for the expression pattern of all
HOXA cluster genes with primers used as described.3
The presence of a NUP214-ABL1 fusion was assessed
by quantitative real-time RT-PCR using the fluorescent TaqMan
methodology. Four NUP214 primers were used (X23, X29, X31,
X34) (E Delabesse, personal communication) in combination
with ABL primer (ENR 561) and probe (ENP541), previously
designed for BCR-ABL transcript quantitation.21 This PCR
reaction can detect all NUP214 breakpoints that have been
described so far.22



















































Expression of HOX11 was assessed using the primers
designed by Ferrando et al.23 in an SYBR green real-time
quantitative RT-PCR as described previously.24
Long-distance PCR and cycle sequencing. For 10
patients showing a TCRb-HOXA rearrangement (eight inv(7)
(p15q34), one t(7;7)(p15;q34) and one triplication on a ring
chromosome), DNA was extracted using the QIAmp DNA mini
kit (Qiagen, Hilden, Germany). Long-distance PCR was per-
formed using the iProof High-Fidelity PCR Kit (BioRad,
Nazareth, Belgium), according to the manufacturer’s instruc-
tions. Forward and reverse primers were selected in the HOXA9
and TCRb, Db1 gene, respectively, as breakpoints of four
patients were suggested to be located between the HOXA9 and
HOXA10 gene on der (7p) and upstream from the Db1 locus of
the TCRb gene on der (7q), respectively.4 Subsequently,
fragments were sequenced using the ABI Prism BigDye
Terminator v3.0 Ready Reactions Cycle Sequencing Kit and
analyzed on an ABI3730 XL Sequence detector.
RT-PCR detection assays. A standard RT-PCR protocol was
used to detect the CALM-AF10 fusion in two separate RT-PCR
assays using one CALM forward primer (50-GCAATCTTGGC
ATCGGAAAT-30) and either AF10 reverse primer AF10AS559
(50-CGATCATGCGGAACAGACTG-30) or AF10AS1002 (50-GCG
CTTCAATGATCCAGATATAGAG-30) as described.8
HOX11L2 was detected using a standard RT-PCR protocol
with forward primer (50-GCGCAT CGGCCACCCCTACCAGA-
30) and reverse primer (50-CCGCTCCGCCTCCCGCTCCTC-30),
according to Bernard et al.25
Detection of the SIL-TAL1 fusion was performed using a
multiplex RT-PCR for simultaneous screening of multiple
chromosomal aberrations in acute leukemia (HemaVision,
BioRad). Primers used were SIL prim (50-CGACCCCAACGTCCC
AGAG-30) and TAL1 prim (50-CGGTCATCCTGGGGC ATATT
T-30) and nested primers SIL nest (50-CCCGCTCCTACCCTGC
AAAC-30) and TAL1 nest (50-AGACCGGCCCCTCTGAATAG-30).26
NOTCH1 mutation detection. Mutation detection of the
NOTCH1 receptor was performed on genomic DNA in 12 out of
14 TCRb -HOXA-positive cases from which DNA was available.
PCR amplification of exons 26, 27 of the HD (heterodimeriza-
tion) domain and of the PEST (proline, glutamate, serine and
threonine) domain encoding region of exon 34 was performed
with the following primer pairs: ex26F (50-TGAGGGAGGACCT
GAACTTG-30) and ex26R (50-TGGAATGCTGCCTCTACTCC-30);
ex27F (50-GTTGGTGGGTATCTGGGATG-30) and ex27R (50-CG
GAGTGCCATTCAGAAAAT-30); and ex34F (50-CCATGGCTAC
CTGTCAGACG-30) and ex34R (50-TGGCTCTCAGAACTTGCTT
GT-30). Subsequent sequencing of PCR products was performed
with primers ex26seq1 (50-GAGGGCCCAGGAGAGTTG-30) and
ex26seq2 (50-CACGCTTGAAGACCACGTT-30) for exon 26;
ex27seq1 (50- CGGGGGAGGAGGAAG-30) and ex27seq2 (50-C
TGCAGGCAGAGCCTGTT-30) for exon 27; and ex34F, ex34R
and ex34seq1 (50-GCTGCACAGTAGCCTTGCTG-30) for exon 34.
Statistical analysis. Statistical analysis was performed using
SPSS Software (SPSS Inc., Chicago, IL, USA) version 12.0. The
non-parametric Mann–Whitney U-test (two-tailed) was used to
evaluate the significance of difference in mean expression levels
between the patients’ subgroups (TCRb-HOXA rearranged
versus TCRb-HOXA non-rearranged patients) for the different
HOXA cluster genes. Differences in the expression level of a
gene were considered statistically significant if P-value o0.05.
Results
FISH analysis was performed in 424 T-ALL cases and real-time
quantitative RT-PCR in 170 of these patients. These series of
patient samples includes the patients analyzed in the first two
studies, that is, 94 patients analyzed with FISH and 26 with real-
time quantitative PCR,3 and 92 patients analyzed with FISH and
21 with real-time quantitative PCR.4 This study also includes
229 patients studied in the HOX11L2 study of the GFCH.16
Incidence and immunophenotypical and molecular
features of TCRb-HOXA rearranged T-ALL
The present study performed on 424 T-ALLs identified five
patients carrying TCRb-HOXA rearrangements in addition to the
first two studies,3,4 which brings the total to 14 cases (3.3% of
T-ALLs studied): nine inv(7), two t(7;7) and one TCRb-HOXA
triplication on a ring chromosome. For the remaining two cases,
no mitoses were available, which hampers a distinction between
an inv(7) or a t(7;7). The median age at diagnosis was 25.7 years
(range 9–49 years) and affected both men and women (M/F: 8/6),
whereas children were less affected (n¼ 5 of 14,o18 years). All
but three (n¼ 11 of 14) TCRb-HOXA T-ALLs showed a typical
CD2-negative immunophenotype, besides CD4 single positivity
and low or lack of TCRab of TCRgd surface expression, pointing
to an immature stage of maturation arrest. Remarkably, none of
these TCRb-HOXA T-ALLs showed additional molecular–cyto-
genetic aberrations commonly observed in T-ALL (HOX11,
HOX11L2, CALM-AF10, NUP214/ABL1, SIL-TAL1), except for
9p21 deletions, which were present in 64% (9/14) of TCRb-
HOXA-positive cases, most of which were mono-allelic dele-
tions. NOTCH1 activating mutations were present in 67% (8/12)
of the TCRb-HOXA T-ALLs, mostly affecting exon 26 of the HD
domain and included deletions, insertions and missense muta-
tions. PEST domain mutations were present in two cases, both
were point mutations that created a premature stop codon,
whereas exon 27 of the HD domain carried a missense mutation
in a single patient. One patient showed both a PEST domain and
an HD domain exon 26 mutation.
Karyotypic findings in TCRb-HOXA-positive
T-ALL patients
Conventional karyotyping showed clonal aberrations in seven
out of 14 TCRb-HOXA rearranged cases. Of these seven
patients, an inv(7)(p15q34) was cytogenetically found in all
metaphases in two patients (case no. 2 and no. 4; Figure 1),
whereas two other patients showed only a del(7)(p15). Taken
together, a chromosome 7 aberration was suggested in four out
of 14 cases. Interestingly, case no. 10 harbored a monosomy
7 and a ring chromosome, which was shown to be derived from
chromosome 7 upon further analysis. Only few additional
chromosomal abnormalities were found in five patients and
included add(6)(qter) (case no. 2), del(6)(q14) (case no. 5),
add(5)(q31) (case no. 8), del(9)(p21) (case no. 5), del(9)(p12p24)
(case no. 4) and þ 11 and þ 21 (case no. 3).
Figure 1 R-banded karyotype from patient no. 2 carrying an
inv(7)(p15q34).



















































TCRb-HOXA triplication as an alternative mechanism
for HOXA upregulation
Based on real-time quantitative RT-PCR results for HOXA10 and
HOXA10b expression in 170 T-ALLs, we could identify five
additional TCRb-HOXA rearranged cases. Among these, there
was a patient showing an interesting hybridization pattern, using
FISH with TCRb and HOXA flanking probes: the TCRb (RP11-
1220K2) and HOXA (RP5-1103I5) proximal flanking BACs
showed 3–6 signals in 98% of interphase cells with deletion of
both the TCRb (RP11-556I13) and HOXA (RP1-167F23) distal
flanking BACs (Figure 2). The majority of metaphases showed a
triplication of these proximal flanking BACs on a ring/marker
chromosome, which was already detected by karyotypic
analysis (see Table 1). Further FISH analysis, using a whole
chromosome paint probe, identified the ring chromosome as
chromosome 7 (data not shown). Given the abnormal hybridi-
zation pattern using TCRb and HOXA flanking FISH clones,
additional FISH was performed with BACs covering the HOXA
and TCRb gene locus (Figure 2) and revealed the same
hybridization pattern for clones RP11-1025G19, RP11-
1132K14 (HOXA covering) and RP11-784K24, RP11-701D14
(TCRb covering), that is, 3–6 fusion signals in both the nuclei
and on the ring chromosome, whereas telomeric HOXA
covering FISH clones showed a deletion in the majority of cells
(RP11-1036C18, RP11-163M21). Finally, a FISH analysis using
a combination of both proximal TCRb and HOXA flanking FISH
probes confirmed the juxtaposition and triplication of these two
loci on the ring chromosome 7.
TCRb-HOXA rearranged T-ALL specifically express
HOXA10b
Real-time quantitative PCR for HOXA10 expression in 170 T-ALL
cases revealed an upregulated expression in 43/170 (25.2%) of
cases, whereas only 14 carried the TCRb-HOXA rearrangement
(8.2%). Upregulation of HOXA10 expression was defined as
expression of more than the mean expression level of all samples
analyzed. Given the fact that within the TCRb-HOXA-positive
group, there was a large fluctuation of expression levels with
some samples showing very low expression (similar to thymo-
cytes), we put the threshold for positivity sufficiently low, in order
to avoid missing any true positive cases. Consequently, it can be
expected that some of the cases included as positive represent
normal HOXA10 expression reflecting their stage of differentia-
tion arrest. Five CALM-AF10-positive patients and two MLL
rearranged patients, which are known to be HOXA-expressing
T-ALL subtypes, were also included in this series. Interestingly,
one patient showing HOXA10 overexpression carried an
NUP214/ABL1 fusion. However, for the remaining 21/170
patients showing elevated HOXA10 expression, there was a lack
of evidence for one of the genetic alterations mentioned above.
In 30 out of the 43 patients showing HOXA10 overexpression,
material was available to detect the presence of the HOXA10b
short transcript. Interestingly, 16 of these 30 patients tested
showed expression of HOXA10b, whereas expression was absent
in the remaining T-ALL patients. Remarkably, these 16 HOX-
A10b-positive patients included all 14 TCRb-HOXA rearranged
cases and only two additional T-ALL patients lacking this
rearrangement or other chromosomal defects. These data
demonstrate that overexpression of this transcript is almost
typically found in the TCRb-HOXA rearranged cases.
HOXA expression profiling of TCRb-HOXA rearranged
T-ALL
Gene expression of the different HOXA cluster genes
(HOXA1, HOXA2, HOXA3, HOXA4, HOXA5, HOXA6,
HOXA7, HOXA9, HOXA10, HOXA11 and HOXA13) was
measured by real-time quantitative RT-PCR in 10 TCRb-HOXA
rearranged T-ALLs and in 21 non-TCRb-HOXA rearranged







Figure 2 Genomic position of the FISH clones (black bars) flanking and covering the TCRb and HOXA gene loci on chromosome 7; tel: telomeric;
cen: centromeric. Position of HOX genes and TCRb is indicated below clones. Lower panels: FISH results using different combinations of clones in
case no. 10.



















































cases. As expected, TCRb-HOXA rearranged cases showed an
upregulation of especially 50 HOXA cluster genes compared to
non-TCRb-HOXA cases (Figure 3). However, upregulation of
individual HOXA cluster genes was statistically significant only
for genes HOXA3 (P¼ 0.007), HOXA9 (P¼ 0.0002), HOXA10
(P¼ 0.001) and HOXA11 (P¼ 1.05 105). Interestingly, case
no. 10 carrying the TCRb-HOXA fusion on a ring chromosome 7
showed an expression pattern of HOXA cluster genes more in
favor of the 30 located HOXA cluster genes (HOXA1, HOXA2,
HOXA3) than 50 located genes HOXA9, HOXA10, HOXA11
and HOXA13. This might suggest a different breakpoint
localization compared to breakpoints clustered in the HOXA9
gene in three other TCRb-HOXA rearranged cases (see below).
Clustered breakpoints in TCRb-HOXA rearranged T-ALL
cases
Long-distance PCR using HOXA9 forward and TCRb-Db1
reverse primers as suggested by Soulier et al.4 was successful
in three out of 10 patients. This revealed amplicons with various
lengths for each patient: patient 2, 2–3 kb; patient 8, 6–7 kb; and
patient 9, 4–5 kb (not shown). Sequencing analysis showed that
all three patients had breakpoints within a 2.9 kb region of intron
1A (total length: 3.8 kb) of the HOXA9 gene and within a 1.1 kb
region of the TCRb gene. Breakpoints within the TCRb gene
were located at the JB segments: JB2.7 (case no. 2), JB2.5 (case
no. 8) and JB2.1 (case no. 9) (Figure 4). RSS sequences were
found at the TCRb, JB segments at 50–100 bp upstream from the
respective breakpoints, suggesting aberrant VDJ recombination
as possible mechanism leading to this translocation. The fact
that this analysis was unsuccessful in the remaining seven
patients, including the TCRb-HOXA triplication, might suggest
the existence of other breakpoints located 30 of HOXA9 gene or
alternative TCRb breakpoints.
Discussion
In this study, we report the findings of a retrospective screening
of 424 T-ALL patients in search for specific clinical and
biological characteristics of T-ALLs carrying a TCRb-HOXA
rearrangement, which we and others4 recently described as a
new cytogenetic entity.3 This large-scale study revealed a
slightly lower incidence of the abnormality than previously
assumed, that is, 3.3% (14/424) compared to our first report
(5%).3 The median age at diagnosis was situated in the third
decade (25.9 years; range 9–49 years) and affects both men and



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3 Geometric mean of expression levels of different HOXA
cluster genes in TCRb-HOXA rearranged cases versus non-rearranged
cases.



















































different from T-ALL in general.27 The number of patients
collected so far (n¼ 14) is rather small to make conclusions
regarding survival. Nonetheless, four out of 14 patients
deceased 24 (n¼ 3) and 48 (n¼ 1) months after diagnosis,
which is comparable to the overall survival in T-ALL.
The reported typical immunological profile of TCRb-HOXA
rearranged cases (CD2, CD4þ , CD8) was confirmed in
all but three cases. T-ALLs used to be classified according to
the European Group for the Immunological Characterization
of Leukemias (EGIL) classification in T1 and T2 (immature
T-ALL) and T3 and T4 (mature T-ALL), largely depending on
the expression of CD1a.18 With this classification, the TCRb-
HOXAþ T-ALLs could be assigned to the group of mature
T-ALLs (T3–T4). Recently, a TCR-based classification of T-ALLs
was described, which demonstrated that T-ALLs largely repro-
duce normal thymic development and allowed separation of
cases into TCRabþ , TCRgdþ T-ALLs and immature/uncom-
mitted, TCR and cytoplasmic TCRb-negative cases.28 Further-
more, the authors demonstrated that specific oncogenetic sub-
classes of T-ALL were associated with a specific, age-indepen-
dent stage of maturation arrest. In line with this classification, it
seems that the oncogenic pathways leading to the TCRb-HOXA
rearrangements are mostly situated at the immature stage
of thymic development based on the lack of expression of
surface TCR.
Interestingly, the 14 TCRb-HOXA rearranged cases failed
to show additional molecular/cytogenetic features frequently
found in T-ALL such as HOX11, HOX11L2, SIL-TAL1 deregula-
tion or CALM-AF10 rearrangements and NUP214-ABL1 ampli-
fication. Recently, the first T-ALL patient carrying a TCRd-HOXA
rearrangement was described and most interestingly, this case
carried a CALM-AF10 aberration,29 raising questions regarding
mechanistic or oncogenic synergy between CALM-AF10 and
HOXA rearrangements. The lack of additional molecular/
cytogenetic features in the TCRb-HOXA rearranged cases is in
contrast to other cytogenetic subgroups like NUP214-ABL1
amplified T-ALL, which is associated with HOX11, HOX11L2
upregulation, but further suggests that the TCRb-HOXA rear-
ranged T-ALLs have a unique oncogenic pathway not shared
with other known oncogenic events. However, deletions of
9p21 harboring the tumor suppressor genes CDKN2A (encoding
p14 and p16) were present in nine out of 14 cases, suggesting a
multistep pathogenesis with deletion of a tumor suppressor gene
acting in concert with activation of HOXA proto-oncogenes.
Similarly, activating NOTCH1 mutations were present in as
much as 67% (8/12) of TCRb-HOXA-positive T-ALLs, which is in
line with previous findings in T-ALL.30 These findings further
suggest that HOXA oncogenes might cooperate with NOTCH1
in T-ALL pathogenesis.
Expression profiling of 10 TCRb-HOXA-positive cases con-
firmed our previous findings, that is, a significant upregulation of
HOXA cluster genes HOXA3 (P¼ 0.007), HOXA9 (P¼ 0.0002),
HOXA10 (P¼ 0.001) and HOXA11 (P¼ 1.05 105), whereas
another study found different levels of upregulation of all HOXA
genes in this subgroup.4 This discordance might be due to a
different approach towards normalizing gene expression data
and lack of statistical analysis. Interestingly, Soulier et al.4
pointed to the presence of a specific short alternative HOXA10b
transcript, which was exclusively present in the TCRb-HOXA
rearranged cases. Real-time quantitative RT-PCR for expression
of HOXA10b revealed a specific expression in all TCRb-HOXA-
positive cases (n¼ 14), whereas MLLþ and CALM-AF10þ
cases lacked expression of this alternative transcript. This finding
further suggests that the TCRb-HOXA subgroup of T-ALL has at
least a specific oncogenic pathway not shared with other
cytogenetic subgroups.
A hallmark of homeobox gene expression seems to be a high
frequency of alternative splicing events leading to transcripts
that would encode partial homeobox proteins lacking either the
homeodomain or transcriptional regulatory domains, or contain-
ing alternative putative regulatory regions.31,32 Alternatively,
spliced homeobox-containing cDNAs from the HOXA10 gene
were cloned first from two myeloid leukemia cell lines32 and
shared the homeodomain and 30 flanking regions but had
unique 50 flanking regions (Figure 5). Expression of the full-
length transcript was detected predominantly in cell lines with a
myeloid phenotype, whereas the short transcript was the major
transcript in a B-cell line (CESS) and a T-cell line (MOLT). The
splicing of HOXA10 in normal bone marrow and primary
samples of myeloid leukemias seemed to be different from that
observed in leukemic cell lines,33 with the full-length HOXA10
transcript being the predominant transcript in this group,
whereas immortalized cell lines contained the additional short
transcript. However, in this study, no HOXA10 expression
was detected in cell lines or primary samples with lymphoid
or erythroid features, whereas we found HOXA10 expression
in 25.2% of primary T-ALLs and in one T-ALL cell line
(RPMI 8402). These conflicting results could be due to the
small number of T-ALL samples analyzed (n¼ 6) and the lower















Figure 4 Genomic breakpoint position of three TCRb-HOXA rear-
ranged T-ALL (black arrows). Breakpoint positions of TCRb-HOXA
patients from Soulier et al. are indicated by white arrows.
HOXA10
isoform a, long transcript
isoform b, short transcript
(3 kb, 496 aa)
(2.2 kb, 94 aa)
ex 1a ex 1b ex 2
translated
untranslated
Figure 5 Genomic structure of the HOXA10 locus with alternative
mRNA transcripts HOXA10a (full length) and HOXA10b (short
transcript).



















































sensitivity of the methods used (RNase protection assay) in this
study. The functional role of the N-terminal region of homeo-
box proteins is largely unknown. However, Zappavigna et al.34
reported the first evidence that sequences in the N-terminal
region of a HOX protein influence transcriptional activity.
Interestingly, we found one patient showing overexpression
of both HOXA10 and HOXA10b, which revealed a triplication
of HOXA and TCRb flanking clones with deletion of the
distal clones on a ring chromosome 7. In this case, HOXA10
overexpression was not only due to the juxtaposition of these
two genes, but also due to gene dosage. Ring chromosome
formation may occur by two mechanisms: (1) double-strand
breaks in each arm of a chromosome with subsequent fusion
of the proximal broken ends; and (2) fusion of dysfunctional
telomeres from the same chromosome.35 FISH with telomeric
probes showed absence of both 7pter and 7qter in the ring
chromosome, suggesting that the first mechanism was respon-
sible for ring formation in this patient. Acquired ring chromo-
somes have been found in many types of human neoplasia,
especially in mesenchymal tumors but infrequent in acute
leukemia.35,36 In this particular patient, the ring chromosome
showed little or no size variation, and lacked telomeric
sequences but carried multiple3–6 copies of the TCRb-HOXA
juxtaposition. So far, proto-oncogene amplification by ring
chromosome formation was mostly described in solid tumors
such as dermatofibrosarcoma protuberans, which is character-
ized by a reciprocal t(17;22)(q22;q13) or more commonly by
supernumerary ring chromosomes containing amplified se-
quences from chromosomes 17, 22 and 8.37,38 In leukemia,
the mechanism of proto-oncogene activation by amplification
on ring chromosomes was never reported in lymphoid leukemia
but only demonstrated in rare myeloid leukemia cases. These
amplifications on ring chromosomes have been described in the
following myeloid leukemia cases: three cases with MLL ampli-
fication,39 one with ETV6 amplification40 and two cases with
AML1 amplification on ring chromosomes.41 Several amplifica-
tion mechanisms have been proposed, that is, looping out of
extra chromosomal sequences42 without evidence of chromo-
somal rearrangements, breakage–fusion–bridge cycles that can
be triggered by fragile site induction43 and a translocation–
deletion–amplification model.44,45 Most of these mechanisms
rely on unequal segregation of chromosome sequences during
mitosis.
Based on karyotypic analysis, the TCRb-HOXA rearrangement
could be readily detected in two patients with exclusively
abnormal metaphases, whereas two patients showed a
del(7)(p15). This suggests that the rearrangement is not fully
cryptic, but detection depends on the percentage of good-
quality abnormal clonal metaphases within the karyotype and
the banding technique (R-banding). Additional karyotypic aber-
rations were found in five separate cases and included add(6)
6(qter), del(6)(q14), add(5)(q31), del(9)(p21), del(9)(p12p24),
þ 11 and þ 21.
Genomic breakpoints in three out of 10 patients showed a
clustered pattern in the TCRb and HOXA gene locus and were
located between the JB2.1 and JB2.7 segments at the TCRb locus
(1.1 kb) and within the intron 1A of the HOXA9 gene (2.6 kb).
The fact that this could not be demonstrated in the remaining
seven patients, including the TCRb-HOXA triplication, might
suggest the existence of other breakpoints in the HOXA and/or
TCRb regions. RSS sequences were found at the TCRb, JB
segments at 50–100 bp upstream from the respective break-
points, suggesting aberrant VDJ recombination as possible
mechanism leading to this translocation. This is in line with
previous reports of genomic breakpoints within TCR genes46,47
suggesting aberrant VDJ recombination as the most important
mechanism leading to these translocations. However, recently,
a t(7;14)(p15;q11) involving HOXA genes on chromosome
7p and TCRd genes at 14q11 failed to show RSS-like sequences
on the derivative chromosome 7, suggesting that other mecha-
nisms might be involved in this TCR rearrangement.29
In conclusion, the present study covers the largest group of
TCRb-HOXA rearranged T-ALLs identified so far and sum-
marizes clinical, immunophenotypical and molecular genetic
characteristics of this subgroup. Most interestingly, this series
includes the first case of oncogene triplication by ring chromo-
some formation in T-ALL, that is, triplication of the TCRb-HOXA
fusion, probably as a secondary genetic event subsequent to
chromosomal rearrangement.
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Paper 4:  
HOXA cluster deregulation by a TCRδ-HOXA chromosomal translocation in a CALM-AF10+ 
T-ALL.  


















































































































































































HOXA cluster deregulation in T-ALL associated with both a TCRD-HOXA and
a CALM-AF10 chromosomal translocation
Leukemia (2006) 20, 1184–1187. doi:10.1038/sj.leu.2404187;
published online 30 March 2006
Recognized T-cell acute lymphoblastic leukemias (T-ALLs)
oncogenic pathways include transcriptional deregulation of
oncogenes by juxtapositioning to the T-cell receptor b (TCRB) or
a/d (TCRA/D) enhancer loci, resulting in overexpression of genes
such as LMO2, LMO1, LYL1, TAL1/SCL, and homeodomain
genes such as TLX1/HOX11, TLX3/HOX11L2 or HOXA. A V(D)J
error-type mechanism has been proposed to explain such
recurrent chromosomal events but other processes are likely to
intervene, particularly those mediating the chromosomal break
at the locus bearing the proto-oncogene.1 Evidence in favor of
V(D)J-mediated errors include the presence of non-templated
nucleotides (n-diversity) at the chromosomal junction and of
recognition signal sequences (RSS) or RSS-like sequences at the
vicinity of the breakpoints on the derivative chromosomes,
although putative RSS-like sequences are usually incomplete.
The HOXA gene cluster on chromosome 7p15 has recently
been described as a new recurrent TCRB partner in T-ALL.2,3 In
cases with TCRB-HOXA translocation, a variable but consistent
combination of individual HOXA genes on both sides of the
breakpoint appears to be upregulated. The juxtapositioning of
TCRB enhancer elements and the HOXA locus disruption in
itself might deregulate the whole cluster expression. In other
cases, trans-regulating factors can deregulate the whole HOXA
cluster. The MLL protein directly regulates HOX family genes4
and chimeric MLL oncoproteins are recognized to mediate
HOX deregulation in AML and B- and T-lineage ALL.5 T-cell
acute lymphoblastic leukemia with CALM-AF10 fusions also
demonstrate HOXA cluster upregulation,2,6 but the mechanisms
mediating gene deregulation in these cases remain to be explored.
We here describe cytogenetic and molecular findings in the
first case of T-ALL with both CALM-AF10 and a t(7;14)(p15;q11),
juxtaposing the HOXA cluster to the TCRD Jd1 gene segment.
A 29-year-old male patient with hepatosplenomegaly but no
mediastinal involvement was diagnosed with T-ALL at Purpan
Hospital (Toulouse, France). White blood cell count was
42 109/l. Immunophenotyping and real time quantitative-
polymerase chain reaction (RQ-PCR) revealed a TCRgdþ ,
CD4/8 double positive, CD1a- phenotype expressing high levels
of RAG-1 and pre-T-cell receptor alpha (PTCRA) transcripts,
previously reported as UPN 3749.7 Karyotype analysis showed
46,XY, t(7;14)(p15;q11),t(10;11)(p13–14;q14–21),add(18)(q23)
[11]/46,XY[9]. RT-PCR analysis revealed the presence of a
CALM-AF10 fusion as predicted by the t(10;11)(p14;q21).7
Southern blot analysis of DNA extracted from a bone marrow
sample at diagnosis revealed two rearranged BglII-digested Jd1
fragments (data not shown). Multiplex TCRD PCR showed one
clonal Vd1–Jd1 rearrangement but the second rearranged allele
was not identified, and as such did not correspond to a classical
TCRD rearrangement.
PvuII digestion and Jd1 amplification by ligation-mediated-
polymerase chain reaction (LM-PCR) generated a product of
approximately 350 bp (Figure 1a), which on sequencing was
shown to contain a Jd1-HOXA junction, with the intact start of
Jd1 separated by nine n-diversity nucleotides from an intronic
fragment of chromosome 7, located between the HOXA6 and
HOXA7 genes. A specifically designed PCR confirmed the
breakpoint sequence (Figure 1b).
To search for the derivative breakpoints, the ligated PvuII-
digested DNA was amplified with the Der(14)S-specific primer,
corresponding to the translocated telomeric part of chromosome
7. Two fragments of 600 and 700 bp were obtained (Figure 1c).
Sequencing revealed that the 600 bp fragment corresponded to
the genomic sequence of chromosome 7, whereas the 700 bp
fragment showed chromosome 7 rearranged with the dREC1
segment on chromosome 14. A specifically designed primer pair
confirmed the junction (Figure 1b) and revealed that the leuke-











Figure 1 (a) Run of DraI and PvuII-digested LM-PCR product using the Jd1-specific primer. The t(7;14) junction was amplified from the PvuII-
digested fragment appearing around 350 bp. The other DraI-digested product of interest measuring around 1 kb represents the Vd1–Jd1
rearrangement of the second allele. The two products for the DraI and PvuII digestions appearing around 450 and 900 bp represent the expected
germline products of 458 and 827 bp, respectively, amplified from the background population. (b) Direct PCR designed to amplify the der(7) and
(14) junctions showing products of expected length. (c) Run of PvuII-digested LM-PCR product using the DerS specific primer. The 600 bp product
corresponds to the genomic chromosome 7 sequence. The 700 bp product corresponds to the der(14).
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The translocation was balanced, with loss of only a single
nucleotide from chromosome 7 (Figure 2). The dREC-chromo-
some 7 translocation most probably happened during attempted
Dd3–Jd1 joining (Figure 3). The addition of n-nucleotides at the
junctions is compatible with a V(D)J error-type translocation
mechanism. However, the heptamer-like sequence in the
vicinity of the der(7) breakpoint diverges from the consensus
heptamer sequence.
This case is of particular interest as it represents the first
description of a TCRD-HOXA translocation, as all nine
previously reported cases of T-ALL with HOXA cluster
translocations involved the TCRB locus. The HOXA breakpoint
between HOXA6 and HOXA7 in the present case is telomeric to
the four TCRB-HOXA cases, which clustered in a 2.6-kb region
between HOXA10 and HOXA9,2 and to the three additional
TCRB-HOXA cases where the breakpoint was clustered in intron
1A of the HOXA9 gene locus (Cauwelier et al., unpublished
data). The relative incidence of TCRB and TCRD-HOXA
translocations needs to be tested by Fluorescence in situ
hybridisation (FISH), as TCRB-HOXA translocations are difficult
to detect on classical caryotyping. The localization of the TCRD
and HOXA loci makes cryptic t(7;14)(p15;q11) unlikely if
mitosis is representative of the leukemic clone.
As for other TCR translocations, to what extent TCR-HOXA
rearrangements represent V(D)J errors is not yet clear. Soulier
et al. described two heptamer-like sequences beside the HOXA
breakpoints on the derivative chromosome 7. In our case,
junctional diversity at the der(7) junction and at the dRec–Dd2–
Dd3 junction on the der(14) is in keeping with RAG-induced
events. However, the heptamer-like sequence 50 to the break-
point on chromosome 7 is not concensus (underscored in
Figure 2). It can therefore be postulated that the strand break on
chromosome 14 and the illegitimate ligation to chromosome 7
are RAG-induced, whereas the mechanism initiating the break
Figure 2 The nucleotide sequence of both derivatives implicated in the t(7;14) translocation. Underscored are recognition signal sequences
(RSS) or RSS-like sequences in the vincinity of the breakpoints. Lowercase letters denote non-templated nucleotides at the junction.
Figure 3 Sequence of events leading to the final translocation. Exons are represented by boxes. Triangles represent recognition signal
sequences and show their orientation. E¼ enhancer.
























































































































on chromosome 7 remains to be defined. Although illegitimate
V(D)J recombination has been proposed to be involved in most
Ig/TCR–proto-oncogene recurrent lymphoid translocations,
functional models do not always support this assumption and
suggest that for certain recurrent translocations the breaks at the
non-immune locus are initiated by other, as yet unknown,
mechanisms.1 The present case is likely to belong to this
category.
As expected, FISH analysis confirmed the colocalization of
TCRD and HOXA probes in six of eight mitosis and in 80% of
interphase nuclei. The CALM-AF10 translocation was confirmed
by FISH in more than 80% of interphase nuclei, thus
demonstrating the existence of the two translocations in the
vast majority of cells and excluding the possibility of two distinct
clones (Figure 4a and b), in accordance with the karyotype
showing both translocations in 11 mitosis. Given that CALM-
AF10þ T-ALL overexpress HOXA genes,2,6 albeit by an
unknown mechanism, it was surprising to find another HOXA
genetic abnormality in the same leukemic clone.
We therefore analyzed HOXA transcript levels in order to
assess the relative impact of CALM-AF10 and TCRD-HOXA on
HOXA overexpression. We compared transcript expression of
the whole HOXA cluster in this case to a series of 12 other
CALM-AF10þ T-ALL with no evident karyotypic abnormalities
involving chromosome band 7p15 (Figure 5). As expected,
HOXA cluster genes were overexpressed although the presence
of the HOXA-TCRD translocation did not give rise to a clearly
distinct pattern of HOXA gene expression in comparison to
CALM-AF10þ T-ALL without apparent TCRD-HOXA rearran-
gement, in particular with respect to the HOXA6 and HOXA7
genes adjacent to the breakpoints. This would suggest that
rupture of the HOXA locus by TCRD is sufficient to lead to
generalized HOXA deregulation on both sides of the breakpoint,
not restricted to the genes adjacent to the breakpoint, as
previously described for HOXA-TCRB.2 HOXA expression may
therefore be deregulated by elements other than the TCRD (or
TCRB) enhancers. Alternatively, as this case also demonstrates a
CALM-AF10 fusion, the HOXA profile may be determined in
this case by CALM-AF10 rather than HOXA-TCRD, thus
explaining the absence of distinct HOXA profiles when
compared with ‘isolated CALM-AF10’ T-ALLs. This is compa-
tible with a predominant trans-mediated influence of CALM-
AF10 on HOXA deregulation, which a cis-mediated effect of the
TCRD-HOXA6/7 juxtaposition does not over-ride.
This case expressed both a surface TCRgd receptor and
PTCRA, which is normally restricted to the TCRab lineage. We
have previously shown that TCRgdþ PTCRAþ T-ALLs often
demonstrate deregulation of orphan homeobox-like genes
(HOX11/TLX1 or HOX11L2/TLX3)8 and that these cases are
characterized by high RAG-1 levels, which suggest active, but
unproductive V(D)J activity with respect to a complete TCR.
Such a scenario is conducive to V(D)J errors, as described here
for the dRec-Jd-HOXA rearrangement identified in the majority
of the leukemic clone.
In conclusion, we report that HOXA deregulation by TCR
juxtapositioning is not restricted to TCRB, with impact for
screening practice. The coexistence of HOXA-TCRD and
CALM-AF10 in this case does not modify the HOXA deregula-
tion profile observed in CALM-AF10 T-ALLs. This would suggest
a dominant trans-mediated mechanism of HOXA deregulation
by CALM-AF10, which merits to be explorated.
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Figure 4 (a) Fluorescence in situ hybridization (FISH) result using
TCRA/D distal (green) and HOXA proximal (orange) FISH probes
showing a fusion signal in six of eight mitosis. (b) FISH result showing
two CALM-AF10 fusion signals.
Figure 5 RQ-PCR quantification of the HOXA transcripts.
Absolute DCt (cycle threshold) value¼TBP CtHOXA Ct.
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The purpose of the present study was to screen a large number of T-ALLs to search for 
cryptic, chromosomal aberrations targeting T cell receptor loci (TCR) and eventually detect 
putative new T cell oncogenes. During previous work on childhood ALL from our group, a cryptic 
chromosomal rearrangement affecting the TCRβ locus (7q34) in a childhood T-ALL patient was 
detected 1. This observation was the trigger to study a large series of childhood and adult T-ALL 
patients to search for additional cryptic rearrangements and possibly new target genes of especially 
the TCRβ locus. 
In a first study, 94 T-ALLs were analyzed using FISH with TCRβ flanking FISH clones 2. This 
analysis uncovered the presence of a new recurrent chromosomal aberration affecting the TCRβ 
gene locus (7q34) and the HOXA gene locus (7p15) in an inversion, inv(7)(p15q34), in 5 of 94 
patients. To further delineate the respective breakpoints, TCRβ and HOXA covering FISH clones 
were carefully selected and applied to all 5 inv(7) patients, which refined the breakpoints within 
the HOXA gene cluster between the HOXA5 and HOXA10 gene (12kb). To further address the 
clinical, immunophenotypical and molecular genetic findings of this chromosomal aberration, we 
studied 330 additional T-ALLs. This revealed TCRβ-HOXA rearrangements in 5 more patients and 
together with 4 patients identified in the study from Soulier 3, brings the total to 14 in 424 patients 
screened (3.3%) 4. Nine cases were inv(7)(p15q34), whereas two patients showed a t(7;7)(p15;q34) 
and one case with TCRβ-HOXA triplication due to ring chromosome formation. This interesting 
observation is discussed in detail below. For the two patients left, no metaphases were available 
which hampers a distinction between an inv(7) and a t(7;7). Cloning of the breakpoints was 
successful in three cases and unraveled clustered breakpoints within the HOXA gene cluster 
(intron1a of HOXA9; 2.3 kb region) as well as in the TCRβ gene locus (Jβ2.1 to Jβ2.7; 1.1kb region). 
This was slightly different to the breakpoints found in 4 patients carrying the TCRβ-HOXA 
rearrangement in the study of Soulier et al. 3. They characterized the breakpoints within the HOXA 
cluster 3’ to the HOXA10 gene and within intron 1b of HOXA9 and within the Dβ1 gene of the TCRβ 
locus respectively. Nevertheless, the region encompassing the HOXA10 and HOXA9 genes remains 
the major breakpoint cluster region. 
This initial study also demonstrated the unexpected high frequency of TCRβ rearrangements 
in as much as 20% of T-ALLs (19/94) screened. This finding was confirmed in a second study where 
we analyzed 32 additional patients (total n=126) and 19 T-ALL cell lines for chromosomal 
aberrations affecting TCRβ locus and the other TCR loci (TCRαδ and TCRγ) 5. TCRβ chromosomal 
rearrangements were found in 19% (24/126) whereas only 3.1% (4/126) of these aberrations were 
detected upon conventional karyotyping. In five other patients, partial deletions or additional 
material of chromosome 7 were found, suggesting a chromosome 7 alteration in 3.9 % (5/126). 
However, 11.1% (14/126) of these TCRβ alterations remained undetected upon previous banding 
analysis. In other words, within the group of TCRβ rearranged cases (n=24), most rearrangements 
remained undetected (58.3%; 14/24) when excluding failures. This high percentage of cryptic TCRβ 
rearrangements could be partly explained by the distal localization of the TCRβ locus (7q34) 
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together with a distal chromosomal position of the partner genes involved namely inv(7)(p15q34), 
t(7;7)(p15;q34), t(7;11)(q34;q24) and t(7;10)(q34;q24). Given these remarkable results on 
rearrangements affecting the TCRβ locus, we also tested the involvement of the two other TCR loci 
(TCRαδ: 14q11 and TCRγ: 7p15) in this series of patients and T-ALL cell lines using flanking FISH 
probes for these respective loci. This resulted in the first assessment of the incidence of 
chromosomal TCR rearrangements in T-ALL 5. Similarly to the TCRB locus, breakpoints in the TCRαδ 
locus were detected in 17.4% using FISH whereas standard cytogenetics only detected 9.4% TCRαδ 
rearrangements. Given the proximal chromosomal position of this locus (in contrast to the TCRβ 
locus) these rearrangements should be readily detectable on G-banding analysis. Some of these 
rearrangements remained undetected due to the involvement of chromosome 14 in more complex 
karyotypes, whereas two cases showed a marker chromosome possibly harboring the derivative 
chromosome 14. In line with previous reports, no TCRγ rearrangements were observed in this series. 
Apparently, these TCRγ rearrangements are only detected in T-cell tumors in patients with ataxia 
telangiectasia (ATM) where these rearrangements are frequently found 6. A possible explanation for 
the high incidence of TCRβ and TCRαδ rearrangements and the lack of alterations affecting the 
TCRγ locus could be the length of the genes (TCRαδ: 1,000 kb; TCRβ: 620 kb; TCRγ: 160 kb) with 
greater susceptibility to double strand breaks and subsequent translocations along with increasing 
length of the respective gene.  
This study also demonstrated the involvement of possible new putative T-cell oncogenes at 
different chromosomal positions: chromosome 11q24, 20p12, 20q12 and 6q22. Another interesting 
observation was the presence of rearrangements of both TCRαδ and TCRβ loci in six patients and 
one cell line. Five of these patients were children, possibly reflecting the higher susceptibility for 
errors in VDJ recombination as a consequence of greater antigen exposure during childhood. In four 
patients, involvement of different T-cell oncogenes by both TCRB and TCRαδ genes was confirmed 
using FISH with the appropriate flanking BAC clones. Interestingly, two patients carried a 
translocation between the two TCR loci. Rearrangements between two TCR loci, TCRγ and TCRαδ, 
have been reported in a high frequency in ATM patients. This aberration has also been found in T-
lymphocytes from healthy individuals at very low frequencies, suggesting that rearrangements 
affecting both TCR loci are not merely chromosomal aberrations associated with tumorigenesis but 
could represent the capacity of the recombinase system to enlarge immune diversity 7, 8. 
 Besides the inversion, inv(7)(p15q34) and translocation, t(7;7)(p15;q34) cases, we also 
found a patient carrying a triplication of the TCRβ-HOXA fusion on a ring chromosome 7 5. This is 
the first report of HOXA10 and HOXA10b overexpression in a TCRβ-HOXA rearranged case not only 
due to juxtaposition of these two genes, but also to gene dosage. Ring chromosome formation may 
occur by double strand breaks in each arm of a chromosome with subsequent fusion of the proximal 
broken ends or by fusion of dysfunctional telomeres from the same chromosome. Given the absence 
of both telomeres 7q and 7p in our patient we assume the first mechanism was responsible for ring 
formation in our patient. Acquired ring chromosomes have been found in many types of human 
neoplasia, especially in mesenchymal tumors but infrequent in acute leukemia 9, 10. In leukemia, the 
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mechanism of proto-oncogene activation by amplification on ring chromosomes was only 
demonstrated rarely in myeloid cases but not in lymphoid leukemia so far.  
Gene expression analysis showed consistent increased expression of especially HOXA10 and 
HOXA11 in all TCRβ-HOXA positive cases compared to T-ALL cases lacking this rearrangement 4. 
Given the breakpoint position within or 3’ to the HOXA9 gene and the sustained high expression of 
the 5’ located HOXA10 and HOXA11 genes, we propose two possible mechanisms leading to this 
aberrant HOXA gene expression. First, the disruption of the HOXA gene cluster could interfere with 
the normal program of sequential up and downregulation following the 3’ to 5’ localization of the 
HOXA genes with 3’ genes being expressed in the more primitive cells and 5’ genes in more 
differentiated cells. Evidence for involvement of HOXA genes in developing thymocytes came from a 
study from Taghon et al. 11 where high HOXA10 expression was found in the earliest T cell 
precursors in human thymus and showed subsequent downregulation in CD4 and CD8 single positive 
mature T cells. Physical disruption of the HOXA gene cluster could therefore block downregulation 
of HOXA10 and HOXA11 required to allow cells to complete their differentiation and maturation. 
The second mechanism that could explain high HOXA10 and HOXA11 expression in these patients, is 
that enhancers embedded within the TCRβ locus lead to sustained high expression levels of HOXA10 
and HOXA11. Given the 10-fold higher expression levels of HOXA10 and HOXA11 observed in the 
TCRβ-HOXA positive patients compared to normal developing thymocytes, we favor the second 
hypothesis.  
As mentioned in the introduction, HOX genes play a significant role not only in regulating 
body formation but also in organization and regulation of hematopoiesis and leukemogenesis. First 
evidence for involvement of HOX genes in human leukemia came from the identification of 
translocations involving the nucleoporin gene (NUP98) and HOXA9 in rare cases of AML and 
subsequently a number of NUP98 fusions with other HOX genes have been described 12-14. Until 
recently, a role for HOXA cluster genes in T-ALL was only suggested by Ferrando et al. 15 who 
demonstrated increased expression levels of a subset of HOX genes in MLL rearranged T- and B-ALL. 
In these cases however, the transcriptional activation of HOXA cluster genes was a direct effect of 
MLL since both HOXA7 and HOXA9 were proven to be direct targets. First evidence for a direct role 
of HOXA genes in T-ALL was demonstrated in our initial study 1 and, together with previous studies 
that showed impairment of final T cell differentiation upon enforced HOXA10 expression in cord 
blood cells, strongly suggest that the HOXA gene cluster is of crucial importance in normal T cell 
development. Shortly after we published the new recurrent cytogenetic abnormality involving the 
HOXA and TCRB gene locus with elevated HOXA gene expression, an other cytogenetic T-ALL 
subgroup was described showing elevated HOXA gene expression namely the CALM-AF10 positive T-
ALL with the t(10;11)(p12;q14-q21) 16. Gene expression data of a large group of T-ALLs further 
confirmed the existence of a HOXA expressing group of T-ALLs consisting of MLL, CALM-AF10 and 
TCRB-HOXA rearranged cases  3. All these findings support the importance of HOXA genes not only in 
myeloid but also in lymphoid leukemogenesis. 
 Given the significant transcriptional upregulation of especially HOXA10 and HOXA11 in 
patients carrying the TCRβ-HOXA rearrangement, we further analyzed 170 T-ALL patients (including 
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14 TCRβ-HOXA positive patients) for the expression of HOXA10 in order to validate the association 
of this chromosomal rearrangement and ectopic HOXA10 expression 5. This revealed overexpression 
of HOXA10 in 25.2% (43/170) of cases, whereas only 8.2% (n=14) carried the TCRβ-HOXA 
rearrangement. In 4.2% of HOXA10 overexpressing cases, either CALM-AF10 or MLL rearrangements 
were present. For the remaining 12.8% of patients with ectopic HOXA10 expression, the exact 
mechanism of HOXA deregulation remains unclear. One possible explanation is that some of the 
cases included as HOXA10 positive, represent normal HOXA10 expression reflecting their stage of 
differentiation arrest. Therefore, HOXA10 expression is not a useful screening marker for TCRβ-
HOXA rearrangements. Interestingly, gene expression data from the group of Soulier 3, pointed to 
the expression of an alternative short HOXA10 transcript, HOXA10b in the subgroup of TCRβ-HOXA 
positive cases. We therefore analyzed all HOXA10 expressing T-ALLs for expression of this short 
transcript which was detected in all 14 TCRβ-HOXA positive cases and could not be detected in MLL 
and CALM-AF10 positive T-ALLs 5. As a consequence, expression of this short HOXA10b transcript 
could serve as a screening marker for the TCRβ-HOXA aberration. Alternative splicing seems to be a 
hallmark of homeobox gene expression, leading to transcripts that encode partial homeobox 
proteins, lacking either the homeodomain, transcriptional regulatory domains, or containing 
alternative regulatory regions. Alternatively spliced homeobox-containing cDNAs from the HOXA10 
gene were first cloned from two myeloid leukemia cell lines 17. These two cDNAs share the 
homeodomain and 3’ flanking regions but have unique 5’ flanking regions. The full length transcript 
could be detected in normal bone marrow and primary myeloid leukemic samples, while 
immortalized cell lines contained the additional short HOXA10b transcript, suggesting a role for 
HOXA10b in immortalization. Differences in biological functions have been suggested for many 
alternatively spliced homeobox genes but Zappavinga et al.18 for the first time provided evidence 
that sequences in the N-terminal region of a HOX protein influence transcriptional activity. 
 Based on karyotypic analysis using R banding techniques, the TCRβ-HOXA rearrangement 
could only be detected in two out of 14 patients carrying an inv(7)(p15q34). The aberration was 
suggested in two other patients by the presence of a del(7)(p15). Additional random clonal 
aberrations were found in 5 patients such as: add(6)(qter), del(6)(q14), add(5)(q31), del(9)(p21), 
+11 and +21, which might suggest the need for other genetic alterations to generate an overt 
leukemia. Other molecular-cytogenetic features frequently found in T-ALL such as HOX11, HOX11L2, 
SIL-TAL1 deregulation, CALM-AF10 rearrangement or NUP214-ABL1 amplification were absent in this 
series. The lack of these additional molecular-cytogenetic features in this cytogenetic subgroup is in 
contrast to other T-ALL subgroups like NUP214-ABL1 amplified T-ALL which is associated with HOX11 
or HOX11L2 upregulation. This suggests that the TCRβ-HOXA rearranged T-ALLs have a different 
oncogenic pathway not shared with other known oncogenic events. Deletions of 9p21 (CDKN2A and 
CDKN2B) and activating NOTCH1 mutations however, were found in a high proportion (64% and 67% 
respectively) of TCRB-HOXA rearranged cases suggesting a multistep pathogenesis with deletion of 
tumor suppressor genes (9p21) or activated NOTCH1 signaling cooperating with HOXA oncogenes. 
HOXA deregulation by TCR juxtapositioning is not restricted to the TCRβ locus as we 
detected the first case of TCRδ-HOXA rearrangement in a CALM-AF10 positive T-ALL 19. The 
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breakpoint within the HOXA cluster was situated between the HOXA6 and HOXA7 genes, which is 
telomeric to the clustered breakpoints in the TCRβ-HOXA cases. In these cases, the breakpoints 
were clustered in a 2.6 kb region between HOXA9 and HOXA10 3 and within intron 1a of HOXA9 4. 
Similarly to the TCRβ-HOXA positive cases, HOXA cluster genes were overexpressed under the 
influence of enhancers within the TCRδ locus. Given that CALM-AF10 positive T-ALLs overexpress 
HOXA genes, it was surprising to find another genetic abnormality disrupting the HOXA gene cluster 
in the same leukemic clone. In order to assess the relative impact of CALM-AF10 and TCRδ-HOXA 
aberrations on HOXA overexpression, HOXA transcript levels of HOXA1 to HOXA13 of CALM-AF10+ 
cases were compared to expression levels in this particular patient. Both showed a similar 
upregulated expression of HOXA3 to HOXA6, HOXA10 and HOXA11. This would suggest that rupture 
of the HOXA locus by TCRδ is sufficient to lead to generalized HOXA deregulation on both sides of 
the breakpoint and not restricted to the genes adjacent to the breakpoint as we described for the 
HOXA-TCRβ rearrangement. HOXA expression may be regulated by elements other than the TCR 
enhancers (cis-mediated) like the trans-mediated influence of the CALM-AF10 fusion which 
overrides the cis-mediated effects. 
Our study on clinical, cytogenetic and molecular characteristics of the TCRβ-HOXA 
rearranged cases 4 showed a median age at diagnosis of 25.9 years (range 9-49 y) which affects both 
men and women (M/F: 8/6) whereas TCRβ negative T-ALL showed a lower age of onset (median 16.6 
years)(P=0.07) and a pronounced male predominance (M/F: 12:1) (P=0.07). Clinical findings were 
not significantly different from other T-ALL. Immunophenotypically, T-ALL can be classified into 
T1,T2 (immature) and T3,T4 (mature) subtypes using the EGIL classification 20 which is largely 
depending on the expression of CD1a. The TCRβ-HOXA rearranged T-ALLs could be assigned to the 
group of mature T-ALLs (T3-T4) based on the surface expression of CD1a (T3) and sCD3 (T4) but 
showed a characteristic immunophenotypic profile of CD2-, CD4+, CD8- and TCR- which is more in 
favor of a differentiation stop in an immature T cell. Recently, a TCR based classification of T-ALLs 
was described which demonstrated that T-ALLs largely reproduce normal thymic development and 
allow separation of cases into TCRαβ+, TCRγδ+ T-ALLs and immature, sTCR (surface TCR) negative 
and cTCRβ (cytoplasmic TCRβ) negative cases 21. Furthermore, the authors demonstrated that 
specific oncogenetic subclasses of T-ALL (HOX11, HOX11L2, SIL-TAL1 and CALM-AF10) were 
associated with a specific, age-independent stage of maturation arrest with TAL1 and HOX11 being 
specific to the αβ lineage, HOX11L2 belonging to an intermediate αβ/γδ population and CALM-AF10 
specific to the γδ lineage 22. In line with this classification, it seems that the oncogenic pathways 
leading to the TCRβ-HOXA rearrangements are almost exclusively situated at the immature stage of 
thymic development based on the lack or weak expression of sTCR. 
 In conclusion, our data for the first time point to a role for class I homeobox genes in T-cell 
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Our results offer several future research perspectives. First of all, given the finding of a 
new recurrent cytogenetic aberration in T-ALL, it is indicated that all newly diagnosed T-ALLs 
should be checked for the presence of a TCRβ-HOXA rearrangement. This should allow us to make 
eventual correlations or predictions towards treatment outcome and survival. Secondly, previous 
undetected partner chromosome regions such as 6q22, 11q24, 20p12 and 20q12 need to be analyzed 
in detail which could result in the detection of new genes involved in T-cell oncogenesis. Thirdly, an 
intriguing finding is the overexpression of HOXA10 in as much as 12.8% of T-ALLs with unknown 
underlying mechanism. Further studies could reveal other mechanisms of transcriptional activation 
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T-cel acute lymfoblasten leukemie (T-ALL) is een aggressieve maligniteit uitgaande van de 
voorlopers van de T cel en komt zowel voor bij kinderen (10-15% van de kinderen met ALL) als bij 
volwassenen (25% van volwassenen met ALL). Het is een vorm van leukemie die in meerdere 
aspecten afwijkt van de veel vaker voorkomende B-cel ALL en een minder gunstige overleving kent 
niettegenstaande talrijke ontwikkelingen van nieuwe behandelingsstrategieën gedurende de laatste 
50 jaar. Zoals andere vormen van leukemie ontstaat deze vorm van kanker door een opeenstapeling 
van genetische veranderingen (mutaties) in een hematopoietische voorlopercel. De meest frequente 
mutaties bij acute leukemie vormen de chromosomale herschikkingen waarin genen zijn betrokken 
die coderen voor transcriptiefactoren. Bij T of -B cel lymfoïde leukemieën komen deze 
transcriptiefactoren vaak onder invloed van regulatorische sequenties gelegen in genen die coderen 
voor de T-cel (TCR) of immunoglobuline receptoren (IG). Als gevolg van deze structurele 
herschikking ontstaat vervolgens een ongecontroleerde transcriptionele opregulatie van deze 
transcriptiefactoren.  
 In de voorbije 20 jaar zijn talrijke studies uitgevoerd die de diagnostische en prognostische 
waarde van het detecteren van chromosomale herschikkingen hebben aangetoond. Bovendien vormt 
het cytogenetisch onderzoek vaak de eerste stap in de richting van het identificeren van 
kandidaatgenen die mede verantwoordelijk zijn voor het ontstaan van een bepaald soort leukemie. 
Ondanks het belang van het cytogenetisch onderzoek dient rekening gehouden te worden met de 
beperkte resolutie (10Mb) waardoor een aantal chromosoomherschikkingen kunnen worden gemist. 
Fluorescentie in situ hybridisatie (FISH) kan een antwoord bieden op de beperkte resolutie van het 
klassieke chromosomenonderzoek en vormt dan ook een belangrijk onderdeel in de diagnostiek en 
onderzoek van hematologische maligniteiten. 
In de huidige studie hebben wij ons gefocuseerd op het ontdekken van nieuwe oncogenen in 
een weinig frequente subklasse van leukemie, T-ALL. Een vorige M-FISH studie uitgevoerd bij 
kinderen met ALL en complexe chromosoomafwijkingen leidde tot de ontdekking van een cryptische 
chromosomale herschikking van de TCRβ locus (7q34) en een nog onbekend oncogen gelegen op 
chromosoom 11q24 in een translocatie t(7;11)(q34;q24). Dit was de aanzet tot het screenen van een 
grote groep T-ALL patiënten (n=94) met het oog op het detecteren van additionele cryptische 
herschikkingen van deze TCRβ locus met behulp van de fluorescentie in situ hybridisatie (FISH) 
techniek. Uit deze studie bleek dat herschikkingen van de TCRβ locus veel vaker voorkomen (20%) 
dan aangenomen op basis van conventionele karyotypering (7%). Dit werd bevestigd in onze studie 
waarin slechts 3.1% van de TCRβ chromosomale herschikkingen gedetecteerd werden met klassieke 
banderingstechnieken. De meest interessante bevinding was echter het ontdekken van een nieuw 
partner gen voor de TCRβ locus in 5 van de 94 patiënten: de HOXA cluster genen op chromosoom 
7p15. Deze 5 patiënten waren drager van een nieuwe recurrente herschikking, namelijk een inversie 
inv(7)(p15q34) met breukpunten gelegen in de HOXA cluster genen (7p15) enerzijds en de TCRβ locus 
anderzijds (7q34). Dit was het eerste rapport waarin betrokkenheid van de HOXA cluster genen in 
chromosomale herschikkingen in T-ALL werd beschreven. Bovendien gaf deze herschikking aanleiding 
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tot overexpressie van HOXA10 en HOXA11 genen in het bijzonder. Samen met voorafgaande 
bevindingen van HOXA genexpressie in de maturatie van normale T cellen, kunnen we 
veronderstellen dat HOXA clustergenen een rol spelen in het onstaan van T-ALLs die drager zijn van 
deze nieuwe herschikking. Dit vormt een aspect van de T-cel oncogenese dat tot noch toe onbekend 
was gebleven. 
In de tweede studie werden naast de TCRβ locus ook de andere TCR loci, TCRαδ (14q11) en 
TCRγ (7p15) onderzocht op chromosomale herschikkingen in 126 T-ALL patiënten en 19 T-ALL 
cellijnen. Deze studie bracht aan het licht dat ook de frequentie van de TCRαδ herschikkingen 
onderschat werd. Bovendien werden chromosomale herschikkingen van zowel de TCRβ als de TCRαδ 
locus samen aangetroffen, waarbij beide loci meestal verschillende T-cel oncogenen troffen alsook 
onderling herschikking vertoonde in 2 patiënten. Naast het voorkomen van talrijke niet eerder 
beschreven chromosomale herschikkingen in T-ALL, werden ook recurrente herschikkingen 
gedetecteerd met mogelijks nieuwe T-cel oncogenen op chromosomen 11q24, 20p12 en 6q22.  
In een derde multi-centrische studie werden in totaal 424 T-ALLs retrospectief onderzocht op 
het voorkomen van de TCRβ-HOXA herschikking en werden klinische, immunofenotypische en 
moleculair-genetische data van deze patiënten nagegaan. Deze studie bracht 5 bijkomende TCRβ-
HOXA positieve patiënten aan het licht welke het totaal op 14 patiënten brengt (3.3%) waarvan 9 
inv(7)(p15q34), 2 t(7;7)(p15;q34) en 1 TCRβ-HOXA triplicatie tengevolge van ringvorming. Voor de 
twee resterende patiënten konden geen mitosen worden gevonden waardoor een onderscheid tussen 
een inv(7) en een t(7;7) werd bemoeilijkt. Voor 170 van de 424 patiënten werd genexpressie analyse 
uitgevoerd voor het HOXA10 gen om de specifieke correlatie met de aanwezigheid van een TCRβ-
HOXA herschikking na te gaan. Overexpressie van HOXA10 werd echter vastgesteld in 25.2% van de T-
ALLs waarvan slechts 8.2% drager waren van een TCRβ-HOXA herschikking (n=14). Expressie van het 
korte HOXA10 transcript (HOXA10b) echter werd bijna exclusief aangetroffen in TCRβ-HOXA positieve 
patiënten (n=14), waardoor een rol in de TCRβ-HOXA gemedieerde oncogenese werd gesuggereerd. 
De chromosomale breukpunten werden gekloneerd in 3 van de 10 patiënten en toonde een clustering 
in zowel de TCRβ locus (1.1 kb) als in de HOXA gen cluster (3.8 kb). Dit was lichtjes verschillend van 
de breukpunten gevonden bij 4 patiënten van de Franse onderzoeksgroep, doch alle breukpunten 
blijven gegroepeerd in de regio rond de HOXA9 en HOXA10 genen. Andere moleculaire en/of 
cytogenetische afwijkingen die vaak voorkomen in T-ALL (SIL-TAL1, CALM-AF10, HOX11, HOX11L2) 
werden niet aangetroffen in de TCRβ-HOXA herschikte patiënten behalve deletie 9p21 en NOTCH1 
activerende mutaties welke aangetroffen werden in respectievelijk 64% en 67% van de TCRβ-HOXA 
herschikte stalen.  
In een vierde korte studie beschrijven we het voorkomen van de eerste HOXA chromosomale 
herschikking met de TCRδ locus in een T-ALL patiënt die tevens drager is van een CALM-AF10 
translocatie. 
Samengevat kunnen we stellen dat we dankzij de FISH techniek erin geslaagd zijn een aantal 
nieuwe chromosomale herschikkingen te detecteren binnen de T-ALL groep welke met de klassieke 





T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of T-cell precursors 
that develop both in children (10-15% of childhood ALL) and adults (25% of adults ALLs). This type of 
leukemia differs in many features from a B-lineage ALL and despite a marked improvement of 
treatment success rates for B- ALL over the past 50 years, less success has been achieved in the 
treatment of T-ALL. Similar to other types of leukemia, T-ALL is caused by a multistep mutagenesis 
involving various genetic alterations within a hematopoietic precursor stem cell. Chromosomal 
translocations affecting genes that encode transcription factors are the most common alterations in 
acute leukemia. In T or B lymphoid leukemias, these genes are frequently translocated downstream 
to the regulatory sequences of genes encoding chains of the T-cell receptor (TCR) or 
immunoglobulin (IG) molecules, resulting in inappropriate expression of the translocated 
transcription factors. 
During last 20 years, many studies have shown that chromosomal abnormalities found in 
leukemia patients were useful diagnostic and prognostic indicators. Moreover, cytogenetic analysis 
is often the first step towards the identification of leukemia-causing genes which are associated 
with the emergence of a certain type of leukemia. Despite the major contribution of cytogenetic 
analysis in unraveling genetic defects in malignant cells, this method suffers from limited resolution 
(10Mb) which can lead to overlooking of some chromosomal rearrangements. The limitations of 
classical karyotyping have been overcome by the introduction of fluorescence in situ hybridization 
(FISH) and offers important possibilities for diagnostic and prognostic purposes in hematological 
malignancies. 
In the present study, we focused on the identification of putative new oncogenes in a minor 
subgroup of leukemias, T-cell acute lymphoblastic leukemia (T-ALL). A previous M-FISH study 
performed on childhood ALL carrying complex chromosomal aberrations, resulted in the 
identification of a cryptic chromosomal translocation, t(7;11)(q34;q24), affecting the TCRβ locus 
(7q34) and an unknown oncogene on chromosome 11q24. This was the trigger to screen a large 
group of T-ALL patients (n=94) using fluorescence in situ hybridization (FISH) in search for additional 
cryptic rearrangements targeting the TCRβ locus. This study unraveled that chromosomal 
rearrangements affecting the TCRβ locus were much more frequent (20%) than assumed based on 
conventional karyotyping (7%). This observation was confirmed in our series of patients where only 
3.1% of TCRβ chromosomal aberrations were detected by classical banding techniques. Most 
interestingly, this screening study lead to the identification of a new TCRβ partner gene in 5 of 94 
patients: the HOXA cluster genes on chromosome 7p15. These 5 patients carried a new, recurrent 
rearrangement i.e. an inversion inv(7)(p15q34) with breakpoints within the HOXA cluster genes 
(7p15) and the TCRβ locus (7q34) respectively. This was the first report of HOXA cluster genes being 
involved in chromosomal rearrangements in T-ALL. This new recurrent rearrangement lead to 
overexpression of HOXA10 and HOXA11 genes in particular. Together with previous findings of HOXA 
gene expression in developing T lymphocytes, we can assume that HOXA cluster genes are involved 
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in T-cell oncogenesis. This was the first report providing evidence for involvement of HOXA genes in 
T-cell oncogenesis. 
In a second study, we analysed involvement of two other TCR loci, TCRαδ (14q11) and TCRγ 
(7p15) besides the TCRβ locus (7q34) in a group of 126 T-ALL patients and 19 T-ALL cell lines. This 
analysis showed that the frequency of TCRαδ rearrangements was also underestimated so far. 
Moreover, chromosomal rearrangements of both the TCRαδ and the TCRβ loci were found in this 
series of patients and mostly targeted different T-cell oncogenes whereas two patients carried 
rearrangements between the two TCR loci. Besides the finding of a series of previously unreported 
chromosomal rearrangements in T-ALL, this study also unraveled recurrent aberrations with 
putative new T-cell oncogenes on chromosomes 11q24, 20p12 and 6q22. 
In a third multi-center study, a total of 424 T-ALL cases were analysed retrospectively to 
search for additional TCRβ-HOXA positive cases and subsequently to address specific clinical, 
immunophenotypical and biological characteristics of T-ALLs carrying this aberration. This revealed  
TCRβ-HOXA rearrangements in 5 additional patients, which brings the total to 14 cases in 424 
patients (3.3%) and included 9 inv(7)(p15q34), 2 t(7;7)(p15;q34) and 1 TCRβ-HOXA triplication due 
to ring chromosome formation. For the two patients left, no metaphases were available which 
hampers a distinction between an inv(7) and a t(7;7). For 170 of these 424 patients, gene expression 
analysis for HOXA10 expression was performed to check the relationship between HOXA10 
overexpression and the presence of the TCRβ-HOXA rearrangement. HOXA10 overexpression was 
detected in 25.2% of cases including all cases with a TCRβ-HOXA aberration (n=14; 8.2%). Expression 
of the short HOXA10 transcript (HOXA10b) however was almost exclusively found in the TCRβ-HOXA 
positive patients (n=14), suggesting a specific role for the HOXA10b short transcript in TCRβ-HOXA 
mediated oncogenesis. Breakpoints of 3 out of 10 cases were cloned and showed a clustering in both 
the TCRβ locus (1.1 kb) and the HOXA gene locus (3.8 kb). This was slightly different to the 
breakpoints found in 4 patients carrying the TCRβ-HOXA rearrangement in the study of Soulier et al. 
where the breakpoints were found 3’ to the HOXA10 gene and within intron 1b of HOXA9 
respectively. Nevertheless, the region encompassing the HOXA10 and HOXA9 genes remains the 
major breakpoint cluster region. 
Other molecular and/or cytogenetic aberrations frequently found in subtypes of T-ALL (SIL-
TAL1, CALM-AF10, HOX11, HOX11L2) were not detected in the TCRβ-HOXA rearranged cases except 
for deletion of 9p21 and NOTCH1 activating mutations which were present in 64% and 67% 
respectively.  
Finally, in a fourth small study, we describe the first case of a HOXA chromosomal 
rearrangement with the TCRδ locus in a T-ALL patient already carrying a CALM-AF10 translocation. 
In conclusion, we clearly illustrated the power of FISH in detecting new chromosomal 








La leucémie aigue lymphoblastiques de la lignée T (LAL-T) représente une forme de cancer 
agressif au départ de précurseurs lymphoïdes T survenant tant chez l’enfant (10 à 15% des LAL de 
l’enfant) que chez l’adulte (25% des LAL de l’adulte). Ce type de leucémie diffère des LAL de la 
lignée B en plusieurs aspects et notamment en termes de survie malgré le développement important 
de nouvelles stratégies thérapeutiques lors des 50 dernières années. Comme pour les autres formes 
de leucémie, son apparition est la conséquence d’une accumulation de plusieurs altérations 
génétiques d’un progéniteur lymphoïde de la lignée T. Des translocations chromosomiques 
impliquant des gènes qui codent pour des facteurs de transcription sont les altérations génétiques le 
plus fréquemment retrouvées dans les leucémies aigues. Le plus souvent ces gènes codant pour des 
facteurs de transcriptions sont par conséquence soumis à l’influence des séquences régulatrices des 
gènes codant pour les récepteurs T (TCR) ou pour les récepteurs à immunoglobulines aboutissant à 
leur expression de façon inappropriée.  
Lors des 20 dernières années, de nombreuses études ont été effectuées démontrant la 
valeur diagnostique et pronostique de ces réarrangements chromosomiques. De plus, l’analyse 
cytogénétique est souvent à la base de l’identification de gènes candidats responsables d’un certain 
type de leucémie. Cependant, contenu de sa résolution limitée de 10 Mb, l’analyse cytogénétique 
classique peut passer à côté de certains réarrangements chromosomiques. L’hybridation de 
fluorescence in situ (FISH) surpasse ce problème et constitue ainsi un outil diagnostique et de 
recherche important dans les hémopathies malignes. 
 Cette étude a pour but l’identification de nouveaux oncogènes impliqués dans une forme 
plus rare de leucémie étant la LAL-T. Une étude M-FISH précédente réalisée sur des échantillons 
d’enfants atteints d’une LAL avec des aberrations chromosomiques complexes, a permis la 
découverte d’une translocation chromosomique t(7;11)(q34;q24). Ceci ayant mené à l’identification 
d’un réarrangement chromosomique cryptique du locus TCRβ (7q34) et d’un nouvel oncogène situé 
sur le bras long du chromosome 11 (11q24). Cette découverte a constitué le point de départ d’un 
dépistage à large échelle (94 patients atteints d’une LAL-T) ayant pour but de détecter des 
réarrangements cryptiques additionnels du locus TCRβ par FISH. Cette étude a montré que des 
réarrangements du locus TCRβ étaient nettement plus fréquents (20%) que la fréquence rapportée 
par l’analyse cytogénétique chromosomale classique (7%). Ceci a été confirmé par notre étude où 
pas plus de 3.0% de réarrangements du locus TCRβ ont été détectés par cytogénétique 
traditionnelle. La découverte la plus intéressante fût celle d’un nouveau gène partenaire du locus 
de TCRβ dans 5 cas sur les 94 : les gènes appartenant au cluster HOXA sur le chromosome 7p15. Ces 
5 patients étaient porteurs d’un nouveau réarrangement récurrent étant une inversion 
inv(7)(p15q34), avec des points de cassure situés dans les gènes appartenant au cluster HOXA (7p15) 
d’une part et au cluster TCRβ (7q34) d’autre part. C’est la première fois qu’une implication des 
gènes appartenant au cluster HOXA a été décrite dans les réarrangements chromosomiques des LAL-
T.  De plus, ce réarrangement a mené à la surexpression des gènes HOXA10 et HOXA11 plus en 
particulier. En plus de la  constatation dans des études précédentes du rôle des gènes HOXA dans le 
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développement des lymphocytes T, ces découvertes nous font supposer que les gènes appartenant 
au cluster HOXA jouent un rôle dans le processus oncogénique des LAL-T possédant ce nouveau 
réarrangement chromosomique. 
Dans la deuxième partie du travail des réarrangements chromosomiques ont également été 
recherchés dans les autres loci TCR, TCRαδ (14q11) et TCRγ (7p15) dans un groupe de 126 patients 
atteints de LAL-T et 19 lignées cellulaires LAL-T.  Cette étude a démontré que la fréquence des 
réarrangements de TCRαδ était également sous-estimée. De plus, une coexistence de 
réarrangements chromosomique de TCRαδ et de TCRβ impliquant le plus souvent des oncogènes 
cellulaires T différents, a été découverte dans cette série de patients et chez 2 d’entre eux il 
existait un réarrangement interne entre ces deux loci. Mis a part ces réarrangements 
chromosomiques non-décrits précédemment dans les LAL-T, d’autres réarrangements récurrents 
impliquant possiblement de nouveaux oncogènes ont été détectés sur les chromosomes 11q24, 
20q12 et 6q22. 
 Une troisième étude multicentrique rétrospective a visé à étudier la survenue de nouveaux 
réarrangements TCRβ-HOXA dans une série de 424 patients avec LAL-T et son rapport avec des 
éléments cliniques, immunophénotypique et moléculaires. Cette étude a permis de mettre en 
évidence 5 autres patients avec réarrangements TCRβ-HOXA ce qui fait un total de 14 patients 
(3.3%) dont 9 avec une inversion inv(7)(p15q34), 2 avec une translocation t(7 ;7)(p15 ;q34) et 1 
patient avec une triplication TCRβ-HOXA suite à la formation d’un chromosome en anneau. Quant 
aux 2 patients restants, la distinction entre une inv(7) et une t(7;7) n’a pu être faite en raison de la 
non-disponibilité de métaphases. Une analyse d’expression du gène HOXA10 a été réalisée dans 170 
cas sur 424 dans le but de rechercher une corrélation spécifique entre une surexpression de ce gène 
et la présence d’un réarrangement TCRβ-HOXA.Une surexpression a été retrouvée dans 25,2 % des 
cas incluant tous les cas porteurs d’un réarrangement TCRβ-HOXA (n=14 ; 8.2%). Le variant de 
transcrit court de HOXA10 (HOXA10b) a cependant été retrouvé presque exclusivement chez les 
patients présentant un réarrangement TCRβ-HOXA ce qui fait suggérer son rôle spécifique dans 
l’oncogenèse médiée par le réarrangement TCRβ-HOXA. Les points de cassure chromosomiques 
clonés dans 3 cas ont montré un regroupement des points aussi bien dans le locus TCRβ (1.1 kb) que 
dans le locus des gènes HOXA (3.8kb). Ceci est légèrement différent par rapport à l’étude de Soulier 
et al. où les points de cassure de 4 patients ont été retrouvés en position 3’ par rapport au gène 
HOXA10 et compris dans l’intron 1b du gène HOXA9 respectivement. Néanmoins, la région englobant 
les gènes HOXA10 et HOXA9 reste la région majeure de regroupement des points de cassure. 
D’autres aberrations moléculaires et/ou cytogénétiques fréquemment retrouvées dans les LAL-T 
(SIL-TAL1, CALM-AF10, HOX11, HOX11L2), n’ont pas été retrouvées dans le groupe de patients 
présentant un réarrangement TCRβ-HOXA, mis à part une délétion 9p21 et des mutations 
activatrices NOTCH1 dans respectivement 64% et 67% des cas. 
 Enfin, dans une quatrième petite étude, nous décrivons pour la première fois la survenue 
d’un réarrangement chromosomique TCRδ-HOXA chez un patient présentant une LAL-T étant 
également porteur d’une translocation CALM-AF10. 
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 En conclusion, nous avons clairement démontré l’apport supérieur de l’analyse par FISH par 
rapport à l’analyse cytogénétique classique à la détection de nouveaux réarrangements 
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